Synthesis and anti-viral activity of novel tripeptidyl compounds, modification of graphene oxides, and synthesis of peptidyl substrates for use in an electrochemical biosensor device by Prior, Allan Mark
 SYNTHESIS AND ANTI-VIRAL ACTIVITY OF NOVEL TRIPEPTIDYL COMPOUNDS, 
MODIFICATION OF GRAPHENE OXIDES, AND SYNTHESIS OF PEPTIDYL 
SUBSTRATES FOR USE IN AN ELECTROCHEMICAL BIOSENSOR DEVICE.   
 
 
by 
 
 
ALLAN MARK PRIOR 
 
 
 
M.Sc., University of KwaZulu-Natal, South Africa, 2009 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Chemistry 
College of Arts and Sciences 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2013 
 
 
  
 Abstract 
Three research projects are described in this dissertation and they consist of the discovery of 
norovirus protease inhibitors, modification of graphene oxides (GO) for the detection of 
norovirus, and design and fabrication of nanoelectronic device based on nanocarbon fibers for 
the detection of breast cancer proteases, legumain and cathepsin B.  
A novel class of tripeptidyl anti-noroviral compounds which strongly inhibit NV3CL
pro
 in 
enzyme and cell based assays was discovered. An example of one of the most active compounds 
is (1-{3-methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-2-
naphthalen-1-yl-ethyl)-carbamic acid benzyl ester, which showed an IC50 value of 0.14 ± 0.2 µM 
(enzyme assay) and EC50 value of 0.04 ± 0.02 µM (cell based assay). This compound has an 
aldehyde warhead, a P1 glutamine surrogate, a P2 leucine, a P3 L-1-napthylalanine and an N-
terminal carboxybenzyl cap. The corresponding bisulfite adduct, 2-[2-(2-
benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methyl-pentanoylamino]-1-
hydroxy-3-(2-oxo-pyrrolidin-3-yl)-propane-1-sulfonic acid monosodium salt, has a comparable 
activity in enzyme and cell based assays (IC50 0.24 ± 0.1 µM; EC50 0.04 ± 0.03 µM). (1-{3-
methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-2-
naphthalen-1-yl-ethyl)-carbamic acid benzyl ester and its ketoamide derivative, (1-{1-[2-
isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-3-methyl-
butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester, exhibited very good broad 
spectrum anti-viral activity, especially in human rhino virus and severe acute respiratory 
syndrome bioassays. 
 
We demonstrated that the surface of graphene oxide can be chemically modified with t-
butylester and carboxylic acid functionalities. Fourier transform infrared spectroscopy, Raman 
spectroscopy and solid state nuclear magnetic resonance spectroscopy confirmed the presence of 
t-butylester and carboxylic acid functional groups. One sided oligonucleotide functionalized 
graphene oxide was synthesized using a solid state technique. A carboxylic acid functionalized 
graphene oxide was deposited onto the surface of electronic chips to bridge two gold electrodes, 
using a direct deposition technique. The carboxylic acid functionalized graphene oxide displayed 
semi-conductive properties and its use in an electronic biosensor device to detect noroviral RNA 
was investigated.   
 Novel redox-active protease substrate peptides H2N-(CH2)4CO-Ala-Ala-Asn-Leu-NHCH2-
ferrocene and H2N-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-ferrocene were synthesized 
successfully and used in an alternating current voltammetry technique to facilitate the detection 
of the cancer related protease enzymes legumain and cathepsin B. After attachment of these 
peptides to the tips of carbon nanofiber nanoelectrode arrays, the presence of active protease 
enzymes could be detected as manifest by an exponential decay in current signal detect when 
monitored by alternating current voltammetry, at initial enzyme concentrations of 80.1 nM 
(legumain) and 30.7 nM (cathepsin B). The peptide cleavage sites were confirmed by analyses of 
the cleaved fragments using high performance liquid chromatography and mass spectrometry. 
Results showed that the cleavage of H2N-(CH2)4CO-Ala-Ala-Asn-Leu-NHCH2-ferrocene at the 
C-terminal side of asparagine residues by legumain and cleavage of H2N-(CH2)4CO-Leu-Arg-
Phe-Gly-NHCH2-ferrocene at the C-terminal side of arginine residues by cathepsin B.  Legumain 
exhibited a specificity constant (kcat/Km) of 11.3 x 10
3 
M
-1
S
-1
 while cathepsin B exhibited a 
higher value of specificity constant (4.3 x 10
4 
M
-1
S
-1
) which agreed with the values obtained 
from fluorescence enzyme assay.  
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syndrome bioassays. 
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butylester and carboxylic acid functionalities. Fourier transform infrared spectroscopy, Raman 
spectroscopy and solid state nuclear magnetic resonance spectroscopy confirmed the presence of 
t-butylester and carboxylic acid functional groups. One sided oligonucleotide functionalized 
graphene oxide was synthesized using a solid state technique. A carboxylic acid functionalized 
graphene oxide was deposited onto the surface of electronic chips to bridge two gold electrodes, 
using a direct deposition technique. The carboxylic acid functionalized graphene oxide displayed 
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I.  Design, Synthesis, and Bioevaluation of Viral Cysteine Protease 
Inhibitors. 
 
I.I. Introduction 
 
Noroviruses (NVs) are prevalent worldwide and are the leading cause (~90%) of severe 
gastroenteritis in children and adults 
1
 and is responsible for ~58% of all food borne illnesses.
2
 
Outbreaks usually occur in conditions where people are sharing living quarters or restrooms such 
as cruise ships, hospitals, nursing homes and dormitories where person to person transmission is 
more favorable.
1
 It has been reported that NVs only need a few virions (~17 virus particles) to 
cause an infection and hence NV is highly infectious.
3
 People don’t develop a long lasting 
immunity against NVs due to the high NV mutation rate and existence of high genetic variation. 
Infection rates are amplified due the resistance of human NVs to common disinfection 
procedures such as hand sanitizers (ethanol) or quaternary ammonium compounds.
4, 5
 NVs utilize 
a fecal-oral route for transmission and propagation and once the host has been infected the NV 
virion will make its way through the gut until it reaches the small intestine where is starts 
replication. After about 2 days in the small intestine, symptoms such as diarrhea, nausea, 
vomiting, abdominal pain, lethargy and headaches will occur, which are normally self limiting 
and last for about 24 to 60 hours. However many deaths are associated with NV infections 
especially among children, the elderly and people with compromised immune systems. It is 
estimated that 200,000 deaths per year occur in young children and infants in developing 
countires.
1
  A common way that NVs can be introduced into the public is through fresh produce 
since farming practices make use of manure and bio-solid based fertilizers.
2
 NVs can also 
contaminate produce at the farm through insects and animals, soil, dust and contaminated water 
used for irrigation.
2
 A recent survey was conducted in Canada, Belgium and France that found 
NVs in packaged leafy greens in 28 to 50 % of samples as determined by real-time reverse-
transcription polymerase chain reaction (RT-PCR).
2
 Although the NVs that were detected have 
not associated with any severe outbreaks, the results suggest that packaged produce could be a 
viable route for NV transmission.
2
 
2 
 
NVs belong to the family of Calicivirdae (CV).
6
 NVs are non-enveloped viruses containing a 
single stranded positive sense ~7.5-kb RNA genome that encodes for many important structural 
and non-structural proteins.
6
 The genome contains three open reading frames (ORFs) as shown 
in Figure 1. 
Figure 1: The Norovirus Genome. 
 
(p48): an amino-terminal protein (~48 kDa). 
(NTP): nucleoside triphosphatase.  
(p22): a 22 kDa 3A-like protein. 
(VPG): a viral genome-linked protein to the 5′ end of the genome.  
(3C): 3C-like protease.  
(RdRp): RNA-dependant RNA polymerase, a 3D-like protein.  
 
ORF1 encodes for six non-structural proteins, p48, nucleoside triphosphatase (NTP), p22, viral 
genome protein (VPG), 3C-like protease (3C) and RNA-dependant RNA polymerase (RdRp). 
ORF2 encodes the major capsid protein (VP1) while ORF3 encodes a minor (VP2) capsid 
protein.
1
 NVs are grouped into five genogroups, GI, GII, GIII, GIV and GV and categorization is 
based on VP1 protein sequence similarity.
1
 Viruses most commonly infecting humans belong to 
GI and GII and both of these genogroups can be further subdivided into different genetic clusters 
or genotypes. GII for example has 19 genotypes, of which genotype 4 (abbreviated GII.4) 
accounts for most of the adult NV outbreaks around the world.
1
 
Figure 2 shows a scheme adapted from Rocha-Pereira et al.
3
 and summarizes the mechanism of 
NV replication. The first step involves attachment of a virion to a carbohydrate receptor such as 
human histo-blood group antigen (HBGA), sialic acid or heparin sulfate present on a host cell 
surface. It has been reported that the virion-receptor binding makes use of the P2 domain of the 
VP1 structural protein of the virion.
3
 The virion then enters the cell through a pH independent 
endocytic pathway that is not mediated by clathrin or caveolin, but rather by dynamin II and 
3 
 
cholesterol. Once inside the cell, a prepackaged non structural protein (VPG) initiates translation 
of ORF1 of the viral RNA genome into a long polyprotein, which, after the action of the 3C-like 
(3CL) protease, releases many nonstructural viral proteins such as p48, NTP, p22, VPG, 3C and 
RdRp.  
Figure 2: Replication of Norovirus. 
 
The proteins p48 and p22 recruit host membrane to form a replication complex, inside of which 
the replication of NV is believed to occur. The replication complex is a membranous structure 
that contains the viral nonstructural proteins, viral RNA genome and host proteins that will 
facilitate viral replication. After transcription of the positive sense RNA into negative sense 
RNA, the RdRp will transcribe many copies of the negative sense RNA back to the genomic 
positive sense RNA for packaging into new virion. Simultaneously the virus will synthesize 
shorter subgenomic RNA that contain ORF2 and ORF3. These are translated into the viral 
structural proteins VP1 and VP2 which assemble to form the new virion capsid. After assembly 
4 
 
of the structural proteins and packaging of new genomic RNA the mature virion can be released 
from the cell, a step that remains poorly understood.
3
 
NV is receiving increasing attention each year due to the significant amount of morbidity and 
mortality and this has driven increasing drug discovery research efforts. Despite this however, no 
anti-noroviral drug or vaccine is available for treatment or for prophylactic purposes.
3
 Although 
anti-noroviral research is in its infancy, researchers have identified possible targets situated at 
different stages of NV replication cycle that could be exploited for potential drug design. This 
information has been captured in a recent review article
3
 and therefore will not be discussed in 
great length, however, a brief summary will be made to set the scene of this research.  
The first step in the viral infection process is the attachment of virion to carbohydrates on the 
cellular surface (HBGA) and hence it has been suggested that drugs that target the HBGA 
binding domain on the virion capsid may be used for prophylactic purposes in the event of a NV 
outbreak.
7-9
 It may also serve to lessen the severity of the infection in people that have already 
contracted it as it would hinder the NV propagation.
10
 There are limitations to this however since 
there are a numerous other carbohydrates (e.g. sialic acid
11
 or heparin sulfate
12
) that are said to 
be recognized by NVs and hence the pool of sugar residue structures that could interact with 
NVs is quite broad making drug development efforts very challenging. Moreover, viral capsid 
proteins can accommodate many structural changes without compromising viral vitality and 
therefore this class of drug would be easily susceptible to mutational drug resistance.
3
  
The nonstructural proteins p48
13, 14
 and p22
15
 are believed to play a role in the formation of the 
replication complex (RC) and hence have been suggested as potential targets for drug 
development. The limitation however is that the function of these proteins in NVs is not well 
defined. The p22 protein, however, has a well conserved section that has been reported to inhibit 
protein trafficking from the endoplasmic reticulum (ER) to the Golgi body by mimicking the 
normal ER export signal.
16, 17
 Although no inhibitors for these proteins have been reported in 
NV, enteroviruses (EVs) and rhinoviruses (RVs) have both experienced inhibition in vitro to 
their structurally similar protein (3A) by enviroxime
18
 and TTP-8307
19
 (Figure 3).    
Small molecules targeting VPg (hippuristanol,
20
 panteamine
21
) and NTP (TBZE-029, MRL-
1237, HBB)
22-24
 have come to light (Figure 3) and show in vitro inhibition to structurally 
5 
 
analogous proteins belonging to the feline calicivirus (FCV) and picornavirus (PV) families 
respectively. Drug development targeting these classes of proteins in NV could therefore be 
highly relevant.  
Figure 3: Examples of Antiviral Drugs. 
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It has been stated that the two most promising nonstructural enzymes to focus drug discovery 
efforts on is the RdRp and 3C protease.
3
 RdRp plays a crucial role in the synthesis of viral RNA 
and is thus central to viral propagation. It keeps a highly conserved catalytic site among all viral 
polymerases, which is an attractive feature when considering targets for drug development.
3
 For 
example, 2’-C-methylcytidine, 2’-C-methyladenosine and 4-azidocytidine (Figure 3) have broad 
spectrum anti-RdRp activity against many positive strand RNA viruses.
25-27
 Moreover, 2’-
arauridine-5’-triphosphate and 3’-deoxyuridine-5’-triphosphate (Figure 3) have anti-RdRp 
activity in a NV assay.
28
 The 3CL protease is another central enzyme essential for viral 
propagation since it is involved in polypeptide processing to release essential nonstructural viral 
proteins, but has been reported recently to have additional roles such as inactivation (cleavage) 
of mitochondrial antiviral signaling protein (MAVS).
15, 29
 The 3C protease also has been shown 
to contain a highly conserved active site among all CVs.
13
 It has been suggested that the 3C 
protease of NV may be the most promising target to aim drug development efforts due to its 
6 
 
important function as well as the availability of detailed structural information.
10
 Rupintrivir
23, 30
 
(Figure 3) is an example of a 3CL protease inhibitors found active against PVs.  
Although other strategies to tackle the problem of NV infection are being investigated such as 
small interfering RNAs (siRNAs)
31
 and vaccine development,
1, 32-34
 our efforts to discover a new 
anti-NV drug will focus primarily on targeting the NV 3C-like protease (NV3CL
pro
).   
NV3CL
pro
 is “3C-like” because it contains chymotrypsin-like folds and belongs to the 
chymotrypsin-like protease family.
35
 The NV3CL
pro
 uses a cysteine (SH side chain) as the 
nucleophile to cleave the peptide substrate scissile bond, whereas, chymotrypsin uses a serine 
(OH side chain) to cleave the substrate. Studies have shown that His30, Glu54 and Cys139  are 
conserved  in all NV3CL
pro
 enzymes and the His30/Cys139 pair work as an acid-base dyad that 
is essential for protease activity.
35
  Glu54 has been shown by mutagenesis studies to be important 
for protease activity because mutation of Glu54 to Ala resulted in loss of proteolytic activity.
36
 
X-ray crystal structures
35
  and NMR solved solution structures
37
 have been reported for 
NV3CL
pro
 which give useful structural information. The substrate binding site of NV3CL
pro 
contains substrate binding pockets (S1, S2, S3…) starting at the active site and labeled in an 
order moving away from the active site toward the bound substrates N-terminus end. The S1 
pocket contains the important residues Thr134,  His157 and Ala160
28
 which can interact with the 
P1 Gln/Glu of the substrate.
37
 The S2 pocket is hydrophobic in nature and encompasses Ile109, 
Arg112 and Val114 and can accommodate bulky hydrophobic P2 side chains such as Leu and 
Phe.
37
  
A report of our intensive research efforts to discover new and potent anti-NV compounds will be 
discussed in the following section.  
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I.II. Results and Discussion 
 
Groutas and coworkers were first to discover a “hit” dipepidyl compound GC373 (Figure 4) that 
showed micromolar inhibition (IC50 = 1.82 µM)
38
 of NV3CL
pro
 in vitro using a fluorescence 
resonance energy transfer (FRET) enzyme assay
39, 40
 and EC50 of  2.1 µM
38
 in a NV cell based 
assay.
40, 41
 In order to clearly distinguish between these activity data, IC50 values represent data 
obtained from a FRET enzyme assay, while EC50 values represent data obtained from the cell 
based assay. The bioactivity data of all synthesized compounds were evaluated by Dr. Kyeong-
Ok Chang and Dr. Yunjeong Kim at the Department of Diagnostic Medicine and Pathobiology, 
Kansas State University. Experimental details describing the FRET enzyme assay
39, 40
 and cell 
based assay
40, 41
 have been previously reported.  
 
Figure 4: Dipeptidyl Compound, GC373. 
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The Groutas group examined the cleavage sites recognized by NV (Figure 5), which helped in 
their discovery of compound GC373. The dashed line in Figure 5 represents the cleavage site 
(scissile bond) of cleavable peptide substrates. The letters represent amino acids that correspond 
to positions (P1, P2, P3…etc.) in the cleavable peptide substrate. The Groutas group used a C-
terminal aldehyde “warhead”, which acts as the electrophilic site for nucleophilic attack from 
Cys139, a P1 Gln “surrogate” that is recognized by the S1 enzyme pocket, a P2 Leu that will be 
recognized by the S2 pocket and a Cbz N-terminal cap. 
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Figure 5: Cleavage Sites Recognized by NV3CL Protease Enzymes. 
 
 
NV proteases are quite specific to the identity of the substrate P1 amino acid side chain and 
require either a Gln (Q) of Glu (E), but higher tolerability is noticed for substrate P2 and P3. 
With knowledge of this, our initial research efforts focused on synthesizing a new class of NV 
protease inhibitors using a structure-activity relationship (SAR) approach.  
First, we decided to keep P2 as alanine, and investigate how the nature of P3 affects activity. A 
series of C-terminal aldehyde compounds were synthesized (Figure 6) along with their 
corresponding C-terminal ketoamides (Figure 7). The structures of these compounds were 
influenced to some extent by a translational anti-viral research project in which a different viral 
protease enzyme was also targeted, however, the name of this enzyme or the bioactivities of 
compounds 1 - 23 against this enzyme are not discussed at this time due to its confidential 
nature. 
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Figure 6: Series of Synthesized P2 Alanine Anti-NV Compounds for Structure Activity 
Relationship Studies to Evaluate P3 Residue. 
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Figure 7: Structures of Anti-NV Candidates with Modification of C-Terminal Warheads. 
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The inhibitory activities of all compounds against NV were evaluated using a FRET-based 
enzyme
39
 and cell-based assays using the NV replicon cell system.
41
 The activities for 
compounds 1 - 23 against NV enzyme and cell assays are shown in Table 1. The initial IC50 and 
EC50 data obtained by Dr. Kyeong-Ok Chang was for screening purposes only, and thus no error 
bars are available. Compounds that showed good activities in the initial screening were assayed 
again, in triplicate, by Dr. Chang, and these IC50 and EC50 values have error bars associated with 
them. Compounds 1 - 6 showed no inhibition in enzyme or cell based assays up to the highest 
concentration tested (50 µM and 10 µM, respectively) except for compound 3, which showed 
inhibition in the enzyme assay only (IC50 2.5 µM). Compounds 1, 3, 4 and 5 were converted into 
ketoamide derivatives to form compounds 13, 14, 15 and 16, respectively of which only 16 
showed inhibition in the enzyme assay (IC50 value of 4.6 µM). 
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Table 1: Bioactivities of Compounds 1 - 23 in NV3CLpro (enzyme) and NV (cell) Assays. 
Compound IC50 
(Enzyme), 
µM 
EC50 
(Cell), 
µM 
Compound 
(ketoamide) 
IC50 
(Enzyme), 
µM 
EC50 
(Cell), 
µM 
1 > 50 > 10 13 > 50 > 10 
2 > 50 > 10    
3 2.5 > 10 14 > 50 > 10 
4 > 50 > 10 15 > 50 > 10 
5 > 50 > 10 16 4.6 > 10 
6 > 50 > 10    
7 1.8 5.6 17 5.1 > 10 
8 2.3 7.6 18 5.3 > 10 
9 ND ND    
10 2.1 > 10 19 4.1 > 10 
11 0.34 0.9 20 5.6 ~9 
12 7.0 8.6    
21 > 50 > 10    
22 > 50 > 10    
23 > 50 > 10    
 
All of the above mentioned compounds did not exhibit cell based inhibition activities, which 
suggests that these structures are not membrane permeable and/or are degraded too quickly by 
the cellular components of the cell based assay to be effective. Nevertheless, we continued with a 
structure-activity relationship study (SARS) to determine whether a lower IC50 and greater 
bioactivity (a lower the EC50) could be achieved. A series of C-terminal aldehydes were 
synthesized having a hydrophobic, unnatural amino acid side chain at the P3 position as shown 
in compounds 7 - 12 (Figure 6). The activity data were obtained and the results showed a much 
improved inhibition of NV3CL
pro
 in enzyme and cell based assays (Table 1). Interestingly, the 
compound that showed the strongest activity was compound 11, which possessed an L-1-
napthylalanine (P3) and an O-t-butyl-L-serine (P2). The hydrophobic nature of the 1-
12 
 
napthylalanine and O-t-butyl-L-serine probably allows for enhanced cell membrane permeability 
and hence inhibition was also observed in the cell based assay. The P2 O-t-butyl group contained 
in compound 11 must fit the S2 pocket of NV3CL
pro
 much more favorably than a P2 methyl 
because compound 11 showed more than 5 fold stronger inhibitory activity in the enzyme assay 
over compound 7, which has a P2 alanine. This confirms speculation in the literature which 
indicates that the S2 pocket is hydrophobic in nature and can accommodate bulky hydrophobic 
P2 side chains, such as Leu and Phe.
37
 The C-terminal amides, compounds 21 and 22, or the C-
terminal ester, compound 23, do not show inhibition up to the highest concentrations tested. This 
suggests that these warhead functionalities reduce the affinity of these compounds for the 
NV3CL
pro
 substrate binding site, probably due to the reduced electrophilicity of their carbonyl 
carbons, lowering the chance of nucleophilic attack from Cys139, as compared to a highly 
electrophilic aldehyde warhead.  
The S2 pocket was probed by changing the side chain of P2 amino acid residue to have bigger, 
hydrophobic groups (compounds 24 - 26) as shown in Figure 8. The activity data (Table 2) show 
that the P2 leucine gave the stronger activity, as suggested by the lowest IC50 value (0.14 µM) 
and EC50 value (0.04 µM). The structures and bioactivity data for compounds 24, 27 - 28, 30 - 32 
and 35 - 36 have been reported recently by us.
42
  
 
Figure 8: NPI Compounds Having Modification at the P2 Site. 
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With this result, the P2 site was fixed to leucine and a series of compounds was synthesized with 
modification of P3 as shown in Figure 9. The P3 side chain was kept hydrophobic as this was 
shown necessary for better activity and cell permeability (vide supra).  
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Figure 9: Synthesized P2 Leucine NPI Candidates Having Modification at P3 Site. 
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Table 2: Activity Data for Compounds 24 - 31 in NV3Cpro (enzyme) and NV (cell) Assays. 
Compound IC50 
(Enzyme), 
µM 
EC50 (Cell), 
µM 
24 0.14 ± 0.2 0.04 ± 0.02 
25 0.15 0.05 
26 0.30 0.25 
27 0.70 ± 0.3 0.45 ± 0.4 
28 0.21 ± 0.1 0.06 ± 0.03 
29 0.20 0.04 
30 0.15 ± 0.1 0.08 ± 0.03 
31 0.18 ± 0.06 0.05 ± 0.05 
 
Compounds 27 - 31 all displayed very good inhibition profiles in both NV enzyme and NV cell 
based assays (Table 2). Compound 27 however, having a D-1-napthylalanine, was 5 fold less 
active than its L-1-napthylalanine isomer (compound 24) which demonstrated that spacial 
recognition between substrate and enzyme is important and the natural configuration (L-
configuration) gives superior binding despite the presence of unnatural (1-napthylalanine) side 
chain. This is not surprising since protease enzymes are built by cells to cleave peptides 
14 
 
containing almost entirely L-configurated amino acids. Compound 24 showed the best in vitro 
inhibition of NV3CL
pro
 and thus the best P3 group (L-1-napthylalanine) was kept fixed along 
with the best P2 group (alanine) and a study was performed to investigate the SAR effects with 
changing to different warhead functionalities. Figure 10 shows a series of compounds that were 
synthesized with modification about the C-terminal warhead region while keeping P2 and P3 
structure constant, with few exceptions in which cyclohexylmethylglycine presented at P2. The 
bioactivity data for this series of compounds are shown in Table 3.   
 
Figure 10: Modification of C-terminal Warhead. 
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Table 3: Activity Data for Compounds 32 - 43 in NV3CLpro (enzyme) and NV (cell) 
Assays. 
Compound IC50 
(Enzyme), 
µM 
EC50 
(Cell), 
µM 
32 2.6 ± 1.5 4.2 ± 2.4 
33 0.51 2 
34 0.60 4.5 
35 0.24 ± 0.1 0.04 ± 0.03 
36 35.5 ± 5.7 0.1 ± 0.3 
37 >50 2 
38 >50 >10 
39 >50 >10 
40 >50 >10 
41 >50 >10 
42 >50 2.5 
43 >50 0.8 
 
Aldehyde functionalities are known to have poor stability in the body due to ease of oxidation 
and are thus not considered optimal for drug development purposes. For this reason, the 
ketoamide warheads 32 - 34 were incorporated onto the C-terminal end of the most active 
compounds (Figure 10). The activity data show that these ketoamide derivatives still show good 
activity, however, they range from having 3 to 18 times lower activity in enzyme assay and 50 to 
100 times lower activity in cell assay (Table 3) compared to their aldehyde precursors. The best 
ketoamide during the initial screening was t-butyl ketoamide 33, as this revealed an IC50 value of 
0.51 µM and EC50 value of 2 µM. The sodium bisulfite adduct 35 showed good enzyme 
inhibition (IC50 0.24 µM) and excellent activity in NV cell assay (EC50 0.04 µM). Interestingly, 
the bisulfite adduct 35 displayed exactly the same cell based activity as its aldehyde precursor 
24, suggesting that the sodium bisulfite may act as a pro-drug, converting the hydroxy bisulfite 
group back to the aldehyde inside the cell. A similar phenomenon was observed within the series 
of dialkylphosphite adducts 37 and 42 - 43, which showed no enzyme inhibition up to the highest 
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concentration tested (50 µM) in FRET assay, however all showed very good inhibition in cell 
based assay ranging from 0.1 to 2.5 µM. The dialkylphosphite adduct may therefore be acting as 
a pro-drug, which can be converted back to aldehyde in the cell, or a transition-state mimic. 
Compounds 38 - 41 were not found active in enzyme or cell based assays.   
In order to assess the possibility of conversion of pro-drug 35 to aldehyde 24, an HPLC study 
was performed as shown in Figure 11.   
Figure 11: HPLC Data of Compounds 24 and 35 to Show Stability of Bisulfite Adduct 35 in 
PBS Buffer, pH 7.4. 
 
1) Aldehyde 24; 2) Bisulfite adduct 35; 3) Bisulfite adduct 35 after dissolved in phosphate buffer 
(25
o
C, pH = 7.4) for 20 minutes; 4) Bisulfite adduct 35 after dissolved in phosphate buffer (25
o
C, 
pH = 7.4) for 60 minutes.  
Chromatogram 1 shows the retention time of aldehyde 24 after injecting 50 µL of a 10 mM 
solution of 24 in DMSO. Mass spectrometry of the peak collected at 18 minutes confirms the 
presence of aldehyde 24. Chromatogram 2 shows the retention time of the sodium bisulfite 
adduct 35 after similarly injecting 50 µL of a 10 mM solution of bisulfite adduct 35 in DMSO. 
The peak at 13 minutes was confirmed to be bisulfite adduct 35 by mass spectrometry analysis. 
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Chromatogram 3 and 4 show the result after the bisulfite adduct 35 (1.3 mM) was allowed to sit 
at room temperature in PBS buffer (pH = 7.4) for 20 minutes (chromatogram 3) and 1 hour 
(chromatogram 4). Mass spectrometry analysis of the peaks at 13 and 18 minutes in 
chromatogram 3 was performed which confirmed the presence of bisulfite adduct 35 and 
aldehyde 24 respectively. The result was promising and supported the hypotheses of pro-drug 35 
converting back to aldehyde in vivo at pH 7.4.     
Some work was done to evaluate the N-terminal caps involvement in activity, but so far only 
three compounds have been synthesized (Figure 12) and tested (Table 4). Compound 44 was 
designed to present an amino-4-methylcoumarin (AMC) fluorophore onto the N-terminal end of 
the peptide to act has a fluorescence probe. The AMC is bulkier than the Cbz, which may not be 
ideal, since the enzyme and cell based inhibitory activity was lower, compared to compound 24. 
The smaller thiazole cap in compound 45 proved to be better than the AMC, however, it was still 
inferior to the Cbz cap (compound 24).  The 3-hydroxyl-Cbz cap (compound 46) was the most 
active of these three, but exhibited slightly lower activity than the Cbz cap (compound 24).  
However, the presence of a hydroxyl function in the cap lowers cLog P value and thereby would 
increase bioavailability. 
Figure 12: Modification of N-Terminal Cap. 
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Table 4: Activity Data for Compounds 44-46 in NV3CLpro (enzyme) and NV (cell) Assays. 
Compound IC50 
(Enzyme), 
µM 
EC50 
(Cell), 
µM 
44 1.5 2.5 
45 0.5 0.08 
46 0.35 0.07 
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It is known that macrocyclic peptides may offer advantages over linear peptides when 
considering drug like characteristics and therefore a macrocyclic skeleton was constructed as 
shown in Figure 13. By closing up the ring using the P1 and P3 side chains, it locks the peptide 
into a β-strand conformation (alternating side chains) which is the conformation  recognized by 
protease enzymes.
43, 44
 The macrocyclization employing P1 and P3 side chains is therefore 
causing “pre-organization” of the  peptide into a β-strand conformation, and this “transition state 
mimic” should provide a stronger binding to the active site of the protease.45, 46 The stronger 
binding should arise because pre-organization can reduce the loss of entropy upon inhibitor 
binding. Other advantages to macrocyclization include better cell permeability and proteolytic 
stability
47
 and improved drug-like characteristics.
48
 Macrocyclic peptides 47 and 48 were 
synthesized and their anti-NV activities were assessed in enzyme and cell based assays (Table 5). 
The activity for aldehyde 48 was not as good as expected and only showed inhibition in enzyme 
assay (IC50 8.5 µM). The ester 47 could not cause inhibition in both enzyme and cell based 
assays which was less surprising since an ester functional group was shown earlier not to be a 
good C-terminal warhead vide supra. 
Figure 13: Macrocyclic anti-NV Candidates. 
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Table 5: Activity Data for Compounds 47-48 in NV3CL
pro
 (enzyme) and NV (cell) Assays. 
Compound IC50 
(Enzyme), 
µM 
EC50 
(Cell), 
µM 
47 >50 >10 
48 8.5 >10 
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To date, the strongest inhibitor of NV3CL
pro
 in enzyme and cell based assays remains compound 
24 (IC50 0.14 µM; EC50 0.04 µM) although compounds 25, 28, 29, 30, 31, 35 and 46 also show 
comparable EC50 values. Compound 24 and its ketoamide derivative, 32, were screened against 
other viral strains in the caliciviridae, picornaviridae and coronaviridae families using enzyme 
and cell based assays. The results were encouraging as both compounds were found to be 
strongly active in all of these viral strains with minimal cell cytotoxicity (Tables 6 and 7). The 
activity data of compounds 24 and 32 (Tables 6 and 7) have recently been reported by us.
42
  
Table 6: IC50 Values of Compounds 24 and 32 against Other Viral 3C
pro
 and 3CL
pro
 in 
Enzyme Assay. 
Compound NV
a
 (µM) MD145
b
 (µM) HRV
c
 (µM) SARS-CoV
d
 
(µM) 
24 0.14 0.1 0.51  0.2 0.15 0.05 0.23  0.1 
32 2.6  2.5 3.1 1.6 0.12  0.2 0.61 0.2 
a) Norovirus enzyme assay (caliciviridae family) 
b) MD145-12 norovirus strain (GII/4) (caliciviridae family) 
c) Human rhino virus (picornaviridae family) 
d) Severe acute respiratory syndrome-coronavirus (coronaviridae family) 
Table 7: EC50 Values of Compounds 24 and 32 against Other Viral Cell Lines and CC50 
Values. 
Compound NV
a
 (µM) MNV-1
b
 
(µM) 
HRV18
c
 (µM) EV-229E
d
 
(µM) 
CC50
e
 (µM) 
24 0.04  0.02 0.6  0.2 0.015  0.03 0.2 0.1 87  6.3 
32 4.2  1.3 4.2 2.1 0.03 0.04 0.5 0.2 > 100 
a) Norovirus cell assay (caliciviridae family) 
b) Murine norovirus (caliciviridae family) 
c) Human rhino virus (picornaviridae family) 
d) Enterovirus (picornaviridae family) 
e) Cell cytotoxicity 
A crystal structure of compound 24 with SARS protease enzyme was obtained, which 
demonstrates that the NPI compounds can target the protease active site (Figure 14). Moreover, 
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structural insight obtained from this data could better help tailor a more suitable compound in the 
future to have stronger inhibition of SARS-CoV protease enzymes.  The study of crystal 
structure was carried out by Dr. Scott Lovell at the University of Kansas, Lawrence, KS.  
Figure 14: X-Ray Crystal structure of Compound 24 in Complex with SARS 3CLpro. 
 
The results shown in Tables 6 and 7 demonstrated that this class of NPIs could act as broad 
spectrum anti-viral compounds with excellent inhibitory activity against protease enzymes 
belonging to noroviruses, picornaviruses and coronaviruses. The initial design was that of 
transition state inhibitors and transition state mimics that should bind to the active site of viral 
3C
pro
 or 3CL
pro
. The presence of a leucine at P2 site, a 1-naphthylalanine residue at P3 site, a Cbz 
cap at the N-terminus and a C-terminal aldehyde warhead was found to be the best in terms of 
activity among all synthesized compounds. Animal studies are currently being pursued with 
compound 24 and SAR studies are ongoing in our lab to try and improve upon broad spectrum 
anti-viral activity.  
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I.III. Synthesis of NPI compounds 1 - 48 
 
The glutamine surrogate methyl ester 53 and glutamine surrogate aldehyde 53a were prepared 
according to a recent literature procedure.
49
 In brief, N-boc glutamic acid 49 was treated with 
sodium iodide and sodium bicarbonate in DMF for 5 days to give N-Boc-glutamic dimethyl ester 
50 (Scheme 1).  
Scheme 1: Synthesis of Glutamine Surrogate Methyl Ester 53 and Glutamine Surrogate 
Aldehyde (53a). 
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Reagents and Conditions: (a) MeI, NaHCO3, DMF, 5 days, 80%; (b) 1. LiHMDS, THF, -78
o
C, 
1h; 2. Bromoacetonitrile, -78
o
C, 3 h, 91%; (c) NaBH4, CoCl2, MeOH, 25
o
C, 18 h, 63%; (d) 4M 
HCl/Dioxane, 25
o
C, 2h, 100%; (e) NaBH4, CH2Cl2/EtOH/MEOH (5:3:2), 0 
o
C, 4 h, 100%; (f) 
DMP, CH2Cl2, 25 
o
C, 2 h, 94%. 
Double deprotonation of 50 using 2 equivalents of lithiumhexamethyldisilazane (liHMDS) 
followed by 1 equivalent of bromoacetonitrile at -78
o
C for 3 hours followed by quenching with 
acetic acid furnished the alkylated nitrile compound 51 with excellent diastereoselectivity, as 
only one diastereomer (1,3-anti) of 51 was observed from the reaction. The nitrile 51 was 
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reduced with sodium borohydride and cobalt(II) chloride in methanol to give an amine 
intermediate which undergoes ring closure by an acyl substitution reaction with the side chain 
ester group to produce the lactam ring as seen in compound 52. The boc protecting group of 52 
can be removed by treatment with 4M HCl in dioxane to form 53, or the ester group of 52 can be 
converted to aldehyde 53a by reduction of 52 with sodium borohydride followed by oxidation of 
the alcohol intermediate by Dess-Martin periodinane (DMP). The surrogate molecules 53 and 
53a are key starting materials for the synthesis of all NPI compounds.  
The high level of 1,3-asymmetric induction obtained in the synthesis of compound 51 (Scheme 
1) has been also been described by Hanessian and Schaum.
50
 It has been speculated that the 
reaction proceeds via the alkylation of a lithium coordinated transition state B as shown in Figure 
15 from the less hindered face to generate a 1,3-anti product.
50
 Narasaka and coworkers
51, 52
 
observed similar asymmetric induction during the alkylation of lithium enolates, generated from 
t-butyl esters of 4-alkyl-substituted 5-hydroxypentanoic acids. A lithium coordinated transition 
state was also proposed in these reactions. 
 
Figure 15: Lithium Coordinated Transition State Proposed by Hanessian and Schaum
50
 
that Accounts for the High Asymmetric Induction Observed in the Synthesis of Compound 
51. 
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The dipeptidyl aldehyde 1 was synthesized by firstly coupling the glutamine surrogate-amine 53 
with Cbz-alanine in the presence of EDCI and DMAP in methylene chloride and DMF (Scheme 
2). The resulting ester 54 was reduced to an alcohol intermediate using sodium borohydride 
followed by DMP oxidation to provide aldehyde 1. The aldehyde 2 was constructed in a similar 
fashion as described for compound 1, but, a mixture of two diastereomers of 2 were obtained.  
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Scheme 2: Synthesis of Dipeptidyl Aldehydes 1 and 2. 
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Reagents and Conditions: (a) EDCI, DMAP, DMF/CH2Cl2, 25 
o
C, 18h; (b) NaBH4, 
CH2Cl2/EtOH/MEOH (5:3:2), 0 
o
C, 4 h; (c) DMP, CH2Cl2, 25 
o
C, 2 h. 
The piperidine-1,2-dicarboxylic acid 1-benzyl ester (a) was synthesized in house according to 
Scheme 3. D,L-2-Piperidinecarboxylic acid was dissolved in water and treated with sodium 
hydroxide and benzylchloroformate at 25
o
C for 18 hours. Pure compound a was obtained after 
purification from silica gel column chromatography, in a 69% yield. 
Scheme 3: Synthesis of Piperidine-1,2-dicarboxylic acid 1-benzyl ester (Compound a). 
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Aldehydes 3, 5 and 7 were synthesized as depicted in Scheme 4. The 2-chlorotrityl-L-alanine 
resin (200 mesh) was coupled with the P3 amino acid residue containing an R side chain using 
solid phase peptide synthesis to form resin-bound intermediates 57 - 59. After separately 
cleaving resin-bound peptides 57 - 59 from resin using TFA, the dipeptidyl carboxylic acids 60 - 
62 could be obtained. Each of these carboxylic acids could be coupled separately with the P1 
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glutamine surrogate-amine 53 to form their corresponding tripeptidyl esters 63 - 64 and 23. Each 
of these esters was reduced and re-oxidized using sodium borohydride and DMP respectively to 
yield aldehydes 3, 5 and 7.  
 
Scheme 4: Synthesis of Tripeptidyl Aldehydes 3, 5 and 7. 
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60, R1 = L-methyl (63%)
61, R1 = D-methyl (86%)
62, R1 = L-1-napthyl (57%)
63, R1 = L-methyl (41%)
64, R1 = D-methyl (53%)
23, R1 = L-1-napthyl (91%)
3, R1 = L-methyl (76%)
5, R1 = D-methyl (52%)
7, R1 = L-1-napthyl (60%)
 
Reagents and Conditions: (a) Cbz-NH-CHR1-CO2H, HBTU, 4.2% DIPEA/DMF, microwave (25 
W, 75
o
C, 5 min); (b) 95% TFA, 2.5% TIPS, 2.5% water, microwave (20 W, 38
o
C, 18 min); (c) 
EDCI, DMAP, DMF/CH2Cl2, 25 
o
C, 18h; (d) NaBH4, CH2Cl2/EtOH/MEOH (5:3:2), 0 
o
C, 4 h; 
(e) DMP, CH2Cl2, 25 
o
C, 2 h. 
 
The tripeptidyl formamide aldehyde 4 and its ketoamide derivative 15 were synthesized 
according to the procedure outlined in Scheme 5. The Cbz-alanine 65 was converted into ester 66 
using Fischer esterification conditions. The ester 66 was converted to aldehyde 67 via reduction 
and re-oxidation using sodium borohydride and DMP respectively. 
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Scheme 5: Synthesis of Tripeptidyl Formamidyl Aldehyde 4 and Corresponding Ketoamide 
15. 
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Reagents and Conditions: (a) MeOH, H2SO4 (cat.), 100%; (b) NaBH4, CH2Cl2/EtOH/MEOH 
(5:3:2), 0 
o
C, 4 h; 100% (c) DMP, CH2Cl2, 25 
o
C, 2 h, 70%; (d) NaCNBH4, MeOH, 40%; (e) 
HCO2H/AcO2O, 93%; (f) NaOH, 1:1 dioxane/water, 96%; (g) glutamine surrogate-amine 53, 
EDCI, DMAP, DMF/CH2Cl2, 25 
o
C, 18h; 55%; (h) NaBH4, CH2Cl2/EtOH/MEOH (5:3:2), 0 
o
C, 
4 h; 100%; (i) DMP, CH2Cl2, 25 
o
C, 2 h, 65%; (j) isopropylisocyanide, AcOH, EtOAc, 25 
o
C, 18 
h; (k) K2CO3, MeOH/H2O (1:1), 25 
o
C, 3 h; (l) DMP, CH2Cl2, 25 
o
C, 2 h, yield 79% over three 
steps. 
 
Aldehyde 67 was condensed with alanine methylester 68 in the presence of sodium 
cyanoborohydride (reductive amination) to afford the coupled product 69. The secondary amine 
of 69 was formylated using a mixed anhydride 70 via premixing a solution of formic acid and 
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acetic anhydride and adding compound 69 to give compound 71. Basic hydrolysis of ester 71 
gave the acid 72 which was coupled to glutamine surrogate-amine 53 using EDCI and DMAP to 
furnish the ester 73. Reduction of the ester 73 gave an alcohol intermediate that was re-oxidized 
to the aldehyde 4 using DMP. The aldehyde 4 was converted into the ketoamide derivative 15 
using a 3 step procedure. Firstly, the aldehyde is treated with isopropylisocyanide to give an 
isopropylisocyanide adduct. Secondly, the isopropylisocyanide adduct was converted into a 
hydroxyamide form employing basic and aqueous reaction conditions. The hydroxyamide 
functionality was lastly oxidized to give the ketoamide 15 using DMP.     
The tripeptidyl aldehydes 7 - 11 and 24 - 31 were synthesized starting from the glutamine 
surrogate-amine 53 in a 5 step manor (Scheme 6). The glutamine surrogate-amine 53 is coupled 
with the P2 amino acid using EDCI and DMAP to form N-boc-dipeptides 74 - 78 in excellent 
yields. The boc protecting group was removed using 10% TFA in methylene chloride to give an 
amine intermediate which was immediately coupled with a Cbz protected P3 amino acid using 
EDCI and DMAP in methylene chloride to give tripeptidyl esters 23 and 80 - 91 in good to 
excellent yields. The esters were reduced and re-oxidized to their corresponding aldehydes using 
sodium borohydride and DMP respectively to give compounds 7 - 11 and 24 - 31 in good to 
excellent yields. The synthesis of compounds 24, 27 - 28, 30 - 32 and 25 - 36 that are captured in 
Schemes 5, 6, 7 and 10 have recently been reported.
42
  
The N-Cbz protected amino acids 86a - 91a were synthesized from commercially available 
amino acids as highlighted in Scheme 7. The amino acids have side chain (R2) was dissolved in 
1:1 dioxane/water and treated with 3 molar equivalents of sodium bicarbonate, followed by 1.2 
molar equivalents of benzylchloroformate. After 3 hours the reactions were worked up and the 
obtained solids were recrystallized from ether/hexane to yield the N-Cbz protected amino acids 
86a - 91a in 72 - 95 % yields.  
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Scheme 6: Synthesis of Tripeptidyl Aldehydes 7 - 11 and 24 - 31. 
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HCl 74, R1 = H (79%)
75, R1 = O-t-butyl (96%)
76, R1 = i-propyl (72%)
77, R1 = cyclohaxane (99%)
78, R1 = phenyl
R1
R1R1
23, R1 = H, R2 = L-1-napthyl (66%)
80, R1 = H, R2 = L-2-napthyl (87%)
81, R1 = H, R2 = L-biphenyl (95%)
82, R1 = H, R2 = E-N-boc-aminobutyl (95%)
83, R1 = O-t-butyl, R2 = L-1-napthyl (69%)
84, R1 = i-propyl, R2 = L-1-napthyl (72%)
85, R1 = cyclohexane, R2 = L-1-napthyl (74%)
86, R1 = phenyl, R2 = L-1-napthyl
87, R1 = i-propyl, R2 = D-1-napthyl (83%)
88, R1 = i-propyl, R2 = L-phenyl (87%)
89, R1 = i-propyl, R2 = L-1-methyl-1-O-t-butyl (43%)
90, R1 = i-propyl, R2 = L-2-napthyl (54%)
91, R1 = i-propyl, R2 = L-biphenyl (73%)
7, R1 = H, R2 = L-1-napthyl (72%)
8, R1 = H, R2 = L-2-napthyl (38%)
9, R1 = H, R2 = L-biphenyl (60%)
10, R1 = H, R2 = E-N-boc-aminobutyl (60%)
11, R1 = O-t-butyl, R2 = L-1-napthyl (45%)
24, R1 = i-propyl, R2 = L-1-napthyl (90%)
25, R1 = cyclohexane, R2 = L-1-napthyl (69%)
26, R1 = phenyl, R2 = L-1-napthyl
27, R1 = i-propyl, R2 = D-1-napthyl (93%)
28, R1 = i-propyl, R2 = L-phenyl (80%)
29, R1 = i-propyl, R2 = L-1-methyl-1-O-t-butyl (63%)
30, R1 = i-propyl, R2 = L-2-napthyl (93%)
31, R1 = i-propyl, R2 = L-biphenyl (79%)
 
Reagents and Conditions: (a)  Boc-NH-CHCH2R1-CO2H, EDCI, DMAP, DMF/CH2Cl2, 25 
o
C, 
18h; (b) 10% TFA/CH2Cl2, 25 
o
C, 4 h, yield 100%; (c) Cbz-NH-CHR2-CO2H, EDCI, DMAP, 
CH2Cl2, 25 
o
C, 18 h; (d) NaBH4, CH2Cl2/EtOH/MEOH (5:3:2), 0 
o
C, 4 h, 100%; (e) DMP, 
CH2Cl2, 25 
o
C, 2 h. 
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Scheme 7: Synthesis of Cbz Protected Amino Acids 86a - 91a. 
86a: R2 = L-1-napthyl (95%)
87a: R2 = D-1-napthyl (86%)
88a: R2 = L-phenyl (94%)
89a: R2 = L-1-methyl-1-O-t-butyl (91%)
90a: R2 = L-2-napthyl (72%)
91a: R2 = L-biphenyl (90%)
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NaHCO3
water/diozane, 
25oC, 3h
 
The biphenylalanine 91d was synthesized starting from commercially available N-Boc-4-bromo-
phenyl alanine 91b as shown in Scheme 8. The key step involved a Suzuki-Miyaura
53
 cross-
coupling reaction between N-Boc-4-bromo-phenylalanine 91b and phenylboronic acid to furnish 
N-Boc-biphenylalanine 91c (Scheme 8). The NMR spectral data for 91c compared favorably to 
literature values.
53
 Subsequent removal of the N-Boc protecting group provided biphenylalanine 
91d in an 86% overall yield from 91b.  
Scheme 8: Synthesis of Biphenylalanine 91d. 
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The ketoamides 13 - 14, 16 - 20 and 32 - 33 were synthesized using a three step procedure 
(Schemes 9 and 10). The aldehyde precursors are treated with isopropylisocyanide which gave 
an isopropylisocyanide adduct. This isopropylisocyanide adduct was converted into a 
hydroxyamide by employing basic, aqueous reaction conditions. The hydroxyamide functionality 
was then oxidized by DMP to give the ketoamides 13 - 14, 16 - 20 and 32 - 33 in good to 
excellent yields.     
Scheme 9: Synthesis of Ketoamide 13. 
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Reagents and Conditions: (a) AcOH, EtOAc, 25 
o
C, 18 h; (b) K2CO3, MeOH/H2O (1:1), 25 
o
C, 3 
h; (c) DMP, CH2Cl2, 25 
o
C, 2 h, yield 46% over three steps. 
 
Scheme 10: Synthesis of Ketoamides 14, 16-20 and 32-33. 
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14, R1 = H, R2 = L-methyl, R3 = i-propyl (64%)
16, R1 = H, R2 = D-methyl, R3 = i-propyl (47%)
17, R1 = H, R2 = L-1-napthyl, R3 = i-propyl (81%)
18, R1 = H, R2 = L-2-napthyl, R3 = i-propyl (94%)
19, R1 = H, R2 = E-N-boc-aminobutyl, R3 = i-propyl (94%)
20, R1 = O-t-butyl, R2 = L-1-napthyl, R3 = i-propyl (53%)
32, R1 = i-propyl, R2 = L-1-napthyl, R3 = i-propyl (79%)
33, R1 = i-propyl, R2 = L-1-napthyl, R3 = t-butyl (54%)
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Reagents and Conditions: (a) AcOH, EtOAc, 25 
o
C, 18 h; (b) K2CO3, MeOH/H2O (1:1), 25 
o
C, 3 
h; (c) DMP, CH2Cl2, 25 
o
C, 2 h. 
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The ketoamide 34 is prepared by treating aldehyde 24 with acetone cyanohydrin and 
triethylamine in methylene chloride followed by oxidation of the cyano adduct to form a 
hydroxyl amide intermediate, which was immediately oxidized by DMP to form the ketoamide 
34 in a 34% overall yield (Scheme 11).  
Scheme 11: Synthesis of Ketoamide 34. 
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Reagents and Conditions: (a) Acetone cyanohydrin, NEt3, CH2Cl2, 25
o
C, 15 h; (b) 30% H2O2, 
LiOH,0
o
C, 3 h; (c) DMP, CH2Cl2, 25
o
C, 2 h. 
 
The tripeptidyl amides 21 and 22 were synthesized using an acyl substitution reaction whereby 
ester 23 was treated with isopropyl amine or cyclopropyl amine in 50
o
C methanol respectively 
(Scheme 12).  
Scheme 12: Synthesis of Tripeptidyl Amides 21-22. 
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Reagents and Conditions: (a) H2N-R1, MeOH, 50
o
C, 48h. 
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The sodiumbisulfite adduct 35 was prepared by treating the aldehyde 24 with sodium bisulfite in 
a mixture of ethyl acetate, ethanol and water at 40
o
C with a 100% yield (Scheme 13).  
Scheme 13: Synthesis of Sodiumbisulfite Adduct 35. 
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Reagents and Conditions: (a) sodium bisulfite, EtOAc/EtOH/H2O (4:2:1), 40
o
C, 2 h. 
 
The dialkylphosphonates 36 - 37 and 42 - 43 were made by treating the aldehyde precursor with 
a dialkyl phosphite and diisopropylethylamine in methylene chloride (Scheme 14). The dialkyl 
phosphite adds to either face of the aldehyde and therefore two diastereomers of 36 - 37 and 42 - 
43 are obtained.   
 
Scheme 14: Synthesis of Dialkylphosphonates 36 - 37 and 42 - 43. 
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36, R1 = i-propyl, R2 = L-1-napthyl, R3 = ethyl (54%)
37, R1 = i-propyl, R2 = L-1-napthyl, R3 = i-propyl (73%)
42, R1 = cyclohexane, R2 = L-1-napthyl, R3 = methyl (64%)
43, R1 = cyclohexane, R2 = L-1-napthyl, R3 = ethyl (90%)
a
 
Reagents and Conditions: (a) Diisopropylethylamine, CH2Cl2, 25 
o
C, 18 h. 
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The nitrile 38 was made by treating the aldehyde 24 to a mixture (diacetoxyiodo)benzene, 
sodium dodecylsulfate and ammonium acetate in water at 70
o
C (Scheme 15). After workup and 
column chromatography over silica gel, the nitrile 38 was obtained in 61% yield.  
Scheme 15: Synthesis of Tripeptidyl-nitrile 38. 
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Reagents and Conditions: (a) PhI(OAc)2, SDS, NH4OAc, water, 70
o
C, 9 h. 
In order to synthesize thiazole warhead 39, a series of reactions were carried out as shown in 
Scheme 16.  
Scheme 16: Synthesis of Tripeptidyl-thiozole 39. 
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Reagents and Conditions: (a) n-Buli, thiazole, THF, -78
o
C, 3h, 36%; (b) DMP, CH2Cl2, 25
o
C, 2 
h, 80%; (c) 10% TFA/CH2Cl2, 25 
o
C, 4 h, yield 100%; (d) Boc-NH-Leu-CO2H, EDCI, DMAP, 
CH2Cl2, 25 
o
C, 18 h, 55%; (e) 10% TFA/CH2Cl2, 25 
o
C, 4 h, yield 100%; (f) Cbz-NH-1-
napthylalanine-CO2H, EDCI, DMAP, CH2Cl2, 25 
o
C, 18 h, 37%. 
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The thiazole methine proton was removed with n-butyllithium and the thiazole anion was treated 
with aldehyde 53a to afford the alcohol 92 as a mixture of two diastereomers. Oxidation of the 
alcohol 92 with DMP provided ketone 93 in excellent yield. The N-boc protecting group of 93 
was quantitatively removed using 10% TFA in methylene chloride and the resulting amine was 
coupled with the P2 leucine to give compound 94 in a 55% yield. The N-boc protecting group of 
94 was similarly removed using 10% TFA in methylene chloride and the resulting amine was 
coupled with the P3 Cbz-N-1-napthylalanine to provide the tripeptidyl thiazole 39 in 37% yield.  
The epoxyketone 40 and 41 were synthesized according to Scheme 17.  An organometallic 
intermediated, formed from the combination of 2-bromopropene and nickel dichloride, was 
added to the aldehyde functionality of 53a to form alcohol 95 as a mixture of two diastereomers. 
The alkene of 95 was converted to epoxide functionality using m-CPBA after which the alcohol 
was oxidized to ketone to furnish two stereoisomers of epoxyketone 96 which were separable by 
silica gel column chromatography. The more polar isomer is denoted 96-mp and the less polar 
isomer is denoted 96-lp and the absolute stereo configuration of each was not determined. The 
two isomers of 96 were treated separately with 10% TFA in methylene chloride to remove the 
boc protecting group followed by EDCI mediated coupling with N-Boc-leucine to afford the 
dipeptides 97-lp and 97-mp. These dipeptides were again separately treated with 10% TFA in 
methylene chloride to remove the boc protecting group followed by EDCI mediated coupling 
with N-Cbz-1-napthylalanine to afford the tripeptides 40 and 41. 
 In order to replace the N-terminal cap with other groups the ester 84 is a convenient starting 
point since the N-terminal Cbz cap can easily be removed by palladium (carbon) and hydrogen 
gas (Scheme 18). This provided the amine 98 in quantitative yield after 3 hours. The alternative 
N-terminal caps were installed by an EDCI mediated coupling of the appropriate carboxylic acid 
to form the amide bond in compounds 99 and 100. The ester groups of 99 and 100 were 
separately converted smoothly into their corresponding aldehydes 44 and 45 by a 
reduction/reoxidation technique using sodium borohydride and DMP respectively. 
 
34 
 
Scheme 17: Synthesis of Tripeptidyl-Epoxyketones 40 and 41. 
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Reagents and Conditions: (a) 2-bromopropene, NiCl2, DMF, 25
o
C, 1 h; (b) m-CPBA, NaHCO3, 
CH2Cl2, 0
o
C, 2h; (c) DMP, CH2Cl2, 25
o
C, 2 h, 55% (2 steps); (d) 10% TFA/CH2Cl2, 25
o
C, 4 h, 
yield 100%; (e) Boc-NH-Leu-CO2H, EDCI, DMAP, CH2Cl2, 25
o
C, 18 h, 51%; (f) 10% 
TFA/CH2Cl2, 25
o
C, 4 h, yield 100%; (g) Cbz-NH-1-napthylalanine-CO2H, EDCI, DMAP, 
CH2Cl2, 25
o
C, 18 h, 72%.    
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Scheme 18: Synthesis of Tripeptides 44 and 45 with Different N-Terminal Caps. 
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Reagents and Conditions: (a) Pd(C), H2(g), MeOH, 25
o
C, 3 h, 100%; (b) R-CO2H, EDCI, 
DMAP, CH2Cl2, 25
o
C, 18 h; (c) NaBH4, CH2Cl2/EtOH/MEOH (5:3:2), 0
o
C, 4 h, 100%; (e) 
DMP, CH2Cl2, 25
o
C, 2 h. 
 
In order to synthesize compound 44 the acid precursor 104 was required to be synthesized as 
shown in Scheme 19. Commercially obtained AMC (101) was alkylated using 
methylbromoacetate in refluxing acetonitrile followed by methylation of the amine with methyl 
iodide and potassium carbonate in refluxing acetonitrile. Lastly, the ester was hydrolyzed using 
sodium hydroxide in dioxane/water to provide the acid 104. 
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Scheme 19: Synthesis of AMC Cap 104. 
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Reagents and Conditions: (a) methylbromoacetate, NaI, DIPEA, CH3CN, 82
o
C, 18 h, 85%; (b) 
MeI, K2CO3, 82
o
C, 18 h, 24%; (c) NaOH, dioxane/water, 25
o
C, 1 h, 100%. 
 
The synthesis of the macrocyclic NPI candidates 47 and 48 was carried out according to Scheme 
20. The crude diene 105 was obtained from Groutas group and was purified by silica gel column 
chromatography before treatment with Grubbs second generation catalyst, to form ring-closing 
metathesis product 106 in good yield. The double bond that resulted was reduced with hydrogen 
and palladium (carbon) to form compound 107 in quantitative yield. Compound 47 was obtained 
by removing the N-boc protecting group of 107 with 10% TFA in methylene chloride and 
replacing it with Cbz using benzylchloroformate in methylene chloride and dioxane. The 
aldehyde 48 was smoothly obtained from 47 using the standard reduction/re-oxidation technique 
with sodium borohydride and DMP respectively.   
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Scheme 20: Synthesis of Macrocyclic Tripeptidyl Ester 47 and Aldehyde 48. 
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Reagents and Conditions: (a) Grubbs catalyst (2
nd
 gen), CH2Cl2, 40
o
C, 48 h, 57%; (b) Pd(C), 
H2(g), MeOH, 25
o
C, 20 h, 100%; (c) 10% TFA/CH2Cl2, 25 
o
C, 4 h, yield 100%; (d) Cbz-Cl, 
DMAP, CH2Cl2/dioxane (4:1), 25
o
C, 2 h, 72%; (e) NaBH4, CH2Cl2/EtOH/MEOH (5:3:2), 0
o
C, 4 
h, 100%; (f) DMP, CH2Cl2, 25
o
C, 2 h, 92%. 
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I.IV. Conclusion 
 
Noroviruses fall into the family of Caliciviridae viruses and are non-enveloped, single stranded 
RNA viruses that are the leading cause of severe gastroenteritis worldwide. Currently no drug or 
vaccine is available for norovirus treatment or prophylaxis. We describe herein a novel class of 
tripeptidyl anti-noroviral compounds which strongly inhibit NV3CL
pro
 in enzyme and cell based 
assays. The most active compound in enzyme and cell based assays was compound 24 (IC50 0.14 
µM; EC50 0.04 µM). This compound has an aldehyde warhead, a P1 glutamine surrogate, a P2 
leucine, a P3 L-1-napthylalanine and an N-terminal Cbz cap. The corresponding bisulfite adduct, 
compound 35 showed comparable activity to 24 in enzyme and cell based assay (IC50 0.24 µM; 
EC50 0.04 µM). The corresponding ketoamide warhead derivative also showed good activity 
with an IC50 of 2.6 µM and EC50 of 4.2 µM. Compounds 25, 28, 29, 30, 31 and 46 also showed 
excellent and very similar EC50 values with 24. Compound 24 and its ketoamide derivative 32 
were screened against other viral strains in the CV, PV and coronaviridae (CoV) viral families 
using enzyme and cell based assays. The results were encouraging as both 24 and 32 were found 
to be strongly active in human rhino virus (HRV) and SARS viral assays. This suggests 
advantageous broad spectrum anti-viral activity for these compounds. The compounds showed 
minimal cell cytotoxicity. An x-ray crystal structure was obtained for compound 24 with SARS 
protease enzyme and proves that 24 binds with and targets the active site. Further SAR studies 
are ongoing to improve activity and bioavailability for the lead compounds.   
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II. Facial Surface Modification of Graphene Oxides with tert-Butyl 
Ester and Carboxylic Acid Functionality and Its Study in a 
Bioelectronic Sensor Device to Detect Noroviral RNA. 
 
II.I. Introduction 
 
Graphene oxide (GO) is a newly discovered material that has a similar two dimensional atomic 
structure to graphene, except, GO has randomly distributed aromatic regions and is highly 
decorated with oxygen containing groups such as hydroxyl, epoxide and carboxylic acid (Figure 
16).
54
   
Figure 16: Structures of Graphene and Graphene Oxide 
 
GO is prepared using strong oxidizing agents in acidic media
55
 (e.g. Hummers method),
56
 
treatment with ozone
57
 or chemical/thermal exfoliation of graphite oxide.
58
 The oxidation 
process removes many of the sp
2
 hybridized carbons and replaces them with sp
3
 hybridized 
carbons with bonds to oxygen. The result is that GO exhibits lower electrical conductivities than 
its graphene precursor. A study by Jeong et al. showed that the band gap of GO is dependent on 
the degree of oxidation (oxygen-to-carbon ratio) and had values ranging from 1.7 to 2.4 eV.
59
  
The band gap values reported by Jeong et al. were extracted from the UV–visible diffuse 
reflection spectroscopy data recorded at room temperate. A study by Huang et al. showed that 
the band gap of GO increases with increasing oxygen-to-carbon ratios.
60
 The band gap is the 
energy difference (in eV) between an outer shell ground state valence electron and the bottom of 
the conduction band. Electrons in the valence shell are immobile whereas electrons excited to a 
40 
 
conduction band are free to move around the solid and be mobile charge carriers. The size of the 
band gap is important because it may determine whether the solid material will behave as a 
conductor, semiconductor or insulator. Usually when the band gap energy is greater than 3 eV an 
insulator exists. Since GO has been found to have band gap energies from around 1.7 to 2.4 eV 
vide supra, they display semiconducting electrical properties.   
GO has attracted a lot of interest due to its semiconductor properties, high intrinsic mobility,
61
 
good water dispersibility, high mechanical strength, large theoretical specific surface area,
61
 high 
Young’s modulus,61 low cell toxicity,62 fluorescence quenching ability63 and facile surface 
modification.
64
 Reports of GO functionalization using the carboxyl groups of GO with PEG,
65
 
chitosan
66, 67
 ferrocene,
68
 imidazolium fragments,
69
 peptides,
70
 triphenylamine-based polymers
71
 
and folic acid
72
 have demonstrated that chemical modification of GO is possible. Reports have 
suggested that the PEG and chitosan modified GO could have use in drug delivery applications 
as they can be internalized by cells and with low cellular toxicities.
62
 Functionalization of GO at 
the sp
2 
hybridized surface has also been demonstrated using carbethoxycarbene under microwave 
irradiation,
73
 photo-initiated radical polymerization with 2-chloro-2-methyl-1-phenyl-1-
propanone
54
 and reactions of diazo-benzoic acid with reduced GOs.
74
 Due to their extraordinary 
chemical and physical properties, GO and its graphene precursor are finding their full potentials 
in important fields such as biomedical, bioanalytical, nanoelectronics, materials science, energy 
technology and catalysis.
64, 75-77
   
Most of the GO modifications have made use of the epoxy
73
 and carboxylic groups
73
 and thus 
little work describing functionalization of GO using the surface hydroxyl groups has been done. 
Our brief work in this area has involved the synthesis and characterization of a t-butyl ester and 
carboxylic acid functionalized GO and probed its potential for application in a biosensor devise. 
Some ground work was also done in synthesizing one sided DNA functionalized GO using a 
solid phase synthesis.  
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II.II. Synthesis and Characterization of t-Butylester and Carboxylic acid 
Functionalized Graphene Oxide 
 
The first requirement for such a project was a synthetic route to access good quality, large, single 
layered GO sheets. The synthetic method that was followed was similar to modified Hummers 
method
56
 except the graphite was pre-expanded using a microwave reactor before any oxidative 
treatments (Scheme 21).  The pre-expansion step proved to be necessary to increase the overall 
yield of GO (~60%) probably because it helps separate the graphite layers allowing for easier 
access of oxidizers and therefore more effective oxidation. The expanded graphite is 
subsequently treated with P2O5 and K2S2O8 in HCl at 85
o
C for 4 hours which causes pre-
oxidation of the graphite to graphitic oxide. The graphitic oxide is then oxidized to graphene 
oxide using KMnO4 in H2SO4 at 40
o
C for 2 hours which oxidizes and exfoliates the graphitic 
oxide into thin sheets of GO. A mixture of suspended GO sheets and insoluble inorganic metal 
compounds is then treated with H2O2 which helps solubilize any metal precipitates. After 
standing at room temperature for 2 days the GO settles to the bottom and can be recovered by 
carefully decanting the supernatant. The GO residue is washed with dilute HCl, dialyzed and 
lyophilized to provide GO 108 as a light brown fluffy solid.   
 
Scheme 21: Synthesis of Graphene Oxide using a Modified Hummers Method. 
OH
OH
O
HO
O
OH
1. Microwave (30 W,  4 min)
2. P2O5, K2S2O8, HCl, 85
oC, 4 h
3. KMnO4, H2SO4, 40
oC, 2 h
4. 30% H2O2, 0
oC
Graphite
OH
O
108  
The FTIR and Raman spectra obtained for the GO compares favorably to literature values. The 
FTIR spectrum of GO has a broad and strong absorption in the region of 3340 cm
-1
 which 
corresponds to O-H stretching vibrations of hydroxyl and carboxyl functionalities. There are also 
prominent absorption bands at 1737 cm
-1
 and 1631 cm
-1
  that result from C=C stretching 
vibrations of the carbon framework that likely contains isolated, conjugated and aromatic C=C 
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functionalities. A strong absorption at 1076 cm
-1
 could be due to C-O stretch vibrations as the 
surface of GO is decorated with many hydroxyl and epoxy groups.  
The Raman spectrum obtained for GO 108 did contain the expected D, G and 2D (also called G’) 
bands that are characteristic for GO (Figure 17). The 2D band is designated “2D” since its 
wavenumber value is approximately double to that of the D band value.
78
 Some prefer to call the 
2D band the G’ band to avoid confusion with the term “two dimensional” (also called 2D).78  
Figure 17: Raman Spectrum of Synthesized GO 108. 
 
The G band resonance corresponds to the first-order scattering of the E2g phonons
79
 and is 
showing the in-plane vibrations of the carbon lattice.
80
 The presence of a D-band is due to 
defects in the GO sheets and higher amount of “edges” as the sheets get smaller.80 The D-band 
does not appear in pristine graphene.
81
 The 2D band is due to second-order zone boundary 
phonons.
81
 The G band in our synthesized GO resonates at 1593 cm
-1
 which is slightly blue field 
shifted when compared to the G band of the graphite starting material (1581 cm
-1
). These values 
were exactly comparable to a literature report that showed the G band to shift from 1581 cm
-1 
in 
OH
OH
O
HO
O
OH
OH
O
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graphite to 1593 cm
-1 
in GO.
80
 The reason for this blue field shift has been attributed to the 
presence of more isolated C=C double bonds in GO which have resonance at slightly higher 
frequencies.
80
 Other observations that were consistent with the literature was the presence of a 
broader G band and a more prominent D band in the Raman spectrum for GO when compared 
with the Raman spectrum of the graphite starting material.
80
 This is attributed to the fact that GO 
has a higher degree of structural defects when compared with graphite or pristine graphene. The 
D-band/G-band intensity ratio, I(D)/I(G), was found to be 0.85.  
The GO 108 was found to exist as mostly single layered sheets as seen by the AFM image 
(Figure 18) which shows the GO thickness to be 1.57 nm.   
Figure 18: AFM image of GO 108 Showing Cross Sectional Height. 
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The synthesis of a t-butyl ester functionalized GO 109 was carried out according to Scheme 22. 
The GO 108 was suspended in distilled DMF and treated with NaH followed by t-butyl-
bromoacetate. The NaH deprotonated the hydroxyl group protons and the resulting alkoxide ions 
underwent SN2 substitution reaction with t-butyl-bromoacetate to form 109.  
 
Scheme 22: Synthesis of t-Butyl Ester Functionalized Graphene Oxide 109. 
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1. NaH
2. BrCH2CO2-t-Bu
OH O
DMF
O
O
108 109  
The reaction was monitored by NMR and FTIR to probe for reaction completeness. The reaction 
was sampled for any un-reacted t-butyl-bromoacetate after 19 and 48 hours by removing 108 µL 
of the reaction solution, spiking it with 10 µmol of an internal standard (phenyl acetic acid) and 
recording a proton NMR spectrum in deuterated chloroform. The theoretical concentration of t-
butyl-bromoacetate inside the solvent before any chemical reaction was calculated to be 94 mM 
and so in the event that no reaction takes place, 10 µmol of t-butyl-bromoacetate should be 
present inside the 108 µL sampled aliquot. When integrating the methylene proton signals at 
3.77 ppm and 3.64 ppm, which correspond to t-butyl-bromoacetate and phenyl acetic acid 
standard respectively, a ratio of 1:6 was found after 19 hours. This showed that after 19 hours 
only 17% of the t-butyl-bromoacetate remained and hence 83% has undergone chemical 
reaction. Since the proton NMR spectrum of the crude reaction did not show signs of significant 
decomposition of t-butyl-bromoacetate it was assumed that the t-butyl-bromoacetate had coupled 
with the GO. The reaction was again sampled after 48 hours and the ratio of the methylene 
proton signals at 3.77 ppm and 3.64 ppm changed to 1:7 respectively suggesting that after 48 
hours only 14% of the original t-butyl-bromoacetate remained and hence 87% reaction 
completion. The additional 29 hours of reaction time only depreciated the amount of remaining t-
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butyl-bromoacetate from 17% to 14% and so it was concluded that the reaction had reached near 
completion. Moreover, a small portion of the reaction mixture was centrifuged at 30000 rpm for 
5 min to isolate GO material from the reaction. After washing the GO sediment with ether (x1) 
and water (x3) the sample was lyophilized and its Raman and FTIR spectrum were recorded 
(Figure 19 and 20). The Raman spectrum for GO-ester 109 (Figure 19) showed a prominent D-
band and G-band at 1345 cm
-1
 and 1589 cm
-1
 respectively with a I(D)/I(G) ratio of 0.96. The 
higher I(D)/I(G) ratio in GO-ester 109 results from a more intense D-band and suggests a higher 
level of disorder in the GO lattice due to chemical functionalization. A small 2D band at 2435 
cm
-1
 in the Raman spectrum was also observed.    
Figure 19: Raman Spectrum of t-Butylester Functionalized Graphene Oxide 109 
 
 
The FTIR spectrum is overlaid with the original GO spectrum for comparison (Figure 20). It is 
evident that many structural features have changed suggesting successful functionalization of the 
surface of GO with t-butylester. Firstly, the strong O-H stretching signal at 3359 cm
-1
 in the GO 
spectrum (top) has reduced in intensity (bottom) showing loss of hydroxyl functionality. The 
bottom spectrum shows the presence of sp
3
 C-H stretching vibrations at 2977 and 2931 cm
-1
 
which should be coming from methylene and methyl C-H bonds contained in the t-butylacetate 
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moiety. The bottom spectrum shows a strong absorption at 1722 cm
-1
 which corresponds to a 
carbonyl (C=O) stretch suggesting the t-butylester group is attached and a strong absorption at 
1141 cm
-1
 which corresponds to a C-O (O-t-butyl) stretching vibration.  
Figure 20: Overlaid FTIR Spectra of GO 108 and t-Butyl Ester Functionalized GO 109. 
 
 
To further validate that these reaction conditions will attach a t-butylacetate functionality to the 
GO surface, a 
13
C labeled t-butylbromoacetate 112 was synthesized and used in the coupling 
reaction with GO. The synthesis of 112 is shown in Scheme 23, and started from commercially 
available 
13
C-acetic acid 110. Compound 110 was first converted into a mixed anhydride 
intermediate using TFA anhydride followed by α-bromination using one equivalent of bromine 
liquid to yield 
13
C labeled bromoacetic acid 111 in quantitative yield. The carboxylic acid moiety 
of 111 was alkylated using isobutylene in dichloromethane to yield the t-butyl ester 112 in 63% 
yield.  
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Scheme 23: Synthesis of 
13
C labeled t-Butyl-bromoacetate 112. 
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With the 
13
C labeled t-butylbromoacetate 112 in hand, the GO alkylation reaction was repeated 
as shown is Scheme 24, employing the same reaction conditions used to previously make 
compound 109. The NaH deprotonated the hydroxyl group protons of GO and the resulting 
alkoxide ions underwent SN2 substitution reaction with 
13
C-labeled t-butyl-bromoacetate to form 
113.  
Scheme 24: Synthesis of 
13
C-labeled t-Butyl Ester Functionalized Graphene Oxide 113. 
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The reaction was similarly monitored by proton NMR using an internal standard vide supra and 
the reaction was deemed complete after 6 days. The reaction was worked up by high speed 
centrifugation to remove un-reacted organic material contained in the supernatant. The 
functionalized GO sediment was washed vigorously with ether (x1) and deionized water (x3) 
using centrifugation and careful removal of the supernatant layer after each wash cycle. The 
washed compound 113 was suspended in deionized water and lyophilized to give 113 as a light 
brown fluffy solid. FTIR analysis of compound 113 showed a reduction in the O-H stretching 
absorbance and the appearance of a strong carbonyl C=O stretching absorbance at 1647 cm
-1
 
suggesting successful alkylation of GO.  Most interesting was the solid state carbon NMR 
spectra for GO 108 and the 
13
C labeled GO 113 which are overlaid in Figure 21.  
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Figure 21: Solid State NMR Spectra for GO 108 and 
13
C-t-Butyl ester Functionalized GO 
113. 
 
The top carbon NMR spectrum in Figure 21 shows the GO starting material, and was recorded 
with 6144 scans. The broad peaks at 128 ppm and 66 ppm arise due to the presence of C=C and 
C-O carbons respectively. The bottom carbon NMR spectrum was obtained for compound 113 
after 6144 scans, and clearly shows the presence of a dominant peak at 166 ppm. This was 
assigned as the 
13
C-labeled carbonyl (*C=O) carbon, and helps to support a successful alkylation 
reaction with t-butyl-bromoacetate. To our knowledge this is the first report of a 
13
C-labeled GO 
where the 
13
C label is grafted onto the GO surface through chemical functionalization.  
Previously, in 2008, a 
13
C-labeled GO with carbon backbone labeling was reported by Cai et 
al..
82
 Their 
13
C-labeled GO was synthesized from 
13
C-graphene. The 
13
C-labeled graphene was 
synthesized by a thermal chemical vapor deposition (CVD) method incorporating 
13
C-methane 
gas.
82
 Cai et al. analyzed their 
13
C-labeled GO with solid state NMR spectroscopy which clearly 
showed strong resonance belonging to the sp
2
 hybridized carbon lattice (C=C) as well as sp
3
 
hybridized C-O functionalities.
82
  
The t-butyl group of 109 was hydrolyzed to carboxylic acid 114 by employing 10% TFA in 
water (Scheme 25). The reaction was monitored by mass spectrometry and FTIR.  
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Scheme 25: Synthesis of Carboxylic Acid Functionalized Graphene Oxide 114. 
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During exposure of the t-butyl ester 109 with TFA, it is expected that the carbonyl oxygen will 
become protonated which catalyses the cleavage of the ester C-O bond giving rise to the 
carboxylic acid and a tertiary carbocation (t-butyl). Since the reaction is carried out under 
aqueous conditions, the tertiary carbocation should be scavenged rapidly by a water molecule to 
form t-butanol. The production of t-butanol coming from the TFA hydrolysis reaction was 
therefore monitored by mass spectrometery equipped with electrospray ionization (ESI), and the 
results are shown in Figure 22.   
Firstly, a dilute solution (~50 µM) of authentic t-butanol was prepared and analyzed by mass 
spectrometry using ESI in the positive mode with a declustering potential of 130 mV. This 
showed that t-butanol can be detected under these mass spec conditions because a prominent 
peak for t-butanol at m/z = 97.2 (M+Na)
+
 was observed. A background mass spectrum was also 
taken by infusing 100% methanol into the mass spectrometer which proved that no peaks in the 
vicinity of 97.2 are coming from the background. 
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Figure 22: Monitoring of the Intensity of t-Butanol (M+Na)
+
 Peak in Mass Spectrum over 
Time During TFA Hydrolysis of 109 to form compound 114. 
 
The TFA hydrolysis reaction was sampled for the presence of t-butanol after 4, 8 and 23 hours 
by infusing exactly 50 µL of the reaction solution into the mass spectrometer after applying a 
1000 fold dilution in clean methanol and filtration through a 0.2 micron syringe tip filter. In each 
case, data was obtained by averaging 54 scans and the intensity (counts per second) for the 
(M+Na)
+
 at m/z 97.2 was recorded and plotted against time. Figure 20 shows a plot of (M+Na)
+
 
peak intensity versus time and shows that the concentration of t-butanol increased during the 
course of the reaction and followed a negative exponential increase (R
2
=1) reaching a maximum 
after 23 hours. This result confirmed that t-butanol is generated from the TFA hydrolysis 
reaction and that the GO-ester 109 is successfully converted into GO-carboxylic acid 114.             
The black suspended GO material was monitored by FTIR during the course of the TFA 
hydrolysis reaction over 24 hours, and the results are shown in Figure 23 as stacked FTIR 
spectra.  
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Figure 23: TFA hydrolysis of t-Butylester 109 to Carboxylic acid 114. 
 
Over the course of 24 hours the O-H stretching absorption at 3359 cm
-1
 increased in intensity and 
took on a broader shape, suggesting the formation of carboxylic acid. The sp
3
 C-H stretching 
vibrations at 2977 and 2931 cm
-1
 diminished in intensity and shifted slightly to 2923 and 2851 
cm
-1
. The strong carbonyl C=O stretch absorption at 1722 cm
-1
 gradually disappeared and a new 
strong absorption at 1674 cm
-1
 appeared, which may be the result of overlapping C=O 
(carboxylic acid) and C=C functional group absorptions. The strong absorption at 1142 cm
-1
 due 
to the C-O (O-t-butyl) stretching vibration in 109 diminished and new peaks at 1200 and 1145 
cm
-1
 were recorded. The strong absorption at ~2400 cm
-1
 seen in the spectrum of TFA 10 hour is 
due to carbon dioxide that was not perfectly subtracted from the recorded background. The 
results from the mass spec and FTIR analysis concludes that the TFA hydrolysis reaction was 
successful at converting the t-butylester functionalized GO 109 into the carboxylic acid 
functionalized GO 114.  Figure 24 shows the overlay FTIR spectra of only t-butylester 109 and 
carboxylic acid functionalized GO 114 which more clearly shows the spectral differences.   
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Figure 24: Overlaid FTIR Spectra of t-Butylester 109 (Top) and carboxylic acid 114 
(Bottom) Functionalized GO. 
 
 
The Raman spectrum for GO-carboxylic acid 114 (Figure 25) was obtained and showed a D 
band at 1350 cm
-1
, a G band at 1591 cm
-1
 and a 2D band at 2436 cm
-1
. The ratio of the I(D)/I(G) 
was calculated to be 0.78 which is lower than the value observed for GO-ester 109. The lower 
I(D)/I(G) ratio was due to a decrease in intensity for the disorder band (D-band) suggesting that 
the GO showed “self-healing” properties (gain in order), a phenomenon that has been reported to 
occur in GO.
80
  The I(D)/I(G) ratio for GO-acid 114 was similar to the value seen for GO 108.  
The GO-carboxylic acid 114 was analyzed by AFM which proved that the material consisted 
mostly of single layer sheets of ~1.5 nm thick. 
To further prove that the TFA hydrolysis reaction removes the t-butylester groups to afford 
carboxylic acid functionalized GO, the 
13
C-labeled t-butylester functionalized GO 113 was 
subjected to analogous hydrolysis reaction conditions employing 10% TFA in water for 48 hours 
(Scheme 26). After the reaction was complete (seen by FTIR analysis) the reaction was worked 
up and the 
13
C-labeled carboxylic acid GO 115 was analyzed by solid state carbon NMR 
spectroscopy (Figure 27).     
 
53 
 
Figure 25: Raman Spectrum of Carboxylic Acid Functionalized Graphene Oxide 114 
 
 
Scheme 26: Synthesis of 
13
C labeled Carboxylic Acid Functionalized Graphene Oxide 115. 
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The solid state carbon NMR spectrum of the 
13
C-labeled carboxylic acid functionalized GO 115 
after 4096 scans is shown in Figure 26 (bottom spectrum). The presence of a dominant peak at 
171 ppm was clearly observed, and corresponds to the 
13
C-labeled carbonyl carbon. This peak 
was downfield shifted from 166 ppm (ester) to 171 ppm (acid) which is expected since the acid 
is now lacking the electron donating t-butyl group, and therefore experiences less shielding via 
inductive effects. 
Figure 26: Overlay of Solid State NMR Spectra of GO (top), 
13
C-t-Butylester (middle) and 
13
C-Carboxylic Acid (bottom) Functionalized Graphene Oxides. 
 
 
The bottom spectrum still contains peaks at 128 ppm and 66 ppm and confirms that the C=C and 
C-O functionality of the GO framework remained intact during exposure to TFA and long 
reaction time.  
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Figure 27 shows microscope images of representative samples of GO, t-butylester functionalized 
GO 109 and carboxylic acid functionalized GO 114.  
Figure 27: Stage Microscope Images of GOs. A) GO 108, scale bar = 10 µm; B) GO, scale 
bar = 100 µm ; C) t-Butylester functionalized GO 109, scale bar = 10 µm; D) t-Butylester 
functionalized GO 109, scale bar = 50 µm ; E) Carboxylic Acid functionalized GO 114, 
scale bar = 10 µm ; F) Carboxylic Acid functionalized GO 114, scale bar = 100 µm.   
 
The images labeled A show the GO at 1000x magnification and the scale bar is 10 µm. The 
image B shows the GO at 100x magnification and the scale bar is 100 µm. It can be seen that 
large, flat and thin GO sheets were obtained (~ 5 - 200 µm in diameter) and mostly are one or 
two layers thick. Images C and D show the t-Butylester functionalized GO 109 at 1000x and 
100x magnification respectively. It was noticed that after the introduction of the t-butyl ester 
function the GO sheets on average had reduced in size to about 1 - 80 µm in diameter and 
contained more wrinkles and creases. This trend continued with the synthesis of carboxylic acid 
functionalized GO 114 which showed further decreases in GO sheet sizes (~1 - 60 µm) and 
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reduction in the surface quality of GO (Images E and F). The decrease in GO sheet size and 
reduced GO surface quality is probably attributed to factors such as chemical modification of GO 
surface, prolonged reaction times spent in solution and lyophilization during workup. 
Nevertheless, FTIR, solid state carbon NMR and Raman spectroscopy show that the GO 
framework is still intact and that GO has be functionalized with additional surface carboxyl 
groups.     
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II.III. Solid State Synthesis of DNA Functionalized Graphene Oxide 
 
With the GO-carboxylic acid 114 in hand we attempted a novel solid state synthesis with the 
intention of selectively functionalizing only one side of GO sheet with an oligonucleotide (19 
mer; 5’-AmMC12-AGC CAG ATT GCG ATC GCC C). The outline for this endeavor is shown 
below in Scheme 27. The reason for synthesizing an oligonucleotide functionalized GO is 
because it may find use in a biosensor electronic devise. GO has semi-conductive properties and 
a grafted oligonucleotide could serve as a probe sequence to detect complementary target 
DNA/RNA sequences through hybridization processes that may be detected electronically 
through changes in current. Stemming from our experience using 2-chlorotrityl polymer resins, 
we decided to use this resin in the solid state synthesis of one sided oligonucleotide 
functionalized GO 118. The first step involved attachment of GO-carboxylic acid 114 to the 2-
chlorotrityl resin (Scheme 27). The glassware used for the reaction was firstly deactivated using 
20% trimethylsilyl chloride in chloroform to block any free hydroxyl groups on the surface of 
the glass. After washing with distilled chloroform and drying, the argon flushed reaction vessel 
was charged with 1 g of 2-chlorotrityl resin and distilled dichloromethane. After resin swell (~30 
min) the 10 mg GO-carboxylic acid 114 was added followed by diisopropylethylamine. The 
mixture was shaken in a shaker for 2 days during which time the GO-carboxylic acid 114 
became attached to the resin to form 116. The resin was washed with dichloromethane to remove 
any excess suspended GO-carboxylic acid and the GO coated resin 116 was functionalized with 
oligonucleotide using HATU in DMF to form 117. Cleavage of the oligonucleotide 
functionalized GO from the resin was slow and required multiple sonication cycles probably 
because the GO sheet is a good chemical barrier and prevents TFA from efficiently cleaving the 
C-O trityl bond. Nevertheless, 5 mg of oligonucleotide functionalized GO 118 was obtained 
which was analyzed by brightfield microscopy, FTIR, Raman and solid state carbon NMR 
spectroscopy. 
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Scheme 27: Solid State Synthesis of oligonucleotide functionalized GO 118. 
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The brightfield microscope images, taken at difference stages of the solid state synthesis, are 
shown in Figure 28.  Figure A shows the 2-chlorotrityl resin starting material comprising of 
white or light colored beads of approximately 100 µm in diameter. After treating the resin with 
GO-carboxylic acid 114 it gets coated with layers of GO and takes on a black appearance as seen 
in image B. Some of the beads were only partially coated with GO acid 114, and these took on a 
light brown appearance as shown in picture C. When oligo-GO coated resin 117 was cleaved 
with 10% TFA in trifluoroethanol, some of the crude mixture was visualized under a stage 
microscope as shown in image D. The resin had taken on a red appearance, and small pieces of 
GO material could be seen suspended in the solvent, which showed that the GO was cleaved 
from the resin. Image E shows the recovered resin after workup, which was red in color. Since 
no GO material remained bound to the resin, it was concluded that successful cleavage fully took 
place. The final oligo-GO 118 is shown in images F, and was found to range from 5-50 µm in 
diameter, and had a rougher surface appearance as compared to GO-carboxylic acid 114. 
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Figure 28: Microscope Images Taken at Different Stages of the Solid State Synthesis of 
Oligonucleotide Functionalized GO 118. A) 2-Chlorotrityl resin at 100x magnification 
(scale bar = 100 µm); B) GO coated resin 116 at 100x magnification (scale bar = 100 µm); 
C) GO coated resin 116 at 300x magnification (scale bar = 100 µm); D) Crude mixture of 
Resin and Oligo-GO 118 in trifluoroethanol at 100x magnification; E) Resin remains after 
cleavage at 100x magnification; F) Oligo-GO 118 after cleavage from resin at 1000x 
magnification (scale bar = 10 µm). 
 
 
      
The DNA functionalized GO 118 was analyzed by FTIR, Raman and solid state carbon NMR 
spectroscopy. FTIR is a well established and useful technique to analyze DNA material because 
it can be performed on crystalline, amorphous or solution state DNA samples.
83
 Another 
advantage of FTIR is that there is no limit to the size and one can analyze high molecular weight 
ds- or ss-DNA or RNA, medium length DNA fragments obtained from enzymatic or chemical 
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cleavage or short synthetic oligonucleotides.
83
 The FTIR spectra for GO-carboxylic acid 114 and 
GO-DNA 118 are overlaid in Figure 29.  
Figure 29: Overlay of FTIR Spectra of GO-acid 114 and GO-DNA 118 (Scale units in cm
-1
). 
 
The two spectra look mostly similar except for subtle differences to the fingerprint region. The 
fingerprint region is shown below is Figure 30. A new absorption in the GO-DNA 118 spectrum 
can be seen at 1058 cm
-1
 and may correspond to phosphate group vibration.
83
 New absorption 
peaks can be seen at 960, 833, 728 and 673 cm
-1
 and these vibrations should result from 
vibrations to the phosphate-sugar backbone.
83
 These resonances are sensitive to molecular 
conformation such as sugar pucker. In-plane C=C stretching from the DNA base pairs (1550-
1720 cm
-1
)
83
 and base-sugar bending motions (1300-1500 cm
-1
)
83
 from the DNA could not be 
observed however, probably due to having weak and overlapping absorptions with the GO 
framework. 
600 1100 1600 2100 2600 3100 3600 
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Figure 30: FTIR Overlay Spectra of Fingerprint Regions of GO-acid 114 and GO-DNA 118 
 
The Raman spectrum (Figure 31) contained a D-band and a G-band, as expected for bulk GO, at 
1589 cm
-1
 and 1343 cm
-1
 respectively, with a I(D)/I(G) ratio of 0.95. The increased I(D)/I(G) 
ratio in 118 compared with GO-acid 114 suggests a higher disorder in the GO structure of 118, 
and this may arise from a decreased sheet size, or because the ssDNA is randomly attached to the 
GO surface undergoing π-π stacking between DNA bases and hexagonal rings of GO. 
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Figure 31: Raman Spectrum of Carboxylic Acid Functionalized Graphene Oxide 114 
 
 
The carboxylic acid functionalized GO 114 was subsequently used in a noroviral electronic 
biosensor device as described in the next section. 
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II.IV. Studies Towards the Development of a Novel Noroviral Bioelectronic 
Sensor Device using Carboxylic acid Functionalized Graphene Oxide 114. 
 
The carboxylic acid functionalized GO 114 was utilized in a novel electrochemical “sensor” 
device with the hope of detecting noroviral RNA by taking advantage of the excellent 
semiconductive property of GO. Since norovirus has been an attractive target for drug 
development in our lab we embarked on a translational research project which involved using 
our chemically modified GO in an electrical sensor device with the goal of detecting noroviral 
ssRNA. The design of the electronic sensor device is shown in Figure 32. A Kiethley source 
meter, capable of measuring small currents/voltages, was connected across gold electrodes on a 
silicon dioxide coated silicon wafer. The newly synthesized GO-acid 114 semi-conductive 
material was deposited on the gold electrodes and chemical/physical changes that occurred on its 
surface was detected electronically, due to changes in current.  
Figure 32: Design of the Electronic Sensor Device. 
 
Figure 33 shows a microscope image of the chip at 100x magnification and the distance between 
gold electrodes is 5 or 10 µm. The entire chip has a dimension of 1 cm x 1 cm. The outline of 
this venture is highlighted in Scheme 28 and involved initial deposition of GO-carboxylic acid 
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114 onto the surface of the chip, to bridge between gold electrodes. The full experimental details 
for these procedures have been recently reported by Duy Le and therefore will not be discussed 
in great detail. In brief, the best method for deposition of GO-carboxylic acid 114 onto the chip 
was found to be a direct deposition method. This involved slow evaporation of a dilute aqueous 
suspension of GO-carboxylic acid 114 (50 µL), placed strategically over the gold electrode lanes. 
Once bound to the chip, the GO sheets remained secure in position (Figure 34), and could not be 
washed away, despite vigorous washing stages, probably due to the presence of strong ionic 
bonds formed between the carboxylate ions (from GO) and ammonium ions (from chip surface). 
The next step was the attachment of small probe oligonucleotides to the surface of the GO by 
making use of the newly installed carboxylic acid groups. These is a terminal amine situated on 
the 5’ end of each oligonucleotide (19 mer). These functional groups are coupled to form an 
amide bond in the presence of HATU coupling reagent. We envisioned that hybridization of 
surface bound oligonucleotide with complementary noroviral ssRNA could be detected by 
carefully monitoring the electrical conductivity of GO before and after the reaction. This forms 
the basis of the electrochemical sensor to detect noroviruses, since noroviruses contains a ssRNA 
genome. Dehydridization of the DNA/RNA duplex with 10M urea should remove the ssRNA 
from the GO surface.   
Figure 33: Microscope Image of Electronic Chip at 100x magnification (Image made by 
Allan Prior but has been included in the MSc thesis of Duy Le). 
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Scheme 28: Experimental Design to Detect Noroviral ssRNA. 
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Figure 34: Microscope Image at 1000x Magnification Showing a Sheet of GO-Carboxylic 
acid 114 Bridging Two Gold electrodes (scale bar = 10 µm). 
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Figure 35 shows a bar chart of current values obtained at 4V during the course of RNA 
hybridization and dehybridization treatments. The first column (purple) shows the chip current 
containing immobilized GO-carboxylic acid 114 only. The second column (blue) shows that 
attachment of probe oligonucleotide (oligo-II) caused a 100% increase in chip current from 0.48 
µA to 0.96 µA. Hybridization with target ssRNA caused a 17% increase in current from 0.96 µA 
to 1.12 µA (green column). Dehybridization with 10M urea caused the current to return to pre-
hybridization values (red column). A drying period of 18-48 hours was required after each event 
to remove excess moisture from affecting current readings.  
Figure 35: Hybridization and Dehybridization of Oligonucleotide Probe with ssRNA 
Target (Current values recorded at +4V). 
 
 
The current was swept from -4V to +4V and the I/V data is shown in Figure 36. The S-shape I/V 
profile is indicative that the GO is behaving as a semiconductor, and not a conductor. The blue 
curve labeled 1 shows the I/V data for oligonucleotide bound GO. The green curve labeled 2 
shows the I/V data after hybridization with complementary target ssRNA, and shows an increase 
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in current. After treating with 10 M urea, the current returned to pre-hybridization levels as 
shown by curve 3 (orange), suggesting successful dehydridization of RNA from the DNA probe.  
Figure 36: Hybridization and Dehybridization of Oligonucleotide Probe with ssRNA 
Target (I/V data was recorded by sweeping the voltage from -4 to +4V). 
 
To confirm that the increase in current was a result of successful hybridization of probe DNA 
with the target RNA, the experiment was repeated using a non-complementary sequence of target 
RNA (Figure 37). The result was interesting because even the non-complementary RNA caused 
a similar increase in current (26%, purple column), as observed for complementary RNA vide 
supra. When the chip current was re-measured after sitting for 5 days at room temperature the 
current remained unchanged (red column), but when treated with a complementary sequence of 
target DNA-FAM a further current increase was observed (blue column), which is a 48% current 
increase from the baseline (Oligo-II only).  
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Figure 37: Treatment of Oligonucleotide Probe with Non-Complementary ssRNA (Current 
values recorded at +4V). 
 
The overall result was suspicious, and indicative that the increase in current was due to non-
specific binding of RNA and DNA to the GO surface, and not due to hybridization effect. This 
conclusion was confirmed by taking fluorescence images of the chips after treatment of DNA-
FAM and SDS washing (Figure 38). The fluorescence image (B, Figure 38) showed intense 
fluorescence on the surface of GO confirming the aggregation of many FAM fluorophores. The 
fluorescence intensity was partially reduced after a treatment with 10 M urea but some 
fluorescence still remained, suggesting a strong affinity of DNA to the GO surface through non-
specific binding. This was further confirmed by treating a fresh GO-carboxylic acid immobilized 
chip with DNA-FAM which proved to similarly develop intense fluorescence from the attached 
FAM fluorophores, due to non-specific binding of DNA to the GO surface (data not shown). 
This conclusion is supported by literature evidence that demonstrates that ssDNA has a strong 
affinity for the surface of GO, due to the flat, conjugated nature of nucleobases that can undergo 
π-π stacking with the randomly distributed flat, aromatic regions of GO.64, 84, 85  Interestingly, the 
literature shows that dsDNA has a much lower affinity for GO surface, due to the effective 
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shielding of the nucleobases deep within the centre of the DNA duplex rendering then 
inaccessible to bind with the GO surface.
64
 Moreover, the highly negative charge of the 
phosphate backbone of the DNA duplex is not attracted onto the GO surface.
64
  In order to thwart 
non-specific binding issues of DNA/RNA to GO surface, a passivation layer such as 
polyethylene glycols (PEGs) must be used in future studies. Another inherent problem that exists 
with using this technique is the suspected adsorption of moisture onto the GO surface, causing 
large changes in the measured current. Prolonged drying periods 48 - 64 hours in a desiccator or 
vacuum tube resulted in loss in current, presumably due to loss of GO surface adsorbed moisture. 
The experiment was repeated many times, but the data shown in Figure 35 and 36 could never be 
reproduced. Instead, it was found that the current varies greatly between experiments, and no 
trend in current could be observed between repeated experiments. It is proposed that nonspecific 
binding of ssRNA to the GO surface, and, adsorbed moisture on the GO surface, are two limiting 
factors that hinder rapid progress in this area.    
Figure 38: Images of Chip After Treatment with Non-Complementary ssRNA and 
Complementary DNA-FAM. A) Bright field Image; B) Fluorescence Image (exposure time 
= 100 ms). 
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II.V. Conclusion 
 
In conclusion, this data shows that the surface of GO can be chemically modified with t-
butylester and carboxylic acid functionalities. FTIR, Raman and solid state NMR spectroscopy 
confirmed the presence of with t-butylester and carboxylic acid functionalized GO. The final 
carboxylic acid functionalized GO 114 was showed by AFM to exist mostly as mono layered 
sheets and ~1 - 60 µm in diameter. One sided oligonucleotide functionalized GO 118 was also 
synthesized using a solid state technique and was characterized by FTIR, Raman and solid state 
NMR spectroscopy. The FTIR data suggests that the oligonucleotide has been attached due to 
new absorption peaks in the fingerprint region that are expected for phosphate and phosphate-
sugar backbone vibrations of DNA. Microscope pictures and Raman spectroscopy showed that 
the GO-acid 114 to had higher quality and less disorder compared to GO-DNA 118 and was 
subsequently used in the development of a noroviral electronic biosensor device. The GO-acid 
114 was successfully deposited onto the surface of an electronic chip bridging two gold 
electrodes using a direct deposition technique. The GO-acid 114 displayed semi-conductive 
properties with currents in the low µA range when applying a voltage of 4V. Attachment of 
oligonucleotide to the surface of the chip caused a 100% increase in conductivity. Although 
hybridization with complementary RNA caused an initial increase in conductivity, a separate 
experiment employing hybridization with a non-complementary RNA caused a similar increase 
in current, and therefore the current increase could not be attributed to a successful hybridization. 
Hybridization with complementary DNA-FAM also showed an increase in conductivity but 
fluorescence images showed intense fluorescence due to non-specific binding and aggregation of 
DNA-FAM on GO surface. In order to circumvent issues with the apparent non-specific binding 
of DNA/RNA to GO surface, incorporation of a passivation layer containing PEG should be 
investigated. Another inherent problem that exists with using this technique is the suspected 
adsorption of moisture onto the GO surface, causing large changes in the measured current. The 
experiment was repeated many times, but no trend in current could be observed between 
repeated experiments. It was proposed that apart from nonspecific binding of ssRNA to the GO 
surface, adsorbed moisture on the GO surface is another limiting factor that currently prevents 
progress with this project.  
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III. Electrochemical Detection of the Breast Cancer Related 
Protease Enzymes Legumain and Cathepsin B using Redox Active 
Peptide Substrates Attached to Carbon Nanofibre Nanoelectrode 
Arrays  
 
III.I. Introduction 
 
Cancer occurs when cells divide uncontrollably and form malignant tumors.
86
 The past 30 years 
or so have generated a vast and complex body of knowledge regarding various types of 
cancers.
87
  The causes can be hereditary or as a result of external factors such as tobacco, 
radiation, chemical pollutants or poor diet and exercise. These factors can damage the genes 
found in DNA leading to compromised cell regulatory function. A recent report by Hanahan and 
Weinberg has suggested the six hallmarks of cancer.
87
 “Self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis/tissue invasion and 
metastasis”. Uncontrolled cell growth can invaded nearby organs compromising their proper 
function or can travel to other parts of the body through the lymphatic system or bloodstream 
(metastases).  According to a recent report 12.7 million cancers were diagnosed worldwide in 
2008 and 7.6 million deaths were reported in just one year.
86
 This accounts for 13% of all deaths 
each year.   
Breast cancer is one of the most common and most challenging diseases that affects woman 
worldwide.
88
 Breast cancer is the leading cause of mortality in females aged 40-59 with more 
than one million new cases each year and a lifetime risk estimate of 1 out of every 9 woman.
88, 89
 
It has been said that the identification of reliable biomarkers in early stage breast cancer for early 
detection is a major challenge.
88
 Early stage detection of breast cancer is recognized as the most 
important criteria to improve prognosis and treatment.
89
 Mammography is the most utilized 
technique to screen for breast cancers and has been proven to successfully reduce breast cancer 
mortalities via population based screening programs.
90
 Mammography however comes with 
certain limitations such as false positive results causing high call back rates, unnecessary 
exposure to radiation from additional mammograms, unnecessary and expensive biopsies and 
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patient anxiety.
90
 False negative results can also occur, especially in woman with dense breast 
tissue, having only 36% sensitivity.
90
  Other breast cancer imaging techniques such as magnetic 
resonance imaging (MRI), computed tomography (CT), mammoscintigraphy and positron 
emission tomography (PET) are used to detect and monitor breast cancers but these are 
expensive and inconvenient for routine screening.  
 
III.II. Results and Discussion 
 
The aim of this research was to develop an electrochemical biosensor devise capable of detecting 
important breast cancer relater biomarkers at an early stage. The biomarkers that were 
investigated in these studies were legumain and cathepsin B which are important protease 
enzymes implicated in breast cancers by over activation or over expression.
91-94
 Legumain is a 
cysteine protease found in metastatic and invasive tumors and is expressed on the cell surface, in 
the macrophage and other membranous vesicles.
91
 The higher activity of legumain in breast 
cancer results in activation of other proteases especially cathepsin B which has the ability to 
degrade connective tissues such as elastin and collagen, assisting in tumor growth.
91
 Cysteine 
protease activity has been shown to be linked to tumor growth because the presence of cysteine 
protease inhibitors attenuated tumor growth and metastasis.
91
 Development of an electrochemical 
device capable of detecting legumain and cathepsin B is highly relevant as this would allow for 
rapid and convenient screening of patients for breast cancers. A device of this nature could also 
be portable allowing for convenient point-of-care screening and treatment monitoring.
91
   
In our recent paper by Syed et al.
95
 we demonstrated that redox active ferrocene (Fc) molecules 
could be electrochemically detected via alternating current voltammetry (ACV) when covalently 
attached to the end of vertically aligned carbon nanofibers (VACNFs) in an embedded 
nanoelectrode array (NEA). The nanofibers are embedded in a layer of silicon dioxide but have 
their tips exposed on the surface as shown in the SEM image below (Figure 39). The VACNFs 
were grown in the lab of Dr. Jun Li using a DC-biased plasma enhanced chemical vapor 
deposition (PECVD) method starting from a Cr-coated silicon wafer.
95
 The VACNFs were then 
coated with a SiO2 encapsulation layer using a process of tetraethyl-ortho-silicate chemical vapor 
deposition. The CNF tips are exposed via mechanical polishing and reactive ion etching.
95
 The 
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CNF tip are lastly electrochemically activated (generate carboxyl groups) by applying four 
cycles of CV -0.10 to 1.20 V in a solution of 1.0 M NaOH.
95
   
 
Figure 39: Field-emission scanning electron microscopy image of VACNFs coated with a 
SiO2 matrix. Reprinted with permission from (Swisher et al., J. Phys. Chem. C: 2013, 117, 
4268-4277). Copyright (2013) American Chemical Society. 
 
The NEA showed better detection sensitivity and temporal resolution compared to conventional 
electrodes because of its extremely small electrode size (nanometers).
95
 This phenomenon allows 
the NEA to be utilized in biosensing applications requiring rapid and highly sensitive 
electroanalysis.
95
  
This ACV technique was therefore expanded upon in order to develop an electrochemical 
biosensor device to detect the breast cancer related protease enzymes legumain and cathepsin B.  
This was achieved by covalently attaching Fc labeled peptide substrates to the end of the CNFs. 
The underlying idea for this electrochemical biosensor technique was that when protease 
enzymes cleave the Fc labeled peptide substrates, a decrease in current should result when 
monitored by ACV, due to loss of redox active Fc moieties from the surface of the CNF 
nanoelectrode.  
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The amino acid sequences for the Fc labeled peptide substrates were carefully designed by 
consulting substrate specificity profiles for legumain and cathepsin B found in literature studies. 
The structures of these peptides are shown below in Figure 40. Compound 119 for legumain 
contained a primary sequence of Ala-Ala-Asn-Leu while compound 120 for cathepsin B 
contained a primary sequence of Leu-Arg-Phe-Gly. In both tetrapeptides a Fc moiety was 
covalently attached to the C-terminal end of the peptide via coupling with an 
aminomethylferrocene group. Both peptides have a 5 carbon linker/spacer attached to the N-
terminal end, the purpose of which was to extend the peptide away from the CNF surface 
reducing the occurrence of any steric interaction that may happen between protease enzymes and 
CNF surface.      
 
Figure 40: Ferrocene labeled peptide substrates for legumain (left, compound 119) and 
cathepsin B (right, compound 120). 
Ala-Ala-Asn-Leu NH
Fe
O
H2N 119
Leu-Arg-Phe-Gly
O
H2N
NH
Fe
120
 
Figure 41 shows the expected cleavage sites for peptide 119 (legumain) and peptide 120 
(cathepsin B). Legumain is an asparaginyl endopeptidase that specifically cleaves peptide bonds 
with P1 asparagine i.e. at the C-terminal side of an asparagine residue.
96
 The literature evidence 
shows that when the P2 and P3 residues are alanine successful peptide cleavage Asn can take 
place.
97, 98
 This prompted us to incorporate this verified Ala-Ala-Asn sequence into our biosensor 
device. The P1’ position is not as important when it comes to substrate specificity and thus the 
Leu at position P1’ was arbitrarily chosen.97 The peptide substrate specificity profile for 
cathepsin B recognition and cleavage was recently uncovered by Choe et al. and was reported in 
2006.
99
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Figure 41: Expected cleavage sites for peptide 119 (legumain) and peptide 120 (cathepsin 
B). 
Ala-Ala-Asn---Leu NH
Fe
O
H2N
119
Leu-Arg---Phe-Gly
O
H2N
NH
Fe120
 
In order to confirm that the designed peptide sequences could be cleaved by legumain and 
cathepsin B enzymes, a HPLC study was performed in conjunction with mass spectrometry. The 
results from this study have been captured in our recent paper by Swisher et al.
91
 Figure 42 
shows the data for the cleavage of peptide 119 by legumain. Chromatogram A shows peptide 119 
in MES buffer (no legumain). The tetrapeptide 119 appeared at 9.7 min in the HPLC chart and 
was confirmed by mass spectrometry analysis. Chromatogram B is a positive control and shows 
the expected cleaved fragment Leu-NHCH2Fc (compound 119) after injection into HPLC as a 
solution in MES buffer. The presence of Leu-NHCH2Fc at 12.2 min was confirmed by mass 
spectrometry analysis. Chromatogram C shows the result after peptide 119 was incubated with 
98.7 ng/µL (2.01 μM) of legumain for 2 hours. The peak at 12.2 min was collected and 
lyophilized and subjected to mass spectrometry analysis which proved it to be Leu-NHCH2Fc 
demonstrating that peptide 119 can be recognized and cleaved by legumain.  
Figure 43 shows the data for the cleavage of peptide 120 by cathepsin B. Chromatogram A 
shows peptide 120 in MES buffer (no cathepsin B). The tetrapeptide 120 appeared at 9.4 min in 
the HPLC chart and was confirmed by mass spectrometry analysis. Chromatogram B is a 
positive control and shows the expected cleaved fragment Phe-Gly-NHCH2Fc (compound 136) 
after injection into HPLC as a solution in MES buffer. The presence of Phe-Gly-NHCH2Fc at 6.7 
min was confirmed by mass spectrometry analysis. Chromatogram C shows the result after 
peptide 120 was incubated with (56 μl, 4.95 ng/μl) of cathepsin B for 2 hours. The peak at 6.7 
min was collected and lyophilized and subjected to mass spectrometry analysis which proved it 
to be Phe-Gly-NHCH2Fc demonstrating that peptide 120 can be recognized and cleaved by 
cathepsin B.   
 
76 
 
Figure 42: HPLC data showing proteolytic activity of legumain. A: Compound 119 only in 
50 mM MES buffer (pH 5.0) and 250 mM NaCl (no legumain). B: Compound 133 only 
(cleavage fragment) in 50 mM MES buffer (pH 5.0) and 250 mM NaCl. C: Compound 119 
in 50 mM MES buffer (pH 5.0) and 250 mM NaCl incubated with 98.7 ng/µL (2.01 μM) 
legumain for 2 hours. Modified with permission from (Swisher et al., J. Phys. Chem. C: 
2013, 117, 4268-4277). Copyright (2013) American Chemical Society. 
 
 
  
77 
 
Figure 43: HPLC data showing proteolytic activity of cathepsin B. A: Compound 120 only 
in 25 mM MES buffer (pH 5.0) (no cathepsin B). B: Compound 136 only in 25 mM MES 
buffer (pH 5.0). C: Compound 120 in 25 mM MES buffer (pH 5.0) incubated with 4.95 ng 
μl-1 (0.17 μM) cathepsin B for 2 hours. Modified with permission from (Swisher et al., J. 
Phys. Chem. C: 2013, 117, 4268-4277). Copyright (2013) American Chemical Society. 
 
 
The tetrapeptides 119 and 120 were then utilized in an electrochemical biosensor device 
developed in the lab of Dr. Jun Li. The electrochemical data were recorded and processed by 
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Luxi Swisher and results from these studies have been captured in our recent paper by Swisher et 
al.
91
 The design of the three electrode ACV electrochemical cell incorporating a covalently 
attached Fc-labeled tetrapeptide is shown below in Figure 44. The working electrode consists of 
Fc-tetrapeptide functionalized VACNFs embedded in a SiO2 matrix. The reference electrode is 
Ag/AgCl and the auxiliary electrode is platinum. The three electrodes are connected to a 
potentiostat which allows the current to be monitored while the AC potential ramp is applied 
during ACV measurements. When the oxidation potential of the Fc is reached, a current is 
recorded in the potentiostat due to the oxidation of ferrocene (Fc) to ferricinium (Fc
+
). When the 
applied potential is turned off an open cell results and the Fc
+
 spontaneously and rapidly reduces 
back to Fc. 
Figure 44: Three electrode ACV electrochemical cell containing covalently attached Fc-
labeled tetrapeptide for legumain and cathepsin B detection. 
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To start, the Fc-peptide 119 was coupled to the surface of both glassy carbon electrode and CNF 
electrode using a conventional EDC coupling technique. The presence of attached Fc-peptide 
119 could be detected on glassy carbon electrode by cyclic voltammetry (CV) as can be seen by 
the peaks at 0.33V (oxidation) and 0.24V (reduction) in Figure 45 (a), which correspond to 
Faradic current due to the oxidation and reduction of Fc and Fc
+
 respectively. The measurements 
were carried out by Luxi Swisher, using a scan rate of 50 mV s
-1
 in 1 mL of 1.0 M KCl.
91
  The 
oxidation and reduction of ferrocene on a VACNF electrode could not be observed by CV as 
shown in Figure 45 (b). The absence of Faradic current signals showed that DC CV technique is 
not adequately sensitive for use with VACNF electrodes. The reason for this is due to the higher 
intrinsic resistance of the VACNF due to their stacked cone structures. This results in a slower 
electron transfer rate (ETR). To solve this problem, ACV was used in place of CV which proved 
to increased ETR for Fc-peptide functionalized VACNFs by a factor of ~100.
91
  The reason for 
the significant increase in current seen in ACV measurements was attributed to the opening up of 
capacitive pathways in the stacked cone structures of VACNFs (due to the alternating current) 
causing a significant decrease in resistance and an increase in ETR.
91, 95
  
Figure 45: Cyclic voltammograms of compound 119 immobilized on (a) GCE and (b) 
VACNF electrode. Reprinted with permission from (Swisher et al., J. Phys. Chem. C: 2013, 
117, 4268-4277). Copyright (2013) American Chemical Society. 
 
When using ACV to record Faradic current, two important factors to consider are the frequency 
of the applied AC potential and the amplitude of the applied AC potential. The frequency of the 
applied AC potential was varied from 0 to 8 KHz for compound 119 attached to GCE and CNF 
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electrode. These results have been captured in our recent publication by Swisher et al.
91
 For GCE 
a maximum current density was obtained at 40 Hz but for CNF electrode the maximum current 
density was observed at 1.75 KHz. The higher current density at higher AC frequency exhibited 
for CNF NEA is advantages since it allows for a faster scan rate giving better temporal 
resolution.
91
 The amplitude of the AC potential was also investigated and was varied from 0.01V 
to 0.5V for compound 119 on GCE and CNF electrode and its effect on current density 
monitored. It was determined that the current density reached a maximum at 0.35V for GCE but 
continued to increase non-linearly in CNF electrode up to 0.5V. Despite the fact the CNF 
electrode produced a higher current density at higher amplitudes, the optimal amplitude value 
that was used for subsequent study was 0.15 V as this provided the best balance between current 
peak resolution and satisfactory current density.
91
 The following ACV measurements for 
compound 119 and legumain studies were therefore recorded using these optimized ACV 
frequency and amplitude values of 1.75 KHz and 0.15V respectively. 
In order to monitor the cleavage of peptide 119 with legumain in real time, the current was 
monitored by continuously repeating ACV measurements. These data were recorded by Luxi 
Swisher and have been captured in our recent publication by Swisher et al.
91
 The ACV potential 
was swept from -0.05 V to +0.65V using a scan rate of 10 mV/s. At a time of 22 minutes 11 µL 
of a 90.9 ng/µL [1.9 µM] solution of activated legumain solution was added into the 
electrochemical cell containing 50 mM MES (pH 5.0) and 250 mM NaCl. Final enzyme 
concentration was 80.1 nM in legumain. Figure 46 shows a plot of peak current vs time for the 
legumain cleavage experiment. Legumain was added at 22 min and the disturbance to the 
electrolyte caused an abrupt spike in the observed current. Thereafter, legumain action on the 
attached peptide 119 was observed by the occurrence of an exponential decay of the ACV 
current. The specificity constant (kcat/Km) for legumain and peptide 119 was calculated to be 11.3 
x 10
3 
M
-1
s
-1 
(Table 8) which compared favorably to a value obtained by fluorescence 
measurements when legumain acted on a commercial substrate (Ala-Ala-Asn-AMC; kcat/Km = 
4.3 x 10
3 
M
-1
s
-1
). Two separate control experiments were performed which involved treating the 
peptide 119 functionalized CNF with either buffer only or, buffer plus deactivated legumain, 
none of which displayed exponential signal decay in ACV measurements.
91
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Figure 46: Plot of peak current (ip,acv) vs time for compound 119 on a VACNF electrode 
showing cleavage of peptide 119 by legumain starting at ~20 minutes with [Eo] of 80.1 nM. 
Adapted with permission from (Swisher et al., J. Phys. Chem. C: 2013, 117, 4268-4277). 
Copyright (2013) American Chemical Society. 
 
 
 
Table 8: Calculated  kcat/Km values for the commercial legumain substrate (Ala-Ala-Asn-
AMC) and compound 119 from fluorescence and electrochemical data respectively. 
Peptide Sequence kcat/Km (M
-1
s
-1
) Method 
Ala-Ala-Asn-AMC (4.3 ± 0.6) x 10
3
 fluorescence data 
Ala-Ala-Asn-Leu-NH-CH2-Fc (11.3 ± 3.8) x 10
3
 electrochemistry data. 
 
The electrochemical ACV experiments were repeated by Luxi Swisher using peptide 120 on 
VACNF employing cathepsin B for cleavage studies. These results have been captured in our 
recent publication by Swisher et al.
91
 The ACV frequency and amplitude were again optimized 
for the new peptide 120, as mentioned previously. The highest current density was observed at a 
frequency of 800 Hz and was therefore used for subsequent ACV measurements. The current 
density increased linearly with increasing ACV amplitude up to 0.5V but as before, an ACV 
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amplitude of 0.15V was used for all measurements in order to prevent the ACV current peak 
from becoming broad and unstable.
91
   
Luxi tracked the cleavage of peptide 120 attached to VACNF by cathepsin B in real time using 
ACV (Figure 47). These results have been captured in our recent publication by Swisher et al.
91
 
The ACV potential was swept from -0.05 V to +0.75V using a scan rate of 10 mV/s. At time 20 
minutes 25 µL of a 9.8 ng/µL [338 nM] solution of cathepsin B in activation buffer (25 mM 
DTT and 25 mM MES @ pH 5.0) was added to the electrochemical cell containing 25 mM MES 
(pH 5.0).  Final enzyme concentration was 30.7 nM in cathepsin B. A small spike in current at 20 
minutes was observed because of disturbance to the electrolyte solution after which exponential 
decay of current signal occurred. Two separate control experiments were again performed and 
involved treating the peptide 120 functionalized CNF with either buffer only or, buffer plus 
deactivated cathepsin B, none of which displayed exponential signal decay in ACV 
measurements.
91
  
Figure 47: Plot of peak Current (ip,acv) for compound 120 on CNF electrode vs time. 
Cathepsin B was added at time 20 Minutes with [Eo] of 30.7 nM. Adapted with permission 
from (Swisher et al., J. Phys. Chem. C: 2013, 117, 4268-4277). Copyright (2013) American 
Chemical Society. 
 
The specificity constant (kcat/Km) for cathepsin B and peptide 120 was calculated to be 4.3 x 10
4
 
M
-1
s
-1 
(Table 9) which compared favorably to a value obtained by fluorescence measurements 
when cathepsin B acted on a commercial substrate (Leu-Arg-AMC; kcat/Km = 2.3 x 10
4 
M
-1
s
-1
). It 
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can be seen that the enzyme activity for cathepsin B is about 4 times higher than for legumain 
(higher specificity constant) and agrees with literature findings.
91, 100-102
 
Table 9: Calculated  kcat/Km Values for the Commercial Cathepsin B Substrate (Leu-Arg-
AMC) and Compound 120 from Fluorescence and Electrochemical Data Respectively. 
Peptide Sequence kcat/Km (M
-1
s
-1
) Method 
Leu-Arg-AMC (2.3 ± 1.7) x 10
4
 fluorescence data 
Leu-Arg-Phe-Gly-NH-CH2-Fc (4.3 ± 0.8) x 10
4
 electrochemistry data. 
 
 
III.III. Synthesis of Peptide Substrates 119 and 120. 
 
The peptide substrate 119 was synthesized using solid phase peptide synthesis followed by post 
cleavage synthetic modification as shown in Scheme 29. The resin bound tetrapeptide 121 was 
constructed using conventional solid phase peptide synthesis starting from commercially 
available Leu-2-chlorotrityl resin. The coupling steps envolved microwave assisted HBTU 
mediated coupling of Fmoc-N-protected amino acids to the amino function of the resin bound 
peptide in DMF containing 4.2% diisopropylethylamine. Deprotection steps involved microwave 
assisted removal of the Fmoc protecting group using 20% piperidine in DMF. The resin bound 
peptide 121 was cleaved from the resin to form compound 122 in 45% overall yield. The N-
terminal amine of 122 was protected with a Boc group using Boc anhydride in dioxane/water to 
furnish an N-Boc intermediate in 96% yield. The carboxyl group of the N-Boc intermediate was 
coupled with aminomethyl ferrocene using HATU in DMF to form 123 in 48% yield after 
purification using preparative HPLC. The aminomethyl ferrocene was made in house according 
to the reported procedure.
103
 The Boc protecting group of 123 was removed using 10% TFA in 
dichloromethane to quantitatively form an amine intermediate which was coupled with N-Boc-5-
aminovaleric acid using HATU to form compound 124 in 45% yield after purification using 
preparative HPLC. The N-Boc protection group of 124 was removed using 10% TFA in 
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dichloromethane in 98% yield to furnish compound 119 in a 9% overall yield as a fluffy green 
solid. The structure of compound 119 was confirmed by mass spectrometry analysis.  
Scheme 29: Synthesis of Legumain Substrate 119. 
Leu-2-Cl-Trt-Resin Ala-Ala-Asn-Leu-Resin Ala-Ala-Asn-Leu
Boc-Ala-Ala-Asn-Leu NH
Fe
Ala-Ala-Asn-Leu NH
Fe
O
N
H
Boc
Ala-Ala-Asn-Leu NH
Fe
O
H2N
a b
c d
e
121 122
123 124
119
 
Reagents and conditions: (a) 1. Fmoc-Asn, HBTU, 4.2 % DIPEA/DMF, microwave; 2. 20% 
piperidine/DMF, microwave; 3. Fmoc-Ala, HBTU, 4.2 % DIPEA/DMF, microwave; 4. 20% 
piperidine/DMF, microwave; 5. Fmoc-Ala, HBTU, 4.2 % DIPEA/DMF, microwave; 6. 20% 
piperidine/DMF, microwave; (b) 95% TFA, 2.5% TIPS, 2.5% water, microwave, 45% overall 
yield; (c) 1. Boc2O, NEt3, dioxane/water (1:1), 25
o
C, 12 h, 96%; 2. HATU, H2NCH2Fc, DMF, 
25
o
C, 2 h, 48%; (d) 1. 10% TFA/CH2Cl2, 25
o
C, 30 min, 100%; 2. HATU, N-Boc-5-aminovaleric 
acid, DMF, 25
o
C, 2 h, 45%; (e) 10% TFA/CH2Cl2, 25
o
C, 30 min, 98%. 
 
The peptide substrate 120 for cathepsin B studies was synthesized using solid phase peptide 
synthesis followed by post cleavage synthetic modification as shown in Scheme 30. The resin 
bound tetrapeptide 125 was constructed using conventional solid phase peptide synthesis starting 
from commercially available Gly-2-chlorotrityl resin.  The coupling steps evolved microwave 
assisted HBTU mediated coupling of Fmoc-N-protected amino acids to the amino function of the 
resin bound peptide in DMF containing 4.2% diisopropylethylamine. Deprotection steps 
involved microwave assisted removal of the Fmoc protecting group using 20% piperidine in 
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DMF. The resin bound peptide 125 was cleaved from the resin to form compound 126 in 94% 
overall yield. The N-terminal amine of 126 was protected with a Boc group using Boc anhydride 
in dioxane/water to furnish an N-Boc intermediate in 99% yield. The carboxyl group of the N-
Boc intermediate was coupled with aminomethyl ferrocene using HATU in DMF to form 127 in 
50% yield after purification using preparative HPLC. The N-Boc protection group from 127 was 
removed using 10% TFA in dichloromethane in 98% yield to furnish compound 120 in a 46% 
overall yield as a fluffy green solid. The structure of compound 120 was confirmed by NMR 
spectroscopy and mass spectrometry analysis.  
Scheme 30: Synthesis of Cathepsin B substrate 120. 
Gly-2-Cl-Trt-Resin
Leu-Arg-Phe-Gly-Resina b
c
d
O
N
H
Boc
Leu-Arg-Phe-Gly
O
H2N
Leu-Arg-Phe-Gly
O
N
H
NH
Fe
Boc
Leu-Arg-Phe-Gly
O
H2N
NH
Fe
125
127
126
120
 
Reagents and conditions: (a) 1. Fmoc-Phe, HBTU, 4.2 % DIPEA/DMF, Microwave; 2. 20% 
piperidine/DMF, microwave; 3. Fmoc-Arg, HBTU, 4.2 % DIPEA/DMF, Microwave; 4. 20% 
piperidine/DMF, microwave; 5. Fmoc-Leu, HBTU, 4.2 % DIPEA/DMF, Microwave; 6. 20% 
piperidine/DMF, microwave; 7. N-Boc-5-aminovaleric acid, HBTU, 4.2 % DIPEA/DMF; 
microwave; 8. 20% piperidine/DMF, microwave; (b) 95% TFA, 2.5% TIPS, 2.5% water, 
microwave, 94% overall yield; (c) 1. Boc2O, NaHCO3, dioxane/water (1:1), 25
o
C, 12 h, 99%; 2. 
HATU, H2NCH2Fc, DMF, 25
o
C, 2 h, 50%; (d) 10% TFA/CH2Cl2, 25
o
C, 30 min, 98%. 
The non-substrate peptide 130 for cathepsin B studies was synthesized using solid phase peptide 
synthesis followed by post cleavage synthetic modification as shown in Scheme 31. The resin 
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bound tetrapeptide 128 was constructed using conventional solid phase peptide synthesis starting 
from commercially available Gly-2-chlorotrityl resin.  
Scheme 31: Synthesis of Cathepsin B Non-Substrate 131. 
Gly-2-Cl-Trt-Resin
Leu-Asn-Phe-Gly-Resina b
c
d
O
N
H
Boc
Leu-Asn-Phe-Gly
O
H2N
Leu-Asn-Phe-Gly
O
N
H
NH
Fe
Boc
Leu-Asn-Phe-Gly
O
H2N
NH
Fe
128
129
130
131
 
Reagents and conditions: (a) 1. Fmoc-Phe, HBTU, 4.2 % DIPEA/DMF, Microwave; 2. 20% 
piperidine/DMF, microwave; 3. Fmoc-Asn, HBTU, 4.2 % DIPEA/DMF, Microwave; 4. 20% 
piperidine/DMF, microwave; 5. Fmoc-Leu, HBTU, 4.2 % DIPEA/DMF, Microwave; 6. 20% 
piperidine/DMF, microwave; 7. N-Boc-5-aminovaleric acid, HBTU, 4.2 % DIPEA/DMF, 
Microwave; 8. 20% piperidine/DMF, microwave; (b) 95% TFA, 2.5% TIPS, 2.5% water, 
microwave, 83% overall yield; (c) 1. Boc2O, NaHCO3, dioxane/water (1:1), 25
o
C, 12 h, 100%; 2. 
HATU, H2NCH2Fc, DMF, 25
o
C, 2 h, 65%; (d) 10% TFA/CH2Cl2, 25
o
C, 30 min, 100%. 
 
The coupling steps evolved microwave assisted HBTU mediated coupling of Fmoc-N-protected 
amino acids to the amino function of the resin bound peptide in DMF containing 4.2% 
diisopropylethylamine. Deprotection steps involved microwave assisted removal of the Fmoc 
protecting group using 20% piperidine in DMF. Since this was designed to be a non-substrate for 
cathepsin B the P3 arginine was replaced with a P3 asparagine because this sequence was shown 
in literature to not be cleaved by cathepsin B. The resin bound peptide 128 was cleaved from the 
resin to form compound 129 in 83% overall yield. The N-terminal amine of 129 was protected 
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with a Boc group using Boc anhydride in dioxane/water to quantitatively furnish an N-Boc 
intermediate. The carboxyl group of an N-Boc intermediate was coupled with aminomethyl 
ferrocene using HATU in DMF to form 130 in 65% yield after purification using preparative 
HPLC. The N-Boc protection group from 130 was quantitatively removed using 10% TFA in 
dichloromethane to furnish compound 131 in a 54% overall yield as a fluffy green solid. The 
structure of compound 131 was confirmed by NMR spectroscopy and mass spectrometry 
analysis.  
The authentic legumain cleaved fragment 133 was synthesized for HPLC study according to 
Scheme 32. Fmoc-Leu was coupled with aminomethyl ferrocene to form 132 in 54% yield after 
purification by column chromatography. The Fmoc protecting group was removed using 20% 
piperidine in DMF for form compound 133 in 67% yield. HPLC and mass spectrometry analysis 
confirmed that legumain does cleave peptide 119 to generate compound 133 as a fragment.   
Scheme 32: Synthesis of Legumain Substrate Fragment 133 for HPLC Study. 
a b
NH
Fe132
Fmoc-Leu
Fmoc-Leu
NH
Fe133
Leu
 
Reagents and conditions: (a) N-Boc-5-aminovaleric acid, HATU, DMF, 25
o
C, 30 min, 54%; (b) 
20% piperidine/DMF, 25
o
C, 30 min, 67%. 
 
The authentic cathepsin B cleaved fragment 136 was synthesized for HPLC study according to 
Scheme 33. The carboxyl group of boc-glycine was coupled with aminomethyl ferrocene using 
HATU to form compound 134 in 36% yield after column chromatography. Removal of Boc 
protecting group by 10% TFA in dichloromethane followed by HATU coupling with N-Boc 
phenylalanine provided compound 135 in 48% yield after purification by column 
chromatography. Removal of the Boc protecting group by 10% TFA in dichloromethane gave 
dipeptide 136 in 98% yield. HPLC and mass spectrometry analysis confirmed that cathepsin B 
does cleave peptide 120 to generate compound 136 as a fragment.   
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Scheme 33: Synthesis of Cathepsin B Substrate Fragment 136 for HPLC Study. 
a b
c Phe-Gly NH
Fe136
Boc-Phe-Gly NH
Fe135
Boc-Gly NH
Fe134
Boc-Gly
 
Reagents and conditions: (a) HATU, H2NCH2Fc, DMF, 25
o
C, 2 h, 36%; (b) 10% TFA/CH2Cl2, 
25
o
C, 30 min, 100%; 2. HATU, N-Boc-Phe, DMF, 25
o
C, 2 h, 48%; (c) 10% TFA/CH2Cl2, 25
o
C, 
30 min, 98%. 
III.IV. Conclusion 
 
The tetrapeptide protease substrates 119 and 120 were successfully synthesized and used in a 
bioelectronic cancer protease detection device. When attached to the tips of CNF NEAs, 
substrates 119 and 120 could successfully detect breast cancer related protease enzymes 
legumain and cathepsin B respectively by employing an ACV technique. In both cases an 
exponential decrease in ACV current could be detected at initial enzyme concentrations of 80.1 
nM (legumain) and 30.7 nM (cathepsin B) showing excellent sensitivity for this technique. 
HPLC peptide cleavage studies confirmed activity and specificity for legumain and cathepsin B 
proteases. Legumain was found to have a specificity constant (kcat/Km) value of 11.3 x 10
3 
M
-1
S
-1
 
while cathepsin B was found to have higher value of kcat/Km  (4.3 x 10
4 
M
-1
S
-1
) which agreed 
with literature findings. Legumain was shown to cleave peptide 119 at the C-terminal side of 
asparagine residue while cathepsin B cleaved peptide 120 at the C-terminal side of arginine 
residue.  Further studies are ongoing and will involve using this technique to detect legumain and 
cathepsin B enzymes in real cancer cell samples as well as investigate the use of alternative 
peptide probes for the detection of other cancer related proteases for example MMP-7.   
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IV. Experimental Section 
 
IV.I. General Experimental Procedures  
 
Nuclear magnetic resonance spectra were obtained from a Varian 400-MHz spectrometer using 
CDCl3 as the solvent unless otherwise stated and all chemical shifts reported in ppm.  Low 
resolution mass spectra were obtained using an API-2000-triple quadrupole electrospray 
ionization (ESI) MS/MS mass spectrometer (Applied Biosystems). High resolution mass spectra 
were obtained using LCT Premier (Waters Corp., Milford MA) time of flight mass spectrometer 
based at the University of Kansas Mass Spectrometry Laboratory. Infrared spectra were taken 
from a ThermoScientific Nicolet 380 FT-IR instrument. A Hewlett-Packard diode array UV/VIS 
spectrophotometer was used in the survey of proteases assays.  Compound 91a is available 
commercially, however, this compound was prepared as described in the manuscript.  The 
enzyme assays for 3Cpro and 3CLpro with FRET-based assays have been previously reported.
39, 
40
 Cell based assays for virus replication for noroviruses, picornaviruses and coronaviruses have 
been previously reported.
40, 41
 FT-Raman spectra were taken using a ThermoScientific DXR 
microRaman Microscope at a laser wavelength of 532 nm; laser power of 5 mW; confocal hole 
diameter of 3.1 μm; entrance slit width of 50 μm; grading of 900 lines/mm and an Olympus 10x 
objective lens. Solid state NMR spectra we obtained using a 3-channel solid-state NMR 
spectrometer with a Tecmag Apollo console attached to a 8.4 T (357 MHz) wide bore magnet. 
Peptides were synthesized using a CEM microwave peptide synthesizer.  The 2-chlorotrityl 
resins (0.54 mmol/g; 200 mesh) were purchased from Peptide International. The experimental 
procedures for chapter 2.2 including ACV data have been reported in the supporting information 
of our recent journal article, Swisher et al. titled “Electrochemical Protease Biosensor Based on 
Enhanced AC Voltammetry Using Carbon Nanofiber Nanoelectrode Arrays.”91 Chemicals were 
purchased from Fisher Scientific, Aldrich Chemical Co., Chem-Impex International, and VWR. 
 
General Procedure A: The N-Boc-dipeptide 76 (1 mmol) was dissolved in 10% TFA/CH2Cl2 (5 
mL) and stirred at 25
o
C for 4 h. The solvent was removed on a rotary evaporator to yield a sticky 
oil that was re-dissolved in chloroform followed by removal of the solvent once again on the 
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rotary evaporator to yield a semi-solid material. After sitting under high vacuum for 0.5 h, a 
white solid (amine intermediate) was obtained in quantitative yield. To this amine intermediate 
(1 mmol) was added (S)-N-Cbz-1-naphthylalanine (1 mmol), EDCI (2 mmol) and DMAP (2 
mmol) followed by dry CH2Cl2 (15 mL) and the resulting solution was stirred at 25
o
C for 18 h 
under argon atmosphere. The reaction mixture was partitioned between water (150 mL) and 
CH2Cl2 (150 mL), the aqueous layer was acidified to pH = 2 using 2 N HCl, and extracted three 
times with CH2Cl2 (150 mL each). The combined organic layers were dried (anhydrous MgSO4), 
filtered, and concentrated to yield a solid which was purified by silica gel chromatography (30:1 
CH2Cl2:MeOH) to yield compound 84, 0.5 g (72% yield) as a white solid. 
General Procedure B: To a solution of ester 84 (0.63 mmol) in CH2Cl2/MeOH (1:1) (8 mL) at 
0
o
C was added NaBH4 (5.6 mmol) in small portions over a period of 4 h. The reaction was 
quenched with water (0.5 mL) and diluted with 100 mL of CH2Cl2. The solution was passed 
through a short plug of silica gel and the organic material washed thoroughly with 30:1 
CH2Cl2/MeOH (100 mL). The filtrate was concentrated to yield a solid which was dissolved in 
distilled CH2Cl2 (15 mL) and treated with Dess-Martin periodinane (DMP) for 2 h at 25
o
C. The 
reaction mixture was filtered and the filtrate was concentrated and purified by silica gel 
chromatography using a gradient solvent elution of 25% acetone/CH2Cl2 to 100% acetone. The 
fractions containing the product were combined and concentrated to give a white solid to which 
was added CHCl3 (20 mL). After sitting for 10 min the mixture was filtered through a glass frit 
funnel (fine) and the filtrate was concentrated to provide aldehyde 24 (90% yield) as a white 
solid. 
General procedure C: Isopropylisocyanide (0.067 mmol) was added to a solution of aldehyde 24 
(0.067 mmol) in distilled EtOAc (2 mL) and AcOH (1 drop) and the resulting solution stirred at 
25
o
C for 18 h. The solvent was removed in vacuo and the residue was dissolved in a 1:1 solution 
of MeOH/H2O (5 mL) and K2CO3 (0.16 mmol). After stirring for 3 h at 25
o
C, the reaction was 
diluted with water and extracted with EtOAc (4 times). The combined organic layers were dried 
(anhydrous MgSO4), filtered, and concentrated to yield a residue. To it, CH2Cl2 (2 mL) was 
added followed by DMP (0.13 mmol) and the reaction was stirred at 25
o
C for 2 h. The solvent 
was removed in vacuo and the residue was purified by silica gel chromatography using a 
gradient solvent elution of 25% acetone/CH2Cl2 to 100% acetone. The fractions containing the 
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product were combined and concentrated to give a white solid to which was added CHCl3 (10 
mL). After sitting for 10 min the mixture was filtered through a glass frit funnel (fine) and the 
filtrate was concentrated to provide ketoamide 32 (36 mg, 79% yield) as a white solid. 
General Procedure D: Diisopropylethylamine (0.25 mmol) was added to a solution of aldehyde 
24 (0.25 mmol) and diethylphosphite (0.25 mmol) in distilled CH2Cl2. After stirring at 25
o
C for 
18 h, the reaction was diluted with ethyl acetate and washed with dilute HCl followed by brine. 
The organic layer was dried (anhydrous MgSO4), filtered, and concentrated to yield an oil which 
was purified by silica gel column chromatography (9:1 CH2Cl2/MeOH) to afford two 
diastereomers (a mixture of R and S at carbon adjacent to phosphorus) of compound 36 (10 mg, 
54% yield) as white solids. 
General Procedure E: To a mixture of glutamine surrogate HCl salt (53, 5.59 mmol), N-Boc-
leucine (5.59 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (10.2 mmol), and 
4-(dimethylamino)pyridine (DMAP) (10.2 mmol) under argon was added dry DMF (10 mL). 
The solution was stirred at 25
o
C and dry CH2Cl2 (25 mL) was added, and the resulting solution 
was stirred for 18 h. The reaction was partitioned between water (150 mL) and CH2Cl2 (150 
mL). The pH of the aqueous layer was adjusted to 3 using 2N HCl. The organic layer was 
removed, and the aqueous layer was extracted twice with CH2Cl2 (150 mL each). The combined 
organic layers were dried (anhydrous MgSO4), filtered and concentrated to yield a sticky solid 
which was purified by silica gel chromatography (30:1 CH2Cl2:MeOH) to yield compound 76, 
1.6 g (72% yield) as a white solid. 
General Procedure F (Coupling): 
To the 2-chlorotrityl resin attached peptide (0.54 mmol) with free N-terminal amine was added a 
solution of Fmoc-amino acid (1.62 mmol, 3 equiv.) and HBTU (1.46 mmol, 2.7 equiv.) in dry 
DMF (13 mL) containing 4.2 % diisopropylethyl amine. The mixture was subjected to 
microwave irradiation (25 W, 5 min, 75 
o
C) with stirring. The reaction mixture was filtered and 
washed with DMF (20 mL each, 5 times). 
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General Procedure G (Fmoc deprotection):  
A solution of 20% piperidine in DMF (20 mL) was added to the 2-chlorotrityl resin attached 
peptide (0.54 mmol) having an Fmoc protected N-terminal amine and subjected to microwave 
irradiation (50 W, 3 min, 75 
o
C). The reaction mixture was filtered and washed with DMF (20 ml 
each, 5 times).   
General Procedure H (Cleavage): 
The 2-chlorotrityl resin attached peptide (0.54 mmol) was washed with dichloromethane (20 mL) 
and mixed with 20 mL of a cleavage cocktail solution consisting of 95% trifluoroacetic acid 
(TFA), 2.5% triisopropylsilane (TIPS), and 2.5% water.  The mixture was irradiated in a 
microwave reactor (20 W, 38 
o
C) for 18 min.  The reaction mixture was filtered into a 100 mL 
flask and diluted with 100 mL of cold hexane:ether (1:1) to precipitate out the desired peptide as 
a white solid.  The solid peptide was collected by centrifugation (2500 rpm) and washed three 
times with cold hexane:ether (1:1) to give the product peptide as a white solid (yields 45-94%). 
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IV.II. Experimental Procedures 
 
{1-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethyl}-carbamic acid benzyl ester 
(1).  
O
N
H
O
N
H
H
NO
O
O
H
 
Followed General Procedure B: Started with ester 54 yielding compound 1 (61%) as a white 
solid. 
1
H NMR δ 9.48 (br. s., 1H), 8.32 (br. s., 1H), 7.28 - 7.39 (m, 5H), 6.02 (br. s., 1H), 5.57 (d, 
J = 6.64 Hz, 1H), 5.11 (s, 2H), 4.28 - 4.41 (m, 2H), 3.27 - 3.39 (m, 2H), 2.33 - 2.50 (m, 2H), 
1.95 (d, J = 5.47 Hz, 1H), 1.78 - 1.90 (m, 1H), 1.70 (br. s., 1H), 1.44 (d, J = 7.03 Hz, 3H); 
13
C 
NMR δ 199.6, 180.0, 173.6, 155.8, 136.3, 128.5, 128.1, 128.0, 66.9, 58.0, 50.5, 40.6, 38.3, 29.6, 
28.8, 19.2; MS, m/z 384.1 (M+Na)
+
. 
2-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-piperidine-1-carboxylic acid benzyl 
ester (2). 
O
N
H
O
H
NO
HN
OO
 
 Followed General Procedure B. Started with ester 55 yielding compound 2 (52%) as a white 
solid. 
1
H NMR δ 9.44 (s, 1H), 8.25 (s, 1H), 7.28 - 7.39 (m, 5H), 5.69 - 5.99 (m, 1H), 5.11 (s, 
2H), 4.80 - 4.98 (m, 1H), 4.02 - 4.40 (m, 1H), 3.20 - 3.39 (m, 2H), 3.80 - 3.11 (m, 2H), 2.21 - 
2.44 (m, 3H), 1.78 - 1.99 (m, 3H), 1.58 - 1.72 (m, 3H), 1.39 - 1.50 (m, 2H); MS, m/z 424.5 
(M+Na)
+
. 
(1-{1-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-ethyl)-
carbamic acid benzyl ester (3).  
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O
N
H
O
N
H
H
NO
O
H
N
O O
H
 
Followed General Procedure B: Started with ester 63 yielding compound 3 (76%) as a white 
solid.  
1
H NMR δ 9.48 (s, 1H), 8.39 (br. s., 1H), 7.29 - 7.38 (m, 5H), 7.00 (br. s., 1H), 6.18 (br. 
s., 1H), 5.64 (br. s., 1H), 5.04 - 5.14 (m, 2H), 4.53 - 4.60 (m, 1H), 4.20 - 4.34 (m, 2H), 3.26 - 
3.37 (m, 2H), 2.34 - 2.51 (m, 2H), 1.90 - 1.97 (m, 2H), 1.77 - 1.88 (m, 1H), 1.42 (d, J = 7.03 Hz, 
3H), 1.38 (d, J = 7.03 Hz, 3H); 
13C NMR δ 199.7, 179.9, 173.4, 172.5, 156.0, 136.2, 128.3, 
128.0, 127.9, 66.7, 57.4, 50.7, 48.9, 40.4, 38.0, 29.7, 28.2, 18.4, 18.3; MS, m/z 455.6 (M+Na)
+
. 
[2-(Formyl-{1-[1-formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethyl}-amino)-1-
methyl-ethyl]-carbamic acid benzyl ester (4). 
O
N
H
O
N
H
NO
N
H
H
OH
O
O
 
 Followed General Procedure B: Started with ester 73 yielding compound 4 (65%) as a white 
solid. 
1
H NMR δ 9.41 - 9.49 (m, 1H), 9.03 (br. s., 1H), 8.81 - 8.87 (m, 1H), 8.55 - 8.60 (m, 1H), 
8.39 (d, J = 5.86 Hz, 1H), 8.27 (br. s., 1H), 7.94 - 8.09 (m, 1H), 7.23 - 7.38 (m, 5H), 6.11 - 6.29 
(m, 1H), 5.53 - 5.78 (m, 1H), 4.95 - 5.14 (m, 2H), 4.08 - 4.42 (m, 2H), 3.78 - 4.01 (m, 2H), 3.59 - 
3.73 (m, 2H), 3.03 - 3.48 (m, 3H), 2.25 - 2.54 (m, 2H), 2.01 - 2.23 (m, 2H), 1.70 - 1.95 (m, 2H), 
1.37 - 1.60 (m, 2H), 1.07 - 1.29 (m, 6H); MS, m/z 469.3 (M+Na)
+
. 
(1-{1-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-ethyl)-
carbamic acid benzyl ester (5). 
O
N
H
O
H
N
H
NO
N
H
H
O
O
O
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 Followed General Procedure B: Started with ester 64 yielding compound 5 (52%) as a white 
solid. 
1
H NMR δ 9.44 (s, 1H), 8.63 (d, J = 5.08 Hz, 1H), 7.30 - 7.39 (m, 5H), 6.96 (d, J = 7.81 
Hz, 1H), 6.18 (d, J = 7.81 Hz, 1H), 6.00 (br. s., 1H), 5.02 - 5.12 (m, 2H), 4.66 (quin, J = 7.32 Hz, 
1H), 4.32 (quin, J = 7.22 Hz, 1H), 4.20 - 4.27 (m, 1H), 3.18 - 3.28 (m, 2H), 2.29 - 2.48 (m, 2H), 
1.86 - 1.92 (m, 2H), 1.74 - 1.85 (m, 1H), 1.37 - 1.45 (m, 6H); 
13C NMR δ 200.1, 180.2, 173.4, 
172.2, 156.2, 136.1, 128.6, 128.3, 128.2, 67.1, 58.2, 50.7, 48.8, 40.7, 38.7, 29.4, 28.8, 18.5, 18.3; 
MS, m/z 455.2 (M+Na)
+
. 
 
(1-{1-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-naphthalen-
1-yl-ethyl)-carbamic acid benzyl ester (7). 
O
N
H
N
H
O
H
NO
HO N
H
O
O  
 Followed General Procedure B: Started with ester 23 yielding compound 7 (72%) as a white 
solid. 
1
H NMR δ 9.40 (s, 1H), 8.16 (d, J = 8.20 Hz, 1H), 8.08 (d, J = 5.86 Hz, 1H), 7.83 (d, J = 
8.98 Hz, 1H), 7.70 - 7.76 (m, 1H), 7.44 - 7.54 (m, 2H), 7.23 - 7.35 (m, 7H), 7.01 (d, J = 7.42 Hz, 
1H), 6.19 (s, 1H), 5.69 (d, J = 7.03 Hz, 1H), 5.02 (s, 2H), 4.56 - 4.66 (m, 1H), 4.45 - 4.53 (m, 
1H), 4.21 (d, J = 4.69 Hz, 1H), 3.60 (dd, J = 6.64, 14.06 Hz, 1H), 3.45 (dd, J = 6.64, 13.86 Hz, 
1H), 3.21 - 3.28 (m, 2H), 2.26 - 2.39 (m, 2H), 1.70 - 1.87 (m, 3H), 1.35 (d, J = 7.07 Hz, 3H);
 13
C 
NMR δ 199.9, 179.9, 173.0, 170.9, 156.1, 136.0, 133.8, 132.5, 132.0, 128.8, 128.5, 128.2, 128.0, 
127.9, 127.7, 126.4, 125.8, 125.3, 123.6, 67.0, 57.7, 55.8, 49.0, 40.5, 38.2, 35.4, 29.7, 29.2, 28.6, 
18.4; MS, m/z 581.4 (M+Na)
+
. 
 
(1-{1-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-naphthalen-
2-yl-ethyl)-carbamic acid benzyl ester (8).  
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O
N
H
N
H
O
H
NO
O N
H
O
O
H
 
Followed General Procedure B: Started with ester 80 yielding compound 8 (38%) as a white 
solid. 
1
H NMR δ 9.36 (s, 1H), 8.26 (d, J = 5.08 Hz, 1H), 7.75 - 7.80 (m, 2H), 7.71 - 7.75 (m, 
2H), 7.62 (s, 1H), 7.42 - 7.46 (m, 2H), 7.21 - 7.34 (m, 7H), 7.12 (d, J = 7.42 Hz, 1H), 6.22 (br. s., 
1H), 5.61 (d, J = 7.42 Hz, 1H), 4.97 - 5.07 (m, 2H), 4.49 - 4.64 (m, 2H), 4.15 - 4.22 (m, 2H), 
3.13 - 3.33 (m, 4H), 2.22 - 2.42 (m, 2H), 1.65 - 1.84 (m, 3H), 1.32 - 1.38 (m, 3H); 
13C NMR δ 
199.9, 180.0, 173.2, 170.9, 156.2, 136.0, 133.8, 133.3, 132.3, 128.5, 128.3, 128.2, 128.1, 127.9, 
127.6, 127.6, 127.4, 126.1, 125.8, 67.1, 57.9, 56.0, 49.0, 40.5, 38.3, 29.5, 29.2, 28.6, 18.5; MS, 
m/z 581.5 (M+Na)
+
. 
 
(2-Biphenyl-4-yl-1-{1-[1-formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-
ethylcarbamoyl}-ethyl)-carbamic acid benzyl ester (9).  
O
N
H
O
N
H
H
NO
O
H
N
O O
H
 
Followed General Procedure B: Started with ester 81 to give compound 9 (60% yield) as a white 
solid.
 
 
1
H NMR δ 9.44 (s, 1H), 8.39 (br. s., 1H), 7.18 - 7.58 (m, 15H), 6.53 (br. s., 1H), 5.74 (d, J 
= 7.03 Hz, 1H), 4.97 - 5.10 (m, 2H), 4.51 - 4.63 (m, 2H), 4.22 - 4.30 (m, 1H), 3.00 - 3.28 (m, 
4H), 2.34 - 2.43 (m, 1H), 2.21-2.32 (m, 1H), 1.88 - 1.98 (m, 1H), 1.79 - 1.88 (m, 1H), 1.67 - 1.78 
(m, 1H), 1.32 - 1.43 (m, 3H);
 13C NMR δ 200.0, 180.3, 173.6, 171.2, 156.4, 140.8, 140.0, 136.3, 
135.5, 130.0, 129.0, 128.8, 128.5, 128.3, 127.5, 127.2, 67.4, 58.2, 56.3, 49.3, 40.8, 38.5, 38.0, 
29.9, 28.8, 19.0; MS, m/z 607.1 (M+Na)
+
. 
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(1-{2-tert-Butoxy-1-[1-formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-
2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (11).  
O
N
H
N
H
O
H
NO
HO N
H
O
O
O
 
Followed General Procedure B: Started with ester 83 yielding compound 11 (45%) as a white 
solid. 
1
H NMR δ 9.46 (s, 1H), 8.20 (d, J = 8.20 Hz, 1H), 7.88 (d, J = 7.03 Hz, 1H), 7.84 (d, J = 
8.59 Hz, 1H), 7.74 (d, J = 7.42 Hz, 1H), 7.46 - 7.57 (m, 2H), 7.27 - 7.38 (m, 7H), 6.91 (d, J = 
7.42 Hz, 1H), 5.63 (br. s., 1H), 5.45 (d, J = 6.64 Hz, 1H), 5.06 (s, 2H), 4.59 - 4.68 (m, 1H), 4.48 
- 4.53 (m, 1H), 4.26 - 4.34 (m, 1H), 3.81 (d, J = 6.64 Hz, 1H), 3.67 (dd, J = 7.03, 14.25 Hz, 1H), 
3.51 (dd, J = 7.03, 14.06 Hz, 1H), 3.19 - 3.32 (m, 2H), 2.25 - 2.36 (m, 2H), 1.72 - 1.85 (m, 3H), 
1.06 (s, 9H); 
13C NMR δ 200.0, 184.7, 179.4, 170.8, 156.3, 135.9, 134.9, 133.9, 132.4, 132.0, 
128.8, 128.5, 128.2, 128.1, 127.7, 126.5, 125.9, 125.4, 123.7, 73.5, 67.3, 61.4, 57.5, 56.0, 53.3, 
40.3, 37.7, 35.4, 29.8, 28.5, 27.3; MS, m/z 653.3 (M+Na)
+
. 
 
(1-{1-[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-2-hydroxy-ethylcarbamoyl}-2-
naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (12).  
O
N
H
N
H
O
H
NO
O N
H
O
O
OH
H
 
The aldehyde 11 (0.0095 mmol) was dissolved in 1:1 TFA:CH2Cl2 (0.5 mL) and stirred at 25
o
C 
for 1 h. The solvents were removed on a rotary evaporator and the remaining residue was 
purified by silica gel column chromatography (1:1 CH2Cl2:2-propanol) to yield compound 12 (4 
mg, 73%) as a white solid. 
1
H NMR δ 9.44 (s, 1H), 8.11 - 8.21 (m, 1H), 7.84 (d, J = 8.20 Hz, 
1H), 7.74 (d, J = 8.20 Hz, 1H), 7.43 - 7.58 (m, 2H), 7.22 - 7.39 (m, 7H), 5.84 - 5.90 (m, 1H), 
5.55 - 5.62 (m, 1H), 5.02 (br. s., 2H), 4.50 - 4.68 (m, 2H), 4.32 - 4.48 (m, 1H), 3.83 - 3.99 (m, 
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2H), 3.57 - 3.70 (m, 2H), 3.40 - 3.50 (m, 1H), 3.20 - 3.21 (m, 1H), 2.36 (br. s., 1H), 1.95 - 2.08 
(m, 1H), 1.13-1.22 (m, 2H); MS, m/z 597.5 (M+Na)
+
. 
 
{1-[2-Isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-ethyl}-
carbamic acid benzyl ester (13).  
O
N
H
O
N
H
H
NO
O
O
N
H
O
 
Followed General Procedure C: Started with aldehyde 1 yielding compound 13 (46%) as a white 
solid. 
1
H NMR δ 8.30 (s, 1H), 7.28 - 7.39 (m, 5H), 6.73 (s, 1H), 5.81 (s, 1H), 5.42 (d, J = 7.22 
Hz, 1H), 5.19 - 5.29 (m, 1H), 5.11 (s, 2H), 4.28 - 4.39 (m, 1H), 3.95 - 4.09 (m, 1H), 3.23 - 3.40 
(m, 2H), 2.41 - 2.59 (m, 2H), 2.05 - 2.15 (m, 1H), 1.85 - 2.01 (m, 2H), 1.39 (d, J = 7.03 Hz, 3H), 
1.13 - 1.21 (m, 6H); 
13C NMR δ 195.5, 180.1, 171.1, 165.9, 158.7, 136.6, 128.7, 128.3, 128.2, 
67.1, 54.1, 50.5, 42.0, 40.8, 39.3, 32.1, 29.5, 28.9, 22.6, 22.5; MS, m/z 469.1 (M+Na)
+
. 
(1-{1-[2-Isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-
ethylcarbamoyl}-ethyl)-carbamic acid benzyl ester (14).  
O
N
H
O
N
H
H
NO
O
H
N
O
O
N
H
O
 
Followed General Procedure C: Started with aldehyde 3 yielding compound 14 (64%) as a white 
solid.
 1
H NMR δ 8.37 (br. s., 1H), 7.29 - 7.38 (m, 5H), 6.90 (br. s., 1H), 6.80 (d, J = 8.20 Hz, 
1H), 6.17 (br. s., 1H), 5.60 (d, J = 6.25 Hz, 1H), 5.20 - 5.27 (m, 1H), 5.05 - 5.15 (m, 2H), 4.52 - 
4.60 (m, 1H), 4.20 - 4.29 (m, 1H), 3.99 - 4.08 (m, 1H), 3.34 (dd, J = 4.30, 8.98 Hz, 2H), 2.50 - 
2.60 (m, 1H), 2.45 (td, J = 4.10, 8.20 Hz, 1H), 2.04 - 2.11 (m, 1H), 1.88 - 2.01 (m, 2H), 1.34 - 
1.43 (m, 6H), 1.21 (d, J = 6.53 Hz, 3H), 1.20 (d, J = 6.54 Hz, 3H); 
13C NMR δ 195.2, 180.0, 
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172.4, 171.9, 158.5, 155.9, 136.2, 128.5, 128.2, 128.0, 67.0, 53.7, 50.7, 48.8, 41.8, 40.6, 39.0, 
31.9, 29.3, 28.4, 22.3, 22.3, 18.7; MS, m/z 540.4 (M+Na)
+
. 
[2-(Formyl-{1-[2-isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-
ethylcarbamoyl]-ethyl}-amino)-1-methyl-ethyl]-carbamic acid benzyl ester (15).  
O
N
H
O
N
H
NO
N
H
OH
O
O
O
N
H
 
Followed General Procedure C: Started with aldehyde 4 yielding compound 15 (79%) as a white 
solid. 
1
H NMR δ 9.21 - 9.29 (m, 2H), 8.59 - 8.65 (m, 1H), 8.33 - 8.41 (m, 1H), 8.20 - 8.29 (m, 
1H), 7.24 - 7.38 (m, 5H), 6.71 - 6.82 (m, 2H), 6.14 - 6.24 (m, 1H), 5.66 (d, J = 7.03 Hz, 1H), 
4.96 - 5.20 (m, 3H), 4.08 - 4.19 (m, 1H), 3.79 - 4.05 (m, 3H), 3.59 - 3.76 (m, 1H), 3.18 - 3.43 (m, 
4H), 2.48 - 2.62 (m, 1H), 2.41 (d, J = 3.91 Hz, 1H), 1.98 - 2.13 (m, 1H), 1.78 - 1.95 (m, 2H), 
1.38 - 1.55 (m, 3H), 1.10 - 1.29 (m, 9H); MS, m/z 554.6 (M+Na)
+
. 
 
(1-{1-[2-Isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-
ethylcarbamoyl}-ethyl)-carbamic acid benzyl ester (16).  
O
N
H
N
H
O
H
NO
O N
H
O
O
O
N
H
 
Followed General Procedure C: Started with aldehyde 5 yielding compound 16 (47%) as a white 
solid. 
1
H NMR δ 8.67 (d, J = 4.30 Hz, 1H), 7.31 - 7.40 (m, 5H), 6.73 - 6.82 (m, 2H), 6.21 (d, J = 
8.20 Hz, 1H), 5.86 (d, J = 13.28 Hz, 1H), 5.15 - 5.22 (m, 1H), 5.04 - 5.13 (m, 2H), 4.59 - 4.67 
(m, 1H), 4.29 - 4.38 (m, 1H), 3.96 - 4.08 (m, 1H), 3.16 - 3.26 (m, 2H), 2.48 - 2.59 (m, 1H), 2.34 - 
2.46 (m, 1H), 2.02 - 2.10 (m, 1H), 1.79 - 1.96 (m, 2H), 1.41 (d, J = 7.42 Hz, 3H), 1.38 (d, J = 
6.64 Hz, 3H), 1.20 (d, J = 6.45 Hz, 3H), 1.19 (d, J = 6.57 Hz, 3H); 
13C NMR δ 195.0, 180.1, 
172.4, 171.9, 158.5, 156.1, 136.1, 128.6, 128.3, 128.3, 67.1, 54.0, 50.7, 48.5, 41.7, 40.7, 39.6, 
31.2, 28.8, 22.3, 22.2, 18.6, 18.4; MS, m/z 540.2 (M+Na)
+
. 
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(1-{1-[2-Isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-
ethylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (17).  
O
N
H
N
H
O
H
NO
O N
H
O
O
O
N
H
 
Followed General Procedure C: Started with aldehyde 7 yielding compound 17 (81%) as a white 
solid. 
1
H NMR δ 8.30 (d, J = 5.47 Hz, 1H), 8.16 (d, J = 7.81 Hz, 1H), 7.84 (d, J = 8.59 Hz, 2H), 
7.74 (d, J = 7.42 Hz, 2H), 7.44 - 7.55 (m, 2H), 7.22 - 7.38 (m, 7H), 6.81 (d, J = 7.81 Hz, 1H), 
6.16 (br. s., 1H), 5.58 (d, J = 7.42 Hz, 1H), 5.15 - 5.22 (m, 1H), 5.02 (s, 2H), 4.55 - 4.64 (m, 1H), 
4.42 - 4.50 (m, 1H), 3.97 - 4.07 (m, 1H), 3.61 (dd, J = 6.44, 14.25 Hz, 1H), 3.46 (dd, J = 6.44, 
14.06 Hz, 1H), 3.26 - 3.35 (m, 1H),  2.37 - 2.56 (m, 2H), 2.00 - 2.08 (m, 1H), 1.86 - 1.97 (m, 
2H), 1.30 (d, J = 7.03 Hz, 3H), 1.15 - 1.22 (m, 6H); 
13C NMR δ 195.5, 180.2, 172.3, 170.9, 
158.7, 156.3, 136.3, 134.1, 132.8, 132.3, 129.1, 128.7, 128.4, 128.2, 128.1, 128.0, 126.7, 126.0, 
125.6, 123.9, 67.2, 56.0, 53.9, 49.1, 42.0, 40.9, 39.3, 35.7, 32.1, 28.7, 22.6, 22.5, 18.9; MS, m/z 
666.5 (M+Na)
+
. 
 
(1-{1-[2-Isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-
ethylcarbamoyl}-2-naphthalen-2-yl-ethyl)-carbamic acid benzyl ester (18).  
O
N
H
N
H
O
H
NO
O N
H
O
O
O
N
H
 
Followed General Procedure C: Started with aldehyde 9 yielding compound 18 (94%) as a white 
solid. 
1
H NMR δ 8.40 (d, J = 5.47 Hz, 1H), 7.77 - 7.81 (m, 1H), 7.71 - 7.76 (m, 2H), 7.61 (s, 
1H), 7.42 - 7.46 (m, 2H), 7.20 - 7.36 (m, 9H), 6.96 - 7.04 (m, 1H), 6.81 (d, J = 7.81 Hz, 1H), 
6.16 - 6.23 (m, 1H), 5.51 (br. s., 1H), 5.15 - 5.22 (m, 1H), 4.98 - 5.07 (m, 2H), 4.51 - 4.62 (m, 
2H), 3.98 - 4.07 (m, 1H), 3.18 - 3.32 (m, 4H), 2.44 - 2.54 (m, 1H), 2.34 - 2.43 (m, 1H), 2.00 - 
2.08 (m, 1H), 1.80 - 1.96 (m, 3H), 1.35 (d, J = 7.03 Hz, 3H), 1.20 (d, J = 6.46 Hz, 3H), 6.62 (d, J 
= 3.12 Hz, 3H); 
13C NMR δ 195.2, 179.9, 172.2, 170.6, 158.4, 156.0, 136.0, 133.8, 133.3, 132.4, 
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128.5, 128.3, 128.1, 127.9, 127.6, 127.4, 126.1, 125.7, 67.0, 55.9, 53.7, 48.8, 41.7, 40.6, 39.0, 
38.3, 31.7, 28.4, 22.3, 22.2, 18.7; MS, m/z 682.6 (M+K)
+
. 
 
(1-{2-tert-Butoxy-1-[2-isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-
ethylcarbamoyl]-ethylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (20).  
 
O
N
H
N
H
O
H
NO
O N
H
O
O
O
N
H
O
 
Followed General Procedure C: Started with aldehyde 11 yielding compound 20 (53%) as a 
white solid. 
1
H NMR δ 8.20 (br. s., 1H), 7.81 - 7.89 (m, 1H), 7.71 - 7.79 (m, 1H), 7.45 - 7.59 (m, 
2H), 7.23 - 7.41 (m, 7H), 6.75 - 6.80 (m, 1H), 6.65 - 6.71 (m, 1H), 6.00 (s, 1H), 5.42 - 5.49 (m, 
1H), 5.35 (d, J = 5.08 Hz, 1H), 4.98 - 5.18 (m, 2H), 4.61 - 4.69 (m, 1H), 4.35 - 4.41 (m, 1H), 
4.01 - 4.09 (m, 1H), 3.96 - 4.01 (m, 1H), 3.75 - 3.82 (m, 1H), 3.62 - 3.74 (m, 1H), 3.47 - 3.57 (m, 
1H), 3.27 - 3.38 (m, 2H), 3.15-3.21 (m, 1H), 2.45 (br. s., 1H), 2.26 - 2.36 (m, 1H), 2.01 (d, J = 
4.69 Hz, 2H), 1.54 - 1.70 (m, 2H), 1.16 - 1.38 (m, 15H); MS, m/z 738.3 (M+Na)
+
. 
 
(1-{1-[1-Isopropylcarbamoyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-
naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (21).  
O
N
H
N
H
O
H
NO
H
NO N
H
O
O  
To a solution of ester 23 (0.03 mmol) in MeOH (0.5 mL) was added isopropylamine (0.03 
mmol) and the solution was heated at 50
o
C for 48 h. The solvent was removed to give a crude 
solid that was purified by silica gel column chromatography (15:1 CH2Cl2:MeOH) to yield 
compound 21 (5 mg, 32%) as a white solid. 
1
H NMR δ 8.51 (d, J = 7.35 Hz, 1H), 8.17 (d, J = 
7.81 Hz, 1H), 8.02 - 8.07 (m, 1H), 7.83 - 7.94 (m, 2H), 7.74 - 7.82 (m, 1H), 7.46 - 7.58 (m, 2H), 
7.28 - 7.43 (m, 5H), 6.81 - 6.94 (m, 2H), 5.99 (br. s., 1H), 5.47 (d, J = 5.86 Hz, 1H), 5.01 (s, 2H), 
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4.51 - 4.66 (m, 1H), 4.26 - 4.40 (m, 1H), 3.98 - 4.07 (m, 1H), 3.63 - 3.73 (m, 1H), 3.32 - 3.44 (m, 
1H), 3.23 - 3.30 (m, 2H), 2.26 - 2.35 (m, 2H), 1.75 - 2.08 (m, 3H), 1.54 - 1.64 (m, 1H), 1.12 - 
1.20 (m, 9H); MS, m/z 638.1 (M+Na)
+
. 
 
(1-{1-[1-Cyclopropylcarbamoyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-
ethylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (22). 
O
N
H
N
H
O
H
NO
H
NO N
H
O
O  
 To a solution of ester 23 (0.03 mmol) in MeOH (0.5 mL) was added cyclopropylamine (0.5 mL) 
and the solution was heated at 50
o
C for 48 h. The solvent was removed to give a crude solid that 
was purified by silica gel column chromatography (15:1 CH2Cl2:MeOH) to yield compound 22 
(14 mg, 91%) as a white solid. 
1
H NMR δ 8.15 (d, J = 8.20 Hz, 1H), 7.91 (d, J = 6.64 Hz, 1H), 
7.85 (d, J = 8.20 Hz, 1H), 7.76 (d, J = 7.81 Hz, 1H), 7.46 - 7.57 (m, 2H), 7.27 - 7.38 (m, 7H), 
7.07 (br. s., 1H), 6.94 (br. s., 1H), 6.00 (br. s., 1H), 5.46 (d, J = 5.86 Hz, 1H), 5.01 (s, 2H), 4.56 - 
4.64 (m, 1H), 4.29 - 4.37 (m, 1H), 4.22 - 4.28 (m, 1H), 3.84 - 3.89 (m, 1H), 3.63 - 3.73 (m, 1H), 
3.34 - 3.43 (m, 1H), 3.23 - 3.29 (m, 2H), 2.67 - 2.78 (m, 1H), 2.35 - 2.40 (m, 1H), 2.24 - 2.33 (m, 
1H), 1.96 - 2.06 (m, 1H), 1.72 - 1.90 (m, 1H), 1.55 - 1.64 (m, 1H), 0.84 - 0.90 (m, 4H), 0.71 - 
0.79 (m, 3H); MS, m/z 636.3 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-propionylamino]-3-
(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (23).  
O
N
H
N
H
O
H
NO
OMeO N
H
O
O  
Followed General Procedure A: The N-Boc-dipeptide 74 was used in place of 76 to give 
compound 23 (91% yield) as a white solid. 
1
H NMR δ 8.16 (d, J = 8.20 Hz, 1H), 7.83 (d, J = 
8.20 Hz, 2H), 7.73 (d, J = 7.03 Hz, 1H), 7.43 - 7.53 (m, 2H), 7.22 - 7.36 (m, 7H), 6.98 (d, J = 
4.30 Hz, 1H), 6.40 (br. s., 1H), 5.65 (d, J = 6.64 Hz, 1H), 5.02 (s, 2H), 4.57 - 4.65 (m, 1H), 4.40 
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- 4.53 (m, 2H), 3.71 (s, 3H), 3.60 (dd, J = 6.25, 14.06 Hz, 1H), 3.45 (dd, J = 6.25, 13.99 Hz, 1H), 
3.23 - 3.32 (m, 2H), 2.30 - 2.43 (m, 2H), 2.07 - 2.16 (m, 1H), 1.75 - 1.90 (m, 2H), 1.31 (d, J = 
7.03 Hz, 3H); 
13C NMR δ 179.8, 172.3, 172.0, 170.8, 156.0, 136.1, 133.8, 132.5, 132.0, 128.8, 
128.5, 128.1, 127.9, 127.8, 127.7, 126.4, 125.7, 125.3, 123.6, 66.9, 55.7, 52.4, 51.5, 49.0, 40.5, 
38.4, 35.5, 32.9, 28.3, 18.5; MS, m/z 611.5 (M+Na)
+
. 
 
(1-{1-[1-Hydroxymethyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-
naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (23a).  
O
N
H
N
H
H
NO
OHO N
H
O
O  
To a solution of ester 23 (0.31 mmol) in CH2Cl2/THF (1:1) (5 mL) at 0
o
C was added LiBH4 
(0.46 mmol) in small portions over a period of 1 h. The reaction was quenched with NH4Cl (0.5 
mL) and diluted with CH2Cl2 (50 mL) and water (50 mL). The organic layer was removed and 
aqueous layer extracted with CH2Cl2 (50 mL x 4). The combined organic layers were dried 
(MgSO4), filtered and concentrated to yield compound 23a (143 mg, 84%) as a white solid. 
1
H 
NMR δ 8.15 (d, J = 8.20 Hz, 1H), 7.84 (d, J = 7.81 Hz, 1H), 7.75 (d, J = 8.20 Hz, 1H), 7.57 (d, J 
= 7.03 Hz, 1H), 7.45 - 7.54 (m, 2H), 7.23 - 7.39 (m, 7H), 6.99 (d, J = 6.64 Hz, 1H), 6.00 (br. s., 
1H), 5.60 (d, J = 6.64 Hz, 1H), 5.02 (s, 2H), 4.58 (d, J = 6.64 Hz, 1H), 4.35 - 4.44 (m, 1H), 3.87 
- 3.96 (m, 1H), 3.49 - 3.67 (m, 3H), 3.41 (dd, J = 7.81, 14.06 Hz, 1H), 3.20 - 3.27 (m, 2H), 2.27 - 
2.38 (m, 2H), 1.66 - 1.94 (m, 3H), 1.27 (d, J = 7.42 Hz, 3H); MS, m/z 583.3 (M+Na)
+
. 
 
(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-
2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (24).  
O
N
H
O
N
H
H
NO
O
H
N
O
O
H
 
104 
 
Followed General Procedure B: To a solution of ester 84 (0.63 mmol) in CH2Cl2/MeOH (1:1) (8 
mL) at 0
o
C was added NaBH4 (5.6 mmol) in small portions over a period of 4 h. The reaction 
was quenched with water (0.5 mL) and diluted with 100 mL of CH2Cl2. The solution was passed 
through a short plug of silica gel and the organic material washed thoroughly with 30:1 
CH2Cl2/MeOH (100 mL). The filtrate was concentrated to yield a solid which was dissolved in 
distilled CH2Cl2 (15 mL) and treated with Dess-Martin periodinane (DMP) for 2 h at 25
o
C. The 
reaction mixture was filtered and the filtrate was concentrated and purified by silica gel 
chromatography using a gradient solvent elution of 25% acetone/CH2Cl2 to 100% acetone. The 
fractions containing the product were combined and concentrated to give a white solid to which 
was added CHCl3 (20 mL). After sitting for 10 min the mixture was filtered through a glass frit 
funnel (fine) and the filtrate was concentrated to provide aldehyde 24 (90% yield) as a white 
solid, mp 85 – 88oC. 1H NMR δ 9.39 (s, 1H), 8.15 (s, 1H), 8.14 (s, 1H), 7.81 - 7.86 (m, 1H), 7.70 
- 7.75 (m, 1H), 7.44 - 7.53 (m, 2H), 7.28 - 7.36 (m, 5H), 7.25 (br. s., 1H), 7.03 - 7.10 (m, 1H), 
6.50 (s, 1H), 5.60 (d, J = 7.8 Hz, 2H), 5.01 (s, 2H), 4.57 - 4.68 (m, 2H), 4.20 - 4.26 (m, 1H), 3.64 
(dd, J = 6.6, 14.1 Hz, 1H), 3.42 (dd, J = 6.6, 14.1 Hz, 1H), 3.25 (d, J = 7.8 Hz, 2H), 2.22 - 2.38 
(m, 2H), 1.95 - 2.08 (m, 2H), 1.39 - 1.84 (m, 6H), 0.89 (d, J = 6.7 Hz, 3H, CH3),  0.88 (d, J = 6.7 
Hz, 3H, CH3);
 13C NMR δ 199.9, 179.8, 173.0, 171.1, 156.2, 135.9, 133.8, 132.5, 132.0, 128.8, 
128.5, 128.2, 127.9, 127.9, 127.7, 126.4, 125.8, 125.3, 123.6, 67.1, 57.5, 55.8, 51.8, 41.6, 40.5, 
38.1, 35.1, 29.7, 28.4, 24.7, 22.8, 21.8; MS, m/z 623.3 (M+Na)
+
;  HRMS calcd for 
C34H40N4O6Na (M+Na)
+
 623.2846, found 623.2860. 
 
(1-{2-Cyclohexyl-1-[1-formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-
2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (25).  
O
N
H
O
N
H
H
NO
O
H
N
O
O
H
 
Followed General Procedure B: Started with ester 85 yielding compound 25 (69%) as a white 
solid. 
1
H NMR δ  9.39 (s, 1H), 8.14 (d, J = 7.81 Hz, 1H), 8.03 (d, J = 5.47 Hz, 1H), 7.82 (d, J = 
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9.37 Hz, 1H), 7.72 (dd, J = 3.51, 5.86 Hz, 1H), 7.43 - 7.52 (m, 2H), 7.20 - 7.35 (m, 7H), 7.08 (d, 
J = 7.81 Hz, 1H), 6.46 (s, 1H), 5.63 (d, J = 7.03 Hz, 1H), 5.01 (br. s., 2H), 4.56 - 4.66 (m, 2H), 
4.19 - 4.28 (m, 1H), 3.63 (dd, J = 6.64, 13.67 Hz, 1H), 3.42 (dd, J = 6.64, 13.50 Hz, 1H), 3.16 - 
3.28 (m, 2H), 2.21 - 2.37 (m, 2H), 2.07 - 2.20 (m, 1H), 1.55 - 1.83 (m, 9H), 1.37 - 1.47 (m, 1H), 
1.20 - 1.29 (m, 1H), 1.07 - 1.17 (m, 2H), 0.79 - 0.95 (m, 2H); 
13C NMR δ 200.1, 180.1, 173.3, 
171.3, 156.4, 136.2, 134.1, 132.8, 132.2, 129.0, 128.7, 128.4, 128.1, 128.1, 127.9, 126.6, 126.0, 
125.6, 123.8, 67.3, 57.7, 56.0, 51.5, 40.7, 40.3, 38.3, 35.4, 34.3, 33.7, 32.7, 30.0, 28.6, 26.5, 26.4, 
26.2; MS, m/z 663.3 (M+Na)
+
. 
 
(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-
2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (27). 
O
N
H
O
N
H
H
NO
O
H
N
O
O
H
 
 Followed General Procedure B: Started with ester 87 giving compound 27 (93% yield) as a 
white solid, mp 95 – 97oC. 1H NMR δ 9.38 (s, 1H), 8.40 (d, J = 5.1 Hz, 1H), 8.15 (d, J = 8.2 Hz, 
1H), 7.82 (d, J = 8.6 Hz, 1H), 7.69 - 7.75 (m, 1H), 7.43 - 7.53 (m, 3H), 7.20 - 7.36 (m, 6H), 6.33 
(d, J = 6.6 Hz, 1H), 6.21 (d, J = 7.4 Hz, 1H), 5.69 (br. s., 1H), 4.94 - 5.04 (m, 2H), 4.60 - 4.69 
(m, 1H), 4.48 - 4.55 (m, 1H), 4.08 - 4.16 (m, 1H), 3.57 (d, J = 6.6 Hz, 2H), 3.09 - 3.18 (m, 2H), 
2.26 (br. s., 2H), 2.07 (br. s., 1H), 1.69 - 1.79 (m, 2H), 1.55 (br. s., 1H), 1.14 (br. s., 2H), 0.70 - 
0.83 (m, 6H, 2 x CH3); 
13C NMR δ 200.4, 180.0, 173.3, 171.2, 156.4, 136.4, 134.1, 133.0, 132.4, 
129.0, 128.8, 128.5, 128.4, 128.3, 128.0, 126.6, 126.0, 125.7, 124.0, 67.2, 58.3, 56.5, 51.8, 41.2, 
40.8, 38.7, 35.6, 29.8, 28.9, 24.7, 23.1, 21.8.  MS, m/z 623.1 (M+Na)
+
; HRMS calcd for 
C34H40N4O6Na (M+Na)
+
 623.2846, found 623.2829. 
 
(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-
2-phenyl-ethyl)-carbamic acid benzyl ester (28).  
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Followed General Procedure B: Started with ester 88 giving compound 28 (80% yield) as a 
white solid, mp 91 – 93oC. 1H NMR δ 9.44 (s, 1H), 8.13 (br. s., 1H), 7.08 - 7.37 (m, 10H), 6.68 
(d, J = 5.1 Hz, 1H), 5.49 (br. s., 1H), 5.00 - 5.08 (m, 2H), 4.60 - 4.68 (m, 1H), 4.46 - 4.53 (m, 
1H), 4.27 - 4.35 (m, 1H), 3.21 - 3.34 (m, 2H), 2.99 - 3.14 (m, 2H), 2.27 - 2.42 (m, 2H), 1.44 - 
2.10 (m, 6H), 0.90 (d, J = 6.3 Hz, 6H, 2 x CH3); 
13C NMR δ 200.1, 180.2, 173.3, 171.3, 156.4, 
136.5, 136.3, 129.6, 128.8, 128.7, 128.5, 128.2, 127.3, 67.4, 57.6, 56.3, 52.0, 42.0, 40.8, 38.3, 
38.2, 30.0, 28.5, 25.0, 23.1, 22.1.  MS, m/z 573.2 (M+Na)
+
; HRMS calcd for C30H39N4O6 
(M+H)
+
 551.2870, found 551.2882. 
 
(2-tert-Butoxy-1-{1-[1-formyl-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-3-methyl-
butylcarbamoyl}-propyl)-carbamic acid benzyl ester (29). 
O
N
H
N
H O
H
NO
HO N
H
O
O
O
 
 Followed General Procedure B: Started with ester 89 yielding compound 29 (63%) as a white 
solid. 
1
H NMR δ 9.49 (s, 1H), 8.12 (d, J = 5.86 Hz, 1H), 7.48 (d, J = 7.81 Hz, 1H), 7.30 - 7.38 
(m, 5H), 6.40 (br. s., 1H), 5.91 (d, J = 4.69 Hz, 1H), 5.04 - 5.16 (m, 2H), 4.45 - 4.55 (m, 1H), 
4.31 - 4.40 (m, 1H), 4.14 - 4.21 (m, 2H), 3.23 - 3.36 (m, 2H), 2.27 - 2.47 (m, 2H), 1.95 - 2.06 (m, 
2H), 1.84 - 1.93 (m, 1H), 1.74 - 1.83 (m, 1H), 1.64 - 1.74 (m, 1H), 1.53 - 1.62 (m, 1H), 1.25 (s, 
9H), 1.06 (d, J = 5.86 Hz, 3H), 0.89 - 0.98 (m, 6H); 
13C NMR δ 199.8, 180.1, 173.0, 169.9, 
156.4, 136.4, 128.8, 128.5, 128.3, 75.6, 67.2, 67.0, 59.2, 57.7, 52.2, 41.9, 40.7, 38.1, 30.0, 28.7, 
28.4, 25.1, 23.1, 22.3, 17.5; MS, m/z 583.3 (M+Na)
+
. 
 
107 
 
(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-
2-naphthalen-2-yl-ethyl)-carbamic acid benzyl ester (30). 
O
N
H
O
N
H
H
NO
O
H
N
O
O
H
 
 Followed General Procedure B: Started with ester 90 yielding compound 30 (93% yield) as a 
white solid, mp 146 – 148oC. 1H NMR δ 9.36 (s, 1H), 8.24 (br. s., 1H), 7.75 - 7.80 (m, 1H), 7.70 
- 7.73 (m, 2H), 7.62 (s, 1H), 7.40 - 7.46 (m, 3H), 7.20 - 7.32 (m, 5H), 6.98 (d, J = 7.8 Hz, 1H), 
6.35 (br. s., 1H), 5.51 (d, J = 7.0 Hz, 1H), 4.98 - 5.07 (m, 2H), 4.56 - 4.65 (m, 2H), 4.20 (q, J = 
7.0 Hz, 1H), 3.13 - 3.32 (m, 4H), 2.20 - 2.39 (m, 2H), 1.75 - 1.82 (m, 2H), 1.61 - 1.74 (m, 2H), 
1.42 - 1.58 (m, 2H), 0.88 (d, J = 6.5 Hz, 3H, CH3), 0.86 (d, J = 6.5 Hz, 3H, CH3); 
13C NMR δ 
200.1, 180.1, 173.3, 171.2, 156.4, 136.2, 134.0, 133.6, 132.6, 128.8, 128.5, 128.45, 128.4, 128.2, 
127.9, 127.6, 126.4, 126.0, 67.4,  58.0, 56.4, 52.1, 41.9, 40.8, 38.5, 38.4, 29.8, 28.8, 25.0, 23.1, 
22.1.  MS, m/z 623.2 (M+Na)
+
; HRMS calcd for C34H41N4O6 (M+H)
+
 601.3026, found 
601.3029. 
 
(2-Biphenyl-4-yl-1-{3-methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-
butylcarbamoyl}-ethyl)-carbamic acid benzyl ester (31). 
O
N
H
O
N
H
H
NO
O
H
N
O O
H
 
Followed General Procedure B: Started with ester 91 to give compound 31 (79% yield) as a 
white solid, mp 127 – 130oC. 1H NMR δ 9.45 (s, 1H), 8.34 (br. s., 1H), 7.20 - 7.56 (m, 14H), 
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6.99 (br. s., 1H), 6.45 (br. s., 1H), 5.51 (br. s., 1H), 5.01 - 5.10 (m, 2H), 4.58 - 4.66 (m, 1H), 4.50 
- 4.57 (m, 1H), 4.23 - 4.30 (m, 1H), 3.19 - 3.32 (m, 2H), 3.05 - 3.19 (m, 2H), 2.33 - 2.44 (m, 1H), 
2.21 - 2.32 (m, 1H), 1.89 - 2.01 (m, 1H), 1.79 - 1.88 (m, 1H), 1.63 - 1.77 (m, 2H), 1.47 - 1.62 (m, 
2H), 0.91 (d, J = 6.2 Hz, 3H, CH3), 0.90 (d, J = 6.2 Hz, 3H, CH3);
 13C NMR δ 199.9, 180.2, 
173.3, 171.2, 156.4, 140.8, 140.1, 136.2, 135.5, 130.0, 129.0, 128.8, 128.5, 128.3, 127.6, 127.5, 
127.1, 67.4, 58.0, 56.3, 52.1, 41.9, 40.8, 38.5, 37.8, 29.9, 28.8, 25.0, 23.1, 22.1.  MS, m/z 649.6 
(M+Na)
+
; HRMS calcd for C36H42N4O6Na (M+Na)
+
 649.3002, found 649.2995. 
 
(1-{1-[2-Isopropylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-3-
methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (32). 
O
N
H O
N
H
H
NO
O HN
O
O
O
N
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Followed General procedure C: Isopropylisocyanide (0.067 mmol) was added to a solution of 
aldehyde 24 (0.067 mmol) in distilled EtOAc (2 mL) and AcOH (1 drop) and the resulting 
solution stirred at 25
o
C for 18 h. The solvent was removed in vacuo and the residue was 
dissolved in a 1:1 solution of MeOH/H2O (5 mL) and K2CO3 (0.16 mmol). After stirring for 3 h 
at 25
o
C, the reaction was diluted with water and extracted with EtOAc (4 times). The combined 
organic layers were dried (anhydrous MgSO4), filtered, and concentrated to yield a residue. To it, 
CH2Cl2 (2 mL) was added followed by DMP (0.13 mmol) and the reaction was stirred at 25
o
C 
for 2 h. The solvent was removed in vacuo and the residue was purified by silica gel 
chromatography using a gradient solvent elution of 25% acetone/CH2Cl2 to 100% acetone. The 
fractions containing the product were combined and concentrated to give a white solid to which 
was added CHCl3 (10 mL). After sitting for 10 min the mixture was filtered through a glass frit 
funnel (fine) and the filtrate was concentrated to provide ketoamide 32 (36 mg, 79% yield) as a 
white solid, mp 119 – 121oC. 1H NMR δ 8.37 (d, J = 5.9 Hz, 1H), 8.16 (d, J = 8.2 Hz, 1H), 7.82 - 
7.86 (m, 2H), 7.74 (d, J = 7.8 Hz, 2H), 7.44 - 7.53 (m, 3H), 7.21 - 7.36 (m, 4H), 6.83 (d, J = 8.6 
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Hz, 1H), 6.80 (d, J = 8.2 Hz, 2H), 6.53 (s, 1H), 5.48 (d, J = 7.4 Hz, 1H), 5.17 - 5.24 (m, 1H), 
5.01 (s, 2H), 4.57 - 4.66 (m, 2H), 3.98 - 4.08 (m, 1H), 3.65 (dd, J = 6.1, 13.9 Hz, 1H), 3.44 (dd, J 
= 6.1, 14.0 Hz, 1H), 3.31 (d, J = 7.8 Hz, 2H), 2.38 - 2.55 (m, 2H), 1.88 - 2.06 (m, 2H), 1.50 - 
1.66 (m, 3H), 1.38 - 1.46 (m, 1H), 1.20 (d, J = 6.6 Hz, 3H, CH3), 1.19 (d, J = 6.5 Hz, 3H, CH3), 
0.89 (d, J = 6.2 Hz, 6H, 2xCH3); 
13C NMR δ 195.4, 180.0, 172.2, 171.1, 158.6, 156.3, 136.2, 
134.1, 132.7, 132.2, 129.0, 128.7, 128.4, 128.2, 128.1, 127.9, 126.6, 126.0, 125.6, 123.8, 67.3, 
55.9, 53.6, 51.7, 42.1, 41.9, 40.8, 39.2, 35.3, 32.1, 28.4, 24.8, 23.0, 22.6, 22.5, 22.2.  MS, m/z 
724.3 (M+K)
+
; HRMS calcd for C38H47N5O7Na (M+Na)
+
 708.3373, found 708.3378.   
 
(1-{1-[2-tert-Butylcarbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-3-
methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (33).  
O
N
H O
N
H
H
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Followed General Procedure C: Started with aldehyde 24 and used tert-butylisocyanide in place 
of isopropylisocyanide yielding compound 33 (54%) as a white solid.
1
H NMR δ 8.28 (br. s., 1H), 
8.17 (d, J = 7.42 Hz, 1H), 7.84 (d, J = 8.20 Hz, 1H), 7.74 (d, J = 7.81 Hz, 1H), 7.43 - 7.54 (m, 
2H), 7.21 - 7.36 (m, 7H), 6.76 (br. s., 1H), 6.44 (br. s., 1H), 5.44 - 5.49 (m, 1H), 5.16 - 5.23 (m, 
1H), 5.01 (br. s., 2H), 4.51 - 4.64 (m, 2H), 3.61 - 3.68 (m, 1H), 3.41 - 3.50 (m, 1H), 3.21 - 3.35 
(m, 2H), 2.38 - 2.55 (m, 2H), 1.99 - 2.03 (m, 1H), 1.89 - 1.98 (m, 2H), 1.52 - 1.66 (m, 2H), 1.38 
(s, 9H), 0.89 (d, J = 5.86 Hz, 6H); 
13C NMR δ 196.0, 180.2, 172.2, 171.1, 158.8, 156.3, 136.3, 
134.1, 132.8, 132.2, 129.1, 128.7, 128.4, 128.2, 128.1, 127.9, 126.6, 126.0, 125.6, 123.8, 67.3, 
56.0, 53.5, 51.8, 42.0, 40.9, 39.3, 35.4, 32.3, 28.5, 24.8, 23.0, 22.2; MS, m/z 722.3 (M+Na)
+
.  
 
(1-{1-[2-Carbamoyl-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-3-methyl-
butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (34). 
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Acetone cyanohydrin (0.084 mmol) was added to a solution of aldehyde 24 (0.042 mmol) and 
NEt3 (0.05 mmol) in CH2Cl2 (0.5 mL) and stirred at 25
o
C for 15 h. The reaction diluted with 
CH2Cl2 (5 mL) and 1M HCl (1 mL). The organic layer was removed and the aqueous layer was 
extracted with CH2Cl2 (5 mL x 4), combined organic layers were dried (Na2SO4), filtered and 
concentrated to yield the cyanohydrin intermediate as clear residue. The cyanohydrin 
intermediate (0.042 mmol) was dissolved in MeOH (1 mL) and cooled to 0
o
C followed by the 
addition of 30% H2O2 (0.29 mmol) and LiOH (0.063 mmol). After stirring at 0
o
C for 3 h the 
reaction was combined with saturated aq. NaHSO3 (1 mL) and water (10 mL). The reaction was 
extracted with CH2Cl2 (4 x 15 mL) and the combined organic extracts were dried (Na2SO4), 
filtered and concentrated to yield a hydroxyamide intermediate as a white solid. The 
hydroxyamide (0.042 mmol) was dissolved in dry CH2Cl2 (2 mL) and DMP (0.09 mmol) was 
added. After stirring at 25
o
C for 2 h the reaction was concentrated to yield a residue that was 
purified by silica gel column chromatography (1:1 CH2Cl2:Acetone) to give compound 34 (10 
mg, 35%) as a white solid. 
1
H NMR δ 8.63 (br. s., 1H), 8.18 (d, J = 7.81 Hz, 1H), 7.85 (d, J = 
8.59 Hz, 1H), 7.75 (d, J = 7.81 Hz, 1H), 7.45 - 7.55 (m, 2H), 7.28 - 7.39 (m, 7H), 6.84 (br. s., 
1H), 6.60 (br. s., 1H), 5.93 (br. s., 1H), 5.65 (br. s., 1H), 5.46 (d, J = 7.42 Hz, 1H), 5.12 (br. s., 
1H), 5.02 (br. s., 2H), 4.58 - 4.66 (m, 1H), 4.45 - 4.52 (m, 1H), 3.61 - 3.69 (m, 1H), 3.41 - 3.51 
(m, 1H), 3.20 - 3.36 (m, 3H), 2.47 - 2.55 (m, 1H), 2.27 - 2.46 (m, 1H), 1.98 - 2.06 (m, 1H), 1.80 - 
1.96 (m, 3H), 1.37 - 1.46 (m, 1H), 0.89 (d, J = 6.25 Hz, 6H); MS, m/z 666.4 (M+Na)
+
 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methyl-
pentanoylamino]-1-hydroxy-3-(2-oxo-pyrrolidin-3-yl)-propane-1-sulfonic acid monosodium 
salt (35). 
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A mixture of aldehyde 24 (0.05 mmol) and sodium bisulfite (0.05 mmol) was dissolved in 4:2:1 
EtOAc/EtOH/H2O (0.7 mL) and stirred at 40
o
C for 2 h. The solution was cooled and filtered, and 
the filtrate was concentrated to yield two diastereomers (a mixture of R and S at carbon adjacent 
to sulfur) of compound 35 as white solids (35 mg, 100% yield), mp 109 – 111oC.  1H NMR δ  
8.50 (d, J = 7.0 Hz, 1H), 8.28 (d, J = 8.6 Hz, 1H), 8.22 (d, J = 8.2, 1H), 8.18 (d, J = 8.2, 1H), 
8.11 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 3.9 Hz, 2H), 7.74 - 7.81 (m, 2H), 7.66 (d, J = 9.4 Hz, 1H), 
7.61 (d, J = 7.8 Hz, 1H), 7.53 - 7.59 (m, 3H), 7.48 - 7.53 (m, 2H), 7.44 (t, J = 4.7 Hz, 3H), 7.34 - 
7.40 (m, 2H), 7.23 - 7.32 (m, 4H), 7.15 (d, J = 6.6 Hz, 3H), 6.90 (br. s., 1H), 5.50 (d, J = 6.3 Hz, 
1H), 5.35 (d, J = 5.9 Hz, 1H), 4.81 - 4.90 (m, 4H), 4.43 (br. s., 2H), 4.30 - 4.37 (m, 1H), 4.26 (br. 
s., 1H), 3.96 - 4.00 (m, 1H), 3.88 (t, J = 5.5 Hz, 1H), 3.64 (br. s., 1H), 3.57 - 3.62 (m, 1H), 3.54 
(d, J = 9.4 Hz, 1H), 2.97 - 3.19 (m, 6H), 1.91 - 2.35 (m, 6H), 1.71 - 1.80 (m, 1H), 1.44 - 1.68 (m, 
8H), 1.18 - 1.25 (m, 1H), 0.77 - 0.93 (m, 12H); 
13C NMR δ 179.9, 179.7, 179.4, 178.9, 173.3, 
172.2, 172.1, 172.0, 156.4, 137.7, 134.8, 134.7, 134.4, 134.0, 132.3, 129.2, 128.9, 128.3, 128.1, 
127.9, 127.6, 127.3, 126.7, 126.2, 126.0, 124.9, 124.6, 124.4, 85.2, 84.5, 65.8, 57.0, 55.9, 52.5, 
52.2, 51.9, 49.8, 49.3, 41.6, 41.2, 38.5, 35.2, 35.0, 34.9, 32.8, 30.6, 29.9, 28.7, 28.3, 28.1, 27.9, 
24.9, 24.8, 23.8, 23.6, 22.5, 22.3.  MS (negative mode, m/z 681.6 (M-Na)
-
; HRMS (negative 
mode) calcd for C34H41N4O9S (M-Na)
-
 681.2594, found 681.2713. 
 
[2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methyl-
pentanoylamino]-1-hydroxy-3-(2-oxo-pyrrolidin-3-yl)-propyl]-phosphonic acid diethyl 
ester (36).  
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Followed General Procedure D: Diisopropylethylamine (0.25 mmol) was added to a solution of 
aldehyde 24 (0.25 mmol) and diethylphosphite (0.25 mmol) in distilled CH2Cl2. After stirring at 
25
o
C for 18 h, the reaction was diluted with ethyl acetate and washed with dilute HCl followed 
by brine. The organic layer was dried (anhydrous MgSO4), filtered, and concentrated to yield an 
oil which was purified by silica gel column chromatography (9:1 CH2Cl2/MeOH) to afford two 
diastereomers (a mixture of R and S at carbon adjacent to phosphorus) of compound 36 (10 mg, 
54% yield) as white solids, mp 85 – 88oC.  1H NMR δ  8.17 (br. s., 1H), 8.12 (d, J = 7.8 Hz, 1H), 
7.82 (d, J = 6.3 Hz, 2H), 7.72 (t, J = 7.4 Hz, 2H), 7.41 - 7.54 (m, 4H), 7.24 - 7.37 (m, 10H), 7.21 
(br. s., 2H), 6.58 (br. s., 1H), 6.47 (br. s., 1H), 6.38 (br. s., 1H), 6.19 - 6.24 (m, 1H), 5.68 (d, J = 
7.4 Hz, 1H), 5.50 - 5.56 (m, 1H), 5.19 - 5.31 (m, 1H), 5.01 (br. s., 1H), 4.97 (br. s., 4H), 4.66 - 
4.75 (m, 1H), 4.60 (br. s., 2H), 4.50 (br. s., 1H), 4.42 (br. s., 1H), 4.31 (br. s., 1H), 4.02 - 4.21 
(m, 8H), 3.88 (br. s., 1H), 3.62 - 3.76 (m, 1H), 3.29 - 3.42 (m, 1H), 3.14 - 3.24 (m, 3H), 2.29 - 
2.40 (m, 2H), 2.18 (br. s., 4H), 1.72 - 1.85 (m, 2H), 1.61 - 1.70 (m, 2H), 1.43 - 1.55 (m, 4H), 
1.19 - 1.37 (m, 12H), 0.80 - 0.92 (m, 12H); 
13C NMR δ 181.1, 181.1, 172.9, 172.7, 172.3, 172.0, 
171.6, 156.6, 136.2, 136.1, 134.1, 133.1, 133.0, 132.2, 129.0, 128.7, 128.3, 128.2, 128.0, 127.7, 
126.6, 126.0, 125.9, 125.6, 123.9, 123.8, 71.5, 71.3, 69.9, 69.7, 67.3, 63.6, 63.5, 63.1, 62.9, 62.8, 
62.7, 56.0, 53.0, 52.7, 50.6, 50.5, 50.2, 48.9, 41.7, 41.5, 40.8, 38.6, 38.1, 35.1, 34.9, 33.7, 33.6, 
32.8, 32.7, 31.4, 31.2, 29.9, 28.7, 28.5, 28.4, 28.0, 25.0, 23.4, 23.3, 21.9, 21.7, 16.7;
 
 MS, m/z 
761.1 (M+Na)
+
; HRMS calcd for C38H51N4O9PNa (M+Na)
+
 761.3291, found 761.3271. 
 
[2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methyl-
pentanoylamino]-1-hydroxy-3-(2-oxo-pyrrolidin-3-yl)-propyl]-phosphonic acid diisopropyl 
ester (37).  
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Followed General Procedure D: Started with aldehyde 24 and used diisopropylphosphite in 
place of diethylphosphite,  yielding compound 37 (73%) as a white solid.
1
H NMR δ 8.15 (d, J = 
7.42 Hz, 1H), 7.83 (d, J = 7.03 Hz, 1H), 7.73 (d, J = 7.03 Hz, 1H), 7.38 - 7.53 (m, 3H), 7.12 - 
7.36 (m, 7H), 6.29 (br. s., 1H), 5.58 (br. s., 1H), 4.98 (br. s., 2H), 4.65 - 4.85 (m, 2H), 4.56 - 4.65 
(m, 1H), 4.41 - 4.50 (m, 1H), 4.26 - 4.35 (m, 1H), 3.76 - 3.84 (m, 1H), 3.65 - 3.73 (m, 1H), 3.34 - 
3.43 (m, 1H), 3.17 - 3.24 (m, 2H), 2.28 - 2.43 (m, 1H), 2.05 - 2.17 (m, 1H), 1.85 (br. s., 1H), 
1.61 - 1.76 (m, 1H), 1.42 - 1.56 (m, 1H), 1.26 - 1.38 (m, 12H), 0.83 - 0.93 (m, 6H); MS, m/z 
789.4 (M+Na)
+
. 
 
(1-{1-[1-Cyano-2-(2-oxo-pyrrolidin-3-yl)-ethylcarbamoyl]-3-methyl-butylcarbamoyl}-2-
naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (38).  
O
N
H
C
N
H
H
NO
O HN
O
O
N
 
Iodobenzenediacetate (0.06 mmol) was added to a solution of aldehyde 24 (0.03 mmol), sodium 
dodecyl sulfate (0.006 mmol) and NH4OAc in water (2 mL) and heated to 70
o
C for 9 h. Aqueous 
sodium thiosulfate (20 mL) and CH2Cl2 (20 mL) were added and the organic layer removed. The 
aqueous layer was extracted with CH2Cl2 (10 mL x 3), the combined organic layers were dried 
(Na2SO4), filtered and concentrated to yield an oil that was purified by silica gel column 
chromatography (9:1 CH2Cl2:MeOH) to give compound 38 (11 mg, 61%) as a white solid.
 1
H 
NMR δ 8.13 (d, J = 7.42 Hz, 1H), 7.99 (br. s., 1H), 7.85 (d, J = 8.59 Hz, 1H), 7.77 (d, J = 7.81 
Hz, 1H), 7.45 - 7.55 (m, 2H), 7.20 - 7.41 (m, 7H), 6.85 (d, J = 7.03 Hz, 1H), 6.30 (s, 1H), 5.54 
(br. s., 1H), 5.03 (br. s., 2H), 4.71 - 4.78 (m, 1H), 4.55 - 4.63 (m, 1H), 4.45 - 4.55 (m, 1H), 3.62 
(dd, J = 6.44, 13.86 Hz, 1H), 3.43 (dd, J = 6.44, 13.24 Hz, 1H), 3.19 - 3.30 (m, 2H), 2.25 - 2.36 
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(m, 2H), 2.11 - 2.23 (m, 1H), 1.70 - 1.87 (m, 2H), 1.58 - 1.68 (m, 1H), 1.44 - 1.54 (m, 1H), 1.35 - 
1.43 (m, 1H), 0.87 (d, J = 6.25 Hz, 6H); 
13C NMR δ 179.1, 172.3, 171.4, 156.5, 136.1, 134.1, 
132.6, 132.2, 129.1, 128.8, 128.5, 128.3, 128.2, 127.9, 126.7, 126.1, 125.7, 123.7, 118.4, 67.4, 
56.1, 51.9, 41.4, 40.7, 39.5, 38.1, 35.4, 34.0, 29.9, 28.4, 24.9, 23.1, 22.1; MS, m/z 620.4 
(M+Na)
+
. 
 
(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-2-thiazol-2-yl-ethylcarbamoyl]-
butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (39).  
O
N
H
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Followed General Procedure A: The N-Boc-dipeptide 94 was used in place of 76, to give 
compound 39 (15 mg, 37% yield) as a white solid.  
1
H NMR δ 8.17 (br. s., 1H), 8.02 (d, J = 3.12 
Hz, 1H), 7.83 (d, J = 8.59 Hz, 1H), 7.73 (d, J = 7.81 Hz, 1H), 7.69 (d, J = 2.73 Hz, 1H), 7.42 - 
7.55 (m, 2H), 7.21 - 7.38 (m, 6H), 6.55 (br. s., 1H), 5.84 (s, 1H), 5.51 - 5.59 (m, 1H), 5.37 (d, J = 
7.81 Hz, 1H), 5.11 (s, 1H), 5.02 (br. s., 2H), 4.56 - 4.64 (m, 1H), 4.48 - 4.55 (m, 1H), 3.61 - 3.70 
(m, 1H), 3.43 - 3.51 (m, 1H), 3.29 - 3.35 (m, 2H), 2.44 - 2.60 (m, 2H), 2.07 - 2.13 (m, 1H), 1.92 - 
2.02 (m, 1H), 1.51 - 1.69 (m, 2H), 1.38 - 1.46 (m, 1H), 0.89 (d, J = 6.25 Hz, 6H); 
13C NMR δ 
190.6, 179.9, 172.0, 170.9, 156.6, 145.1, 134.1, 132.8, 132.2, 131.1, 129.1, 128.7, 128.4, 128.2, 
128.1, 128.0, 127.0, 126.7, 126.0, 125.6, 123.9, 67.3, 56.0, 55.1, 52.1, 42.1, 40.8, 39.2, 35.4, 
33.4, 28.9, 24.9, 23.1, 22.3; MS, m/z 706.1 (M+Na)
+
. 
 
(1-{3-Methyl-1-[2-(2-methyl-oxiranyl)-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-
ethylcarbamoyl]-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester 
(40).  
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Followed General Procedure A: The N-Boc-dipeptide 97-lp was used in place of 76, to give 
compound 40 (19 mg, 72% yield) as a white solid.  
1
H NMR δ 8.12 - 8.24 (m, 1H), 7.84 (d, J = 
8.98 Hz, 1H), 7.74 (d, J = 7.81 Hz, 1H), 7.44 - 7.55 (m, 2H), 7.22 - 7.38 (m, 8H), 6.55 (d, J = 
7.42 Hz, 1H), 6.16 (br. s., 1H), 5.41 (d, J = 7.81 Hz, 1H), 5.02 (br. s., 2H), 4.54 - 4.62 (m, 1H), 
4.42 - 4.52 (m, 1H), 4.29 - 4.36 (m, 1H), 3.62 (dd, J = 6.05, 13.86 Hz, 1H), 3.39 - 3.51 (m, 1H), 
3.21 - 3.38 (m, 3H), 2.90 (d, J = 5.08 Hz, 1H), 2.35 - 2.46 (m, 2H), 1.75 - 1.94 (m, 2H), 1.54 - 
1.62 (m, 2H), 1.50 (s, 3H), 1.31 - 1.45 (m, 2H), 0.84 - 0.92 (m, 6H); 
13C NMR δ 206.7, 179.9, 
172.3, 170.9, 156.3, 134.1, 132.9, 132.3, 129.0, 128.7, 128.4, 128.2, 128.0, 127.9, 126.6, 126.0, 
125.6, 123.8, 67.2, 59.6, 56.0, 52.9, 51.8, 42.2, 40.8, 39.3, 31.9, 29.9, 28.7, 28.5, 24.8, 23.0, 22.3, 
17.0; MS, m/z 679.3 (M+Na)
+
. 
 
(1-{3-Methyl-1-[2-(2-methyl-oxiranyl)-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-
ethylcarbamoyl]-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester 
(41).  
O
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Followed General Procedure A: The N-Boc-dipeptide 97-mp was used in place of 76, to give 
compound 41 (16 mg, 61% yield) as a white solid. 
1
H NMR δ 8.16 - 8.21 (m, 1H), 7.98 - 8.04 
(m, 1H), 7.86 (d, J = 7.81 Hz, 1H), 7.77 (d, J = 7.81 Hz, 1H), 7.45 - 7.59 (m, 2H), 7.21 - 7.41 (m, 
7H), 6.44 - 6.50 (m, 1H), 5.58 - 5.63 (m, 1H), 5.32 (d, J = 7.03 Hz, 1H), 4.97 - 5.06 (m, 2H), 
4.67 - 4.76 (m, 1H), 4.53 - 4.59 (m, 1H), 4.43 - 4.51 (m, 1H), 3.64 - 3.75 (m, 1H), 3.36 - 3.48 (m, 
1H), 3.25 - 3.32 (m, 1H), 2.98 (d, J = 5.08 Hz, 1H), 2.84 (d, J = 5.08 Hz, 1H), 2.33 - 2.44 (m, 
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2H), 1.98 - 2.08 (m, 1H), 1.87 - 1.97 (m, 1H), 1.75 - 1.84 (m, 1H), 1.64 - 1.74 (m, 1H), 1.48 - 
1.55 (m, 1H), 1.38 - 1.46 (m, 2H), 1.25 (s, 3H), 0.83 - 0.92 (m, 6H); MS, m/z 679.4 (M+Na)
+
. 
 
[2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-3-cyclohexyl-
propionylamino]-1-hydroxy-3-(2-oxo-pyrrolidin-3-yl)-propyl]-phosphonic acid dimethyl 
ester (42).  
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Followed General Procedure D: Started with aldehyde 25 and dimethylphosphite was used in 
place of diethylphosphite, yielding compound 42 (64%) as a white solid.  
1
H NMR δ  8.12 (d, J = 
8.20 Hz, 1H), 7.84 (d, J = 9.37 Hz, 1H), 7.73 (d, J = 7.81 Hz, 1H), 7.43 - 7.53 (m, 2H), 7.19 - 
7.40 (m, 8H), 6.38 (br. s., 1H), 5.47 (d, J = 6.64 Hz, 1H), 5.25 (br. s., 1H), 5.01 (br. s., 2H), 4.50 
- 4.64 (m, 2H), 4.25 - 4.31 (m, 1H), 3.87 - 3.93 (m, 1H), 3.78 - 3.83 (m, 3H), 3.71 - 3.77 (m, 3H), 
3.64 - 3.70 (m, 1H), 3.30 - 3.39 (m, 1H), 3.17 - 3.28 (m, 2H), 2.29 - 2.40 (m, 1H), 2.10 - 2.20 (m, 
1H), 1.55 - 1.79 (m, 10H), 1.39 - 1.48 (m, 1H), 1.05 - 1.26 (m, 3H), 0.79 - 0.96 (m, 2H); MS, 
m/z 773.5 (M+Na)
+
. 
 
[2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-3-cyclohexyl-
propionylamino]-1-hydroxy-3-(2-oxo-pyrrolidin-3-yl)-propyl]-phosphonic acid diethyl ester 
(43).  
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Followed General Procedure D: Started with aldehyde 25, yielding compound 43 (90%) as a 
white solid. 
1
H NMR δ 8.19 (d, J = 7.81 Hz, 1H), 8.11 (d, J = 7.42 Hz, 1H), 7.79 - 7.86 (m, 2H), 
7.68 - 7.77 (m, 2H), 7.41 - 7.55 (m, 4H), 7.17 - 7.38 (m, 7H), 5.50 - 5.66 (m, 1H), 5.19 - 5.34 (m, 
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1H), 4.95 - 5.04 (m, 2H), 4.50 - 4.64 (m, 3H), 4.37 - 4.47 (m, 1H), 4.26 - 4.34 (m, 1H), 3.94 - 
4.21 (m, 4H), 3.76 - 3.88 (m, 1H), 3.60 - 3.73 (m, 1H), 3.29 - 3.40 (m, 1H), 3.13 - 3.27 (m, 2H), 
2.25 - 2.41 (m, 1H), 2.11 - 2.23 (m, 1H), 1.71 - 1.87 (m, 1H), 1.53 - 1.69 (m, 2H), 1.39 - 1.49 (m, 
1H), 1.19 - 1.37 (m, 8H), 1.05 - 1.17 (m, 2H), 0.77 - 0.97 (m, 4H); 
13C NMR δ 181.1, 180.8, 
173.0, 127.7, 127.4, 171.8, 171.5, 157.0, 156.6, 156.5, 136.2, 136.0, 134.2, 134.1, 133.1, 133.0, 
132.2, 129.0, 128.7, 128.4, 128.1, 127.9, 127.6, 126.7, 126.5, 126.0, 125.9, 125.7, 125.6, 123.9, 
123.8, 67.5, 67.3, 63.5, 63.3, 62.8, 56.4, 55.9, 52.4, 52.0, 51.4, 50.2, 48.6, 40.8, 40.3, 39.5, 38.5, 
38.0, 35.1, 34.4, 34.0, 33.8, 32.6, 32.4, 29.9, 28.7, 28.4, 26.6, 26.6, 26.5, 26.4, 26.3, 26.2, 16.7; 
MS, m/z 801.2 (M+Na)
+
. 
 
4-Methyl-2-(2-{2-[methyl-(4-methyl-2-oxo-2H-chromen-7-yl)-amino]-acetylamino}-3-
naphthalen-1-yl-propionylamino)-pentanoic acid [1-formyl-2-(2-oxo-pyrrolidin-3-yl)-
ethyl]-amide (44).  
O
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Followed General Procedure B: Started with ester 99, yielding compound 44 (81%) as a white 
solid. 
1
H NMR δ  (major isomer) 9.48 (s, 1H), 8.30 - 8.38 (m, 1H), 8.10 (d, J = 8.98 Hz, 1H), 
7.83 - 7.93 (m, 1H), 7.76 (d, J = 8.59 Hz, 1H), 7.62 (d, J = 8.98 Hz, 1H), 7.42 - 7.51 (m, 2H), 
7.18 - 7.29 (m, 4H), 6.81 (d, J = 8.59 Hz, 1H), 6.70 (d, J = 6.25 Hz, 1H), 6.42 (s, 1H), 6.33 (br. 
s., 1H), 6.07 (s, 1H), 5.80 - 5.86 (m, 1H), 4.75 - 4.83 (m, 1H), 4.54 - 4.62 (m, 1H), 4.45 - 4.53 
(m, 1H), 4.26 - 4.35 (m, 1H), 3.85 - 3.89 (m, 2H), 3.65 - 3.75 (m, 2H), 3.29 - 3.38 (m, 2H), 2.72 
(s, 3H), 2.36 (s, 3H), 1.37 - 1.93 (m, 6H), 0.88 - 0.93 (m, 6H); MS, m/z 718.3 (M+Na)
+
. 
 
2-Methyl-thiazole-5-carboxylic acid (1-{1-[1-formyl-2-(2-oxo-pyrrolidin-3-yl)-
ethylcarbamoyl]-3-methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-amide (45).  
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Followed General Procedure B: Started with ester 100, yielding compound 45 (45%) as a white 
solid. 
1
H NMR δ 9.42 (s, 1H), 8.25 (d, J = 8.59 Hz, 1H), 8.17 (d, J = 5.86 Hz, 1H), 7.80 - 7.85 
(m, 1H), 7.73 (d, J = 8.20 Hz, 1H), 7.51 - 7.57 (m, 1H), 7.45 - 7.51 (m, 1H), 7.32 - 7.43 (m, 3H), 
6.96 (d, J = 7.03 Hz, 1H), 6.84 (d, J = 7.81 Hz, 1H), 5.89 (br. s., 1H), 4.97 - 5.05 (m, 1H), 4.46 - 
4.54 (m, 1H), 4.20 - 4.27 (m, 1H), 3.62 - 3.67 (m, 2H), 3.25 - 3.40 (m, 2H), 2.66 (s, 3H), 2.32 - 
2.41 (m, 1H), 1.60 - 1.94 (m, 5H), 1.39 - 1.56 (m, 2H), 0.81 - 0.90 (m, 6H); 
13C NMR δ 200.1, 
180.1, 173.0, 170.9, 161.0, 143.7, 135.9, 134.2, 133.5, 132.7, 132.3, 129.2, 128.3, 128.1, 126.8, 
126.1, 125.7, 123.9, 58.3, 54.9, 52.5, 41.5, 40.8, 38.7, 35.1, 30.0, 29.2, 25.0, 23.1, 22.0, 19.8; 
MS, m/z 614.4 (M+Na)
+
. 
 
14-Benzyloxycarbonylamino-2-isobutyl-3,8,15-trioxo-1,4,9triaza-cyclopentadecane-5-
carboxylic acid methyl ester (47).  
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Compound 107 (0.11 mmol) was dissolved in 10% TFA/CH2Cl2 (2 mL) and stirred at 25
o
C for 1 
h. The solvent was removed and remaining residue was placed under high vacuum to yield the 
amine intermediate as a sticky solid. The de-Boc intermediate was immediately dissolved in 
(4:1) CH2Cl2/dioxane (4 mL) and treated with DMAP (0.34 mmol) and benzylchloroformate 
(0.14 mmol) followed by stirring at 25
o
C for 2 h. The reaction was combined with water (50 mL) 
and CH2Cl2 (50 mL) and the aqueous layer was acidified to pH 2 using aq. HCl. The organic 
layer was removed and the aqueous layer was extracted with CH2Cl2 (40 mL x 3). The combined 
CH2Cl2 layers were dried (MgSO4), filtered and concentrated using a rotary evaporator to yield a 
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solid which was purified by silica gel column chromatography (15:1 CH2:Cl2: MeOH) to give 
compound 47 (42 mg, 72%) as a white solid.
 1
H NMR δ  7.87 (d, J = 5.43 Hz, 1H), 7.77(d, J = 
5.23 Hz, 1H), 7.30 - 7.42 (m, 5H), 6.81 - 6.88 (m, 1H), 5.99 (d, J = 6.01 Hz, 1H), 5.09 (s, 2H), 
4.49 - 4.56 (m, 1H), 4.39 - 4.46 (m, 1H), 4.19 - 4.28 (m, 1H), 3.59 (s, 3H), 2.89 - 2.97 (m, 1H), 
2.27 - 2.39 (m, 2H), 1.87 - 1.98 (m, 1H), 1.51 - 1.84 (m, 6H), 1.36 - 1.46 (m, 2H), 1.15 - 1.31 (m, 
2H), 0.87 - 1.00 (m, 6H);
 13C NMR δ 173.1, 173.0, 172.6, 156.0, 136.3, 128.6, 128.3, 128.0, 
67.0, 54.2, 52.4, 52.1, 51.5, 40.8, 37.7, 31.4, 31.2, 28.1, 25.5, 24.6, 22.7, 22.0, 20.4; MS, m/z 
541.0 (M+Na)
+
. 
 
(5-Formyl-2-isobutyl-3,8,15-trioxo-1,4,9triaza-cyclopentadec-14-yl)-carbamic acid benzyl 
ester (48).  
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Followed General Procedure B: Started with ester 107, yielding compound 48 (92%) as a white 
solid. 
1
H NMR (DMSO-d6) δ  9.37 (s, 1H), 8.16 (d, J = 5.64 Hz, 1H), 7.42 - 7.47 (m, 1H), 7.27 - 
7.38 (m, 6H), 7.16 (d, J = 5.54 Hz, 1H), 4.97 - 5.04 (m, 2H), 4.35 - 4.43 (m, 1H), 4.29 - 4.34 (m, 
1H), 4.07 - 4.14 (m, 1H), 2.75 - 2.83 (m, 1H), 2.17 - 2.33 (m, 2H), 2.03 - 2.16 (m, 2H), 1.51 - 
1.61 (m, 6H), 1.44 - 1.50 (m, 1H), 1.25 - 1.32 (m, 2H), 0.82 - 0.93 (m, 6H); MS, m/z 511.3 
(M+Na)
+
. 
 
[1-Formyl-2-(2-oxo-pyrrolidin-3-yl)-ethyl]-carbamic acid tert-butyl ester (53a).  
O
O N
H
O
H
NO
H
 
Followed General Procedure B: Started with ester 52, yielding compound 53a (94%) as a white 
solid. 
1
H NMR δ 9.57 (s, 1H), 6.10 - 6.22 (m, 1H), 4.14 - 4.23 (m, 1H), 3.29 - 3.43 (m, 2H), 2.39 
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- 2.53 (m, 2H), 1.77 - 2.07 (m, 3H), 1.46 (s, 9H); 
13C NMR δ 200.5, 180.0, 156.3, 80.3, 58.9, 
40.6, 38.0, 30.6, 28.8, 28.5. 
 
2-(2-Benzyloxycarbonylamino-propionylamino)-3-(2-oxo-pyrrolidin-3-yl)-propionic acid 
methyl ester (54). 
O
N
H
O
N
H
H
NO
O
O
O
 
A solution of Cbz-Ala-OH (0.84 mmol) and CDI (0.94 mmol) in dry THF (4 mL) was added to a 
solution of 53 (0.70 mmol) and NEt3 (1.4 mmol) in DMF (4 mL). The resulting solution was 
stirred at 25
o
C for 18 h. The Reaction was partitioned between water (30 mL) and EtOAc (30 
mL). The organic layer was removed and the aqueous layer was extracted with EtOAc (3 x 20 
mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give an oil 
that was purified by silica gel column chromatography (20:1 CH2Cl2:MeOH) to afford 54 (198 
mg, 72%) as a white solid. 
1
H NMR δ 7.94 (s, 1H), 7.40 - 7.25 (m, 5H), 6.75 (s, 1H), 5.86 (s, 
1H), 5.09 (s, 2H), 4.42 - 4.51 (m, 1H), 4.38 - 4.42 (m, 1H), 3.71 (s, 3H), 3.24 - 3.39 (m, 2H), 
2.33 - 2.50 (m, 2H), 2.11 - 2.23 (m, 1H),  1.71 - 1.91 (m, 2H), 1.40 (d, J = 6.83 Hz, 3H); 
13
C 
NMR δ 180.1, 173.3, 172.4, 156.0, 136.6, 128.7, 128.3, 128.2, 67.0, 52.6, 51.5, 50.6, 40.7, 38.6, 
33.3, 28.3, 19.4; MS, m/z 414.1 (M+Na)
+
. 
 
2-(2-Benzyloxycarbonylamino-propionylamino)-propionic acid (60).  
O
OH
H
N
O
N
H
O
O
 
(S)-Alanine-2-chlorotritylresin (0.6 mmol) was swelled in DMF (2 mL) for 30 min and then 
filtered. To the alanine resin was added a solution of (S)-N-cbz-alanine (1.8 mmol) and HBTU 
(1.6 mmol) in 4.2% DIPEA in DMF (14 mL). Subjected to microwave irradiation (25 W, 75
o
C, 5 
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min) and then filtered and washed with DMF (15 mL x3) and CH2Cl2 (15 mL x 2). The resin was 
then treated with cleavage cocktail (95% TFA, 2.5% TIPS, 2.5% water; 20 mL) and heated in the 
microwave reactor (20 W, 38
o
C, 18 min). The reaction was filtered and the filtrate was 
concentrate on a rotary evaporator to yield an oil that was purified by silica gel chromatography 
(15:1 CH2Cl2:MeOH) to give the product 60 (63%) as a white solid. 
1
H NMR δ 9.53 (br. s., 1H), 
7.25 - 7.39 (m, 5H), 7.12 (br. s., 1H), 5.82 (br. s., 1H), 5.02 - 5.18 (m, 2H), 4.46 - 4.60 (m, 1H), 
4.28 - 4.39 (m, 1H), 1.28 - 1.52 (m, 6H). 
 
2-(2-Benzyloxycarbonylamino-propionylamino)-propionic acid (61). 
O
OH
H
N
N
H
O
O
O
 
 (S)-Alanine-2-chlorotritylresin (0.59 mmol) was swelled in DMF (2 mL) for 30 min and then 
filtered. To the alanine resin was added a solution of (R)-N-cbz-alanine (0.94 mmol) and HBTU 
(0.88 mmol) in 4.2% DIPEA in DMF (13 mL). Subjected to microwave irradiation (25 W, 75
o
C, 
5 min) and then filtered and washed with DMF (15 mL x3) and CH2Cl2 (15 mL x 2). The resin 
was then treated with cleavage cocktail (95% TFA, 2.5% TIPS, 2.5% water; 10 mL) and heated 
in the microwave reactor (20 W, 38
o
C, 18 min). The reaction was filtered and the filtrate was 
concentrate on a rotary evaporator to yield an oil that was purified by silica gel chromatography 
(15:1 CH2Cl2:MeOH) to give the product 61 (150 mg, 86%) as a white solid. 
1
H NMR δ 7.30 - 
7.38 (m, 5H), 5.95 (d, J = 6.45 Hz, 1H), 5.01 - 5.13 (m, 2H), 4.51 - 4.59 (m, 1H),  4.41 - 4.51 (m, 
1H), 1.39 (d, J = 7.42 Hz, 3H), 1.42 (d, J = 7.42 Hz, 3H); MS, m/z 317.0 (M+Na)
+
. 
 
2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-propionic acid (62).  
O
N
H
OHO N
H
O
O  
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(S)-Alanine-2-chlorotritylresin (0.6 mmol) was swelled in DMF (2 mL) for 30 min and then 
filtered. To the alanine resin was added a solution of (S)-N-cbz-1-napthylalanine (1.8 mmol) and 
HBTU (1.6 mmol) in 4.2% DIPEA in DMF (14 mL). Subjected to microwave irradiation (25 W, 
75
o
C, 5 min) and then filtered and washed with DMF (15 mL x3) and CH2Cl2 (15 mL x 2). The 
resin was then treated with cleavage cocktail (95% TFA, 2.5% TIPS, 2.5% water; 20 mL) and 
heated in the microwave reactor (20 W, 38
o
C, 18 min). The reaction was filtered and the filtrate 
was concentrate on a rotary evaporator to yield an oil that was purified by silica gel 
chromatography (15:1 CH2Cl2:MeOH) to give the product 62 (135 mg, 57%) as a white solid. 
1
H 
NMR δ 8.10 (d, J = 7.42 Hz, 1H), 7.79 (d, J = 7.42 Hz, 1H), 7.69 (d, J = 5.08 Hz, 1H), 7.39 - 
7.52 (m, 2H), 7.21 - 7.38 (m, 7H), 6.47 (d, J = 6.25 Hz, 1H), 5.80 (d, J = 7.81 Hz, 1H), 5.03 (br. 
s., 2H), 4.61 - 4.70 (m, 1H), 4.31 - 4.41 (m, 1H), 3.39 - 3.57 (m, 2H), 1.28 (d, J = 7.03 Hz, 3H); 
13C NMR δ 175.4, 171.1, 156.1, 135.9, 133.8, 132.1, 131.8, 128.9, 128.5, 128.2, 128.0, 126.5, 
125.8, 125.3, 123.4, 67.2, 55.5, 48.3, 36.0, 17.8; MS, m/z 443.1 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-propionylamino)-propionylamino]-3-(2-oxo-pyrrolidin-3-
yl)-propionic acid methyl ester (63).  
O
N
H
O
N
H
H
NO
O
H
N
O
O
O
 
Followed General Procedure E: The N-Cbz-dipeptide 60 was used in place of N-Boc-leucine, to 
give compound 63 (41% yield) as a white solid. 
1
H NMR δ 8.00 (d, J = 5.47 Hz, 1H), 7.29 - 7.38 
(m, 5H), 6.95 (d, J = 5.86 Hz, 1H), 6.11 (s, 1H), 5.60 (d, J = 7.42 Hz, 1H), 5.05 - 5.15 (m, 2H), 
4.51 - 4.60 (m, 1H), 4.44 - 4.51 (m, 1H), 4.21 - 4.30 (m, 1H), 3.72 (s, 3H), 3.30 - 3.36 (m, 2H), 
2.35 - 2.48 (m, 2H), 2.11 - 2.20 (m, 1H), 1.87 - 1.95 (m, 1H), 1.80 - 1.87 (m, 1H), 1.35 - 1.43 (m, 
6H); 
13C NMR δ 179.8, 172.6, 172.1, 172.0, 155.9, 136.2, 128.5, 128.1, 128.0, 66.9, 52.4, 51.6, 
50.6, 48.8, 40.5, 38.4, 33.0, 28.4, 18.7, 18.7; MS, m/z 485.3 (M+Na)
+
. 
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2-[2-(2-Benzyloxycarbonylamino-propionylamino)-propionylamino]-3-(2-oxo-pyrrolidin-3-
yl)-propionic acid methyl ester (64).  
O
N
H
O
H
N
H
NO
N
H
OMe
O
O
O
 
Followed General Procedure E: The N-Cbz-dipeptide 61 was used in place of N-Boc-leucine, to 
give compound 64 (54% yield) as a white solid. 
1
H NMR δ 8.19 (d, J = 7.03 Hz, 1H), 7.29 - 7.38 
(m, 5H), 7.21 (d, J = 8.20 Hz, 1H), 6.52 - 6.61 (m, 1H), 6.12 (d, J = 7.42 Hz, 1H), 5.01 - 5.13 (m, 
2H), 4.58 - 4.67 (m, 1H),  4.41 - 4.49 (m, 1H), 4.26 - 4.35 (m, 1H), 3.69 (s, 3H), 3.16 - 3.31 (m, 
2H), 2.37 - 2.47 (m, 1H), 2.28 - 2.36 (m, 1H), 2.08 - 2.19 (m, 1H), 1.81 - 1.90 (m, 1H), 1.73 - 
1.81 (m, 1H), 1.33 - 1.42 (m, 6H); 
13C NMR δ 180.0, 172.8, 172.2, 156.0, 136.1, 128.5, 128.1, 
128.1, 66.9, 52.4, 51.6, 50.5, 48.7, 40.5, 38.5, 32.6, 28.2, 18.7, 18.3; MS, m/z 485.3 (M+Na)
+
. 
 
2-Benzyloxycarbonylamino-propionic acid methyl ester (66).  
O
N
H
O
O
O
 
N-Cbz-alanine (1.0 mmol) was dissolved in dry MeOH (3 mL) and 1 drop conc. HCl was added. 
The solution was stirred at 25
o
C for 18 h after which it was concentrate to yield 66 (240 mg, 
100%) as an oil that was used without further purification. 
1
H NMR δ 7.25 - 7.39 (m, 5H), 5.32 
(br. s., 1H), 5.11 (s, 2H), 4.35 - 4.42 (m, 1H), 3.72 (s, 3H), 1.40 (d, J = 7.42 Hz, 3H); 
13
C NMR δ 
173.8, 156.0, 136.6, 128.7, 128.3, 128.3, 67.1, 52.6, 49.8, 18.6; MS, m/z 260.1 (M+Na)
+
. 
 
(1-Methyl-2-oxo-ethyl)-carbamic acid benzyl ester (67).  
O
N
H
O
O
H
 
Followed General Procedure B: Started with ester 66, yielding compound 67 (70%) as a white 
solid. 
1
H NMR δ 9.55 (s, 1H), 7.29 - 7.39 (m, 5H), 5.46 (br. s., 1H), 5.12 (s, 2H), 4.26 - 4.35 (m, 
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1H), 1.36 (d, J = 7.42 Hz, 3H); 
13C NMR δ 199.0, 155.8, 136.1, 128.5, 128.2, 128.1, 67.0, 55.9, 
14.7; MS, m/z 230.1 (M+Na)
+
. 
 
2-(2-Benzyloxycarbonylamino-propylamino)-propionic acid methyl ester (69). 
O
O
H
N
N
H
O
O
 
 (1-Methyl-2-oxo-ethyl)-carbamic acid benzyl ester 67 (0.60 mmol) was added to a solution of 
alanine-methylester 68 (0.60 mmol) and NEt3 (0.60 mmol) in MeOH (2mL) and the reaction 
allowed to stir overnight. NaCNBH3 (0.90 mmol) was added and the reaction stirred for 3 h. The 
reaction was quenched with sat. aq. NH4Cl (5 mL) and the reaction partitioned between water 
(20 mL) and EtOAc (25 mL). The organic layer was removed and the aqueous layer was 
extracted with EtOAc (3 x 25 mL), the combined organinc layers were dried (MgSO4), filtered 
and concentrated to yield an oil that was purified by silica gel column chromatography (1:1 
EtOAc:Hexane) to yield 69 (70 mg, 40%) as a white solid. 
1
H NMR δ 7.29 - 7.39 (m, 5H), 5.10 
(s, 2H), 3.73 - 3.78 (m, 1H), 3.71(s, 3H), 3.28 - 3.38 (m, 1H), 2.68 (dd, J = 5.10, 11.60 Hz, 1H), 
2.49 (dd, J = 5.10, 11.83 Hz, 1H), 1.27 (d, J = 7.09 Hz, 3H), 1.17 (d, J = 7.08 Hz, 3H); 
13
C NMR 
δ 176.2, 156.3, 136.9, 128.7, 128.3, 128.3, 66.7, 57.0, 52.8, 52.0, 47.4, 19.1; MS, m/z 317.0 
(M+Na)
+
. 
 
2-[(2-Benzyloxycarbonylamino-propyl)-formyl-amino]-propionic acid methyl ester (71).  
O
O
N
N
H
OH
O
O
 
Formic acid (1.84 mmol) was dissolved in dry CH2Cl2 (2 mL) and cooled to 0
o
C. Acetic 
anhydride (0.31 mmol) was added and stirred for 2 h at 25
o
C to form a mixed anhydride 70. The 
solution was cooled to 0
o
C and the amine 69 (0.15 mmol) was added followed by stirring for 8 h 
at 25
o
C. The solvent was removed on a rotary evaporator and the residue was purified by silica 
gel column chromatography (15:1 CH2Cl2:MeOH) to give compound 71 (46 mg, 93%) and a 
white solid. 
1
H NMR (two diastereomers) δ 7.99 - 8.22 (m, 2H), 7.25 - 7.29 (m, 10H), 5.02 - 
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5.12 (m, 4H), 4.41 - 4.48 (m, 1H), 4.12 - 4.21 (m, 1H), 3.81 - 3.91 (m, 1H), 3.71 (s, 6H), 3.61 - 
3.73 (m, 1H), 3.40 - 3.45 (m, 1H), 3.20 - 3.29 (m, 1H), 3.01 - 3.09 (m, 1H), 1.47 - 1.60 (m, 6H), 
1.12 - 1.26 (m, 6H);
 13C NMR δ 172.1, 172.0, 164.9, 164.3, 163.6, 163.5, 156.3, 155.9, 136.9, 
136.5, 128.8, 128.6, 128.5, 128.3, 128.2, 67.0, 66.6, 56.8, 56.3, 53.2, 53.0, 52.7, 51.8, 48.2, 47.7, 
47.4, 46.9, 46.7, 19.4, 19.1, 18.3, 18.1, 17.2, 17.0, 14.7, 14.6; MS, m/z 345.1 (M+Na)
+
. 
 
2-[(2-Benzyloxycarbonylamino-propyl)-formyl-amino]-propionic acid (72).  
O
OH
N
N
H
OH
O
O
 
The ester 71 (1.24 mmol) was dissolved in 1:1 dioxane:water (6 mL) and treated with 6N NaOH 
(1 mL). After stirring at 25
o
C for 1 h the reaction was partitioned between water and ether, the 
ether layer was removed and the aqueous layer was acidified to pH 2 using aq. HCl. The aqueous 
layer was extracted with CH2Cl2 (30 mL x 5), the combined CH2Cl2 layers were dried (Na2SO4), 
filtered and concentrated to yield compound 72 (366 mg, 96%) as a clear oil. 
1
H NMR (two 
diastereomers) δ 7.97 - 8.24 (m, 2H), 7.24 - 7.29 (m, 10H), 5.45 - 5.52 (m, 1H), 4.99 - 5.18 (m, 
4H), 4.31 - 4.43 (m, 1H), 4.13 - 4.20 (m, 1H), 3.84 - 3.94 (m, 1H), 3.36 - 3.48 (m, 1H), 3.20 - 
3.30 (m, 1H), 3.02 - 3.13 (m, 1H), 1.47 - 1.60 (m, 6H), 1.12 - 1.24 (m, 6H); MS, m/z 331.1 
(M+Na)
+
. 
 
2-{2-[(2-Benzyloxycarbonylamino-propyl)-formyl-amino]-propionylamino}-3-(2-oxo-
pyrrolidin-3-yl)-propionic acid methyl ester (73).  
O
N
H
O
N
H
NO
N
H
O
OH
O
O
 
The acid 72 (0.11 mmol) and CDI (0.14 mmol) were dissolved in dry DMF (1 mL) and stirred 
for 20 min. Concurrently and separately, the amine 53 was dissolved in dry DMF and treated 
with NEt3 (0.11 mmol) and stirred for 20 min. The amine solution was added to the CDI solution 
and the resulting solution was stirred for 18 h at 25
o
C. The reaction was dissolved in EtOAc (20 
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mL) and water (20 mL) was added. The organic layer was removed and the aqueous layer was 
extracted with EtOAc (3 x 15 mL), the combined organic layers were dried (MgSO4), filtered 
and concentrated to give an oil that was purified by silica gel chromatography (5:1 
CH2Cl2:MeOH) to provide compound 73 (29 mg, 55%) as a sticky oil and as two diastereomers. 
1
H NMR δ 9.60 (s, 1H), 8.89 - 8.89 (m, 1H), 8.21 - 8.29 (m, 1H),  7.95 - 8.06 (m, 1H),  7.59 (s, 
1H), 7.22 - 7.39 (m, 10H), 7.08 (s, 1H), 5.58 - 5.65 (m, 1H), 4.99 - 5.12 (m, 4H), 4.25 - 4.51 (m, 
3H), 4.05 - 4.18 (m, 1H), 3.72 (s, 3H), 3.70 (s, 3H), 3.20 - 3.39 (m, 4H), 3.05 - 3.18 (m, 1H), 
2.30 - 2.50 (m, 4H), 2.01 - 2.20 (m, 2H), 1.62 - 1.95 (m, 4H), 1.21 (d, J = 6.53 Hz, 6H), 1.20 (d, 
J = 6.54 Hz, 6H); MS, m/z 499.3 (M+Na)
+
. 
 
2-(2-tert-Butoxycarbonylamino-propionylamino)-3-(2-oxo-pyrrolidin-3-yl)-propionic acid 
methyl ester (74).  
O
N
H
N
H
O
H
NO
OMeO
O  
Followed General Procedure E: N-Boc-alanine was used in place of N-Boc-leucine to give 
compound 74 (79% yield) as a white solid. 
1
H NMR δ 7.81 (d, J = 7.42 Hz, 1H), 7.03 (br. s., 
1H), 5.43 (d, J = 7.42 Hz, 1H), 4.44 - 4.52 (m, 1H), 4.20 - 4.29 (m, 1H), 3.66 (s, 3H), 3.22 - 3.33 
(m, 2H), 2.28 - 2.46 (m, 2H), 2.10 - 2.20 (m, 1H), 1.72 - 1.84 (m, 2H), 1.36 (s, 9H), 1.32 (d, J = 
7.03 Hz, 3H); 
13C NMR δ 179.8, 173.4, 172.2, 155.2, 79.5, 52.3, 50.8, 49.8, 40.4, 38.1, 33.1, 
28.2, 27.9, 18.9; MS, m/z 380.1 (M+Na)
+
. 
 
2-(3-tert-Butoxy-2-tert-butoxycarbonylamino-propionylamino)-3-(2-oxo-pyrrolidin-3-yl)-
propionic acid methyl ester (75).  
O
N
H
N
H
O
H
NO
OMeO
O
O
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Followed General Procedure E: N-Boc-O-t-butyl-serine was used in place of N-Boc-leucine to 
give compound 75 (96% yield) as a white solid.  
1
H NMR δ  7.42 - 7.50 (m, 1H), 6.11 - 6.24 (m, 
1H), 5.41 - 5.50 (m, 1H), 4.63 - 4.72 (m, 1H), 4.20 - 4.27 (m, 1H), 3.79 - 3.86 (m, 1H), 3.73 (s, 
3H), 3.38 - 3.45 (m, 1H), 3.26 - 3.38 (m, 3H), 2.36 - 2.50 (m, 2H), 2.17 - 2.27 (m, 1H), 1.80 - 
1.91 (m, 2H), 1.47 (s, 9H), 1.18 (s, 9H); 
13C NMR δ 179.5, 172.0, 170.8, 155.4, 80.1, 73.8, 61.8, 
54.3, 52.4, 50.6, 40.3, 37.8, 34.2, 28.3, 28.1, 27.3; MS, m/z 452.6 (M+Na)
+
. 
 
2-(2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-(2-oxo-pyrrolidin-3-yl)-
propionic acid methyl ester (76).  
O
N
H
O
O
N
H
O
H
NO
OMe
 
Followed General Procedure E: To a mixture of glutamine surrogate HCl salt 53 (5.59 mmol), 
N-Boc-leucine (5.59 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (10.2 
mmol), and 4-(dimethylamino)pyridine (DMAP) (10.2 mmol) under argon was added dry DMF 
(10 mL). The solution was stirred at 25
o
C and dry CH2Cl2 (25 mL) was added, and the resulting 
solution was stirred for 18 h. The reaction was partitioned between water (150 mL) and CH2Cl2 
(150 mL). The pH of the aqueous layer was adjusted to 3 using 2 N HCl. The organic layer was 
removed, and the aqueous layer was extracted twice with CH2Cl2 (150 mL each). The combined 
organic layers were dried (anhydrous MgSO4), filtered and concentrated to yield a sticky solid 
which was purified by silica gel chromatography (30:1 CH2Cl2:MeOH) to yield compound 76, 
1.6 g (72% yield) as a white solid, mp 70 – 73oC. 1H NMR δ 7.84 (d, J = 7.03 Hz, 1H), 6.96 (br. 
s., 1H), 5.18 (d, J = 8.59 Hz, 1H), 4.43 - 4.50 (m, 1H), 4.25 - 4.33 (m, 1H), 3.70 (s, 3H), 3.24 - 
3.38 (m, 2H), 2.30 - 2.46 (m, 2H), 2.18 - 2.27 (m, 1H), 1.76 - 1.88 (m, 2H), 1.57 - 1.75 (m, 2H), 
1.43 - 1.50 (m, 1H), 1.40 (s, 9H), 0.94 (d, J = 6.06 Hz, 3H, CH3),  0.93 (d, J = 6.12 Hz, 3H, 
CH3); 
13C NMR δ 180.0, 173.6, 172.5, 155.9, 80.0, 53.0, 52.6, 51.3, 42.5, 40.7, 38.5, 33.3, 28.5, 
28.3, 24.8, 23.1, 22.4; MS, m/z 422.3 (M+Na)
+
. 
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2-(2-tert-Butoxycarbonylamino-3-cyclohexyl-propionylamino)-3-(2-oxo-pyrrolidin-3-yl)-
propionic acid methyl ester (77).  
O
N
H
O
N
H
H
NO
O
O
OMe
 
Followed General Procedure E: N-Boc-cyclohexylalanine was used in place of N-Boc-leucine to 
give compound 77 (99% yield) as a white solid. 
1
H NMR δ  7.71 (br. s., 1H), 6.83 (br. s., 1H), 
5.18 (br. s., 1H), 4.49 - 4.57 (m, 1H), 4.25 - 4.34 (m, 1H), 3.72 (s, 3H), 3.26 - 3.40 (m, 2H), 2.33 
- 2.50 (m, 3H), 2.17 - 2.27 (m, 1H), 1.77 - 1.91 (m, 4H), 1.60 - 1.74 (m, 5H), 1.43 (s, 9H), 1.09 - 
1.30 (m, 3H), 0.84 - 1.03 (m, 2H); 
13C NMR δ 179.9, 173.5, 172.4, 155.7, 79.9, 52.5, 52.4, 51.2, 
40.8, 40.6, 38.4, 34.1, 33.7, 33.4, 32.8, 28.4, 28.2, 26.6, 26.4, 26.3; MS, m/z 462.2 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-2-yl-propionylamino)-propionylamino]-3-
(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (80). 
O
N
H
N
H
O
H
NO
O N
H
O
O
OMe
 
Followed General Procedure A:  (S)-N-Cbz-2-napthylalanine was used in place of (S)-N-Cbz-1-
napthylalanine and N-Boc-dipeptide 74 was used in place of N-Boc-dipeptide 76, to give 
compound 80 (87% yield) as a white solid. 
1
H NMR δ 8.03 (d, J = 7.03 Hz, 1H), 7.74 - 7.79 (m, 
1H), 7.69 - 7.73 (m, 2H), 7.61 (s, 1H), 7.40 - 7.44 (m, 2H), 7.27 - 7.34 (m, 3H), 7.22 - 7.26 (m, 
2H), 7.18 - 7.22 (m, 2H), 6.57 (s, 1H), 5.70 (d, J = 7.81 Hz, 1H), 5.07 (d, J = 4.30 Hz, 1H), 4.94 
- 5.06 (m, 2H), 4.57 - 4.65 (m, 2H), 4.38 - 4.47 (m, 1H), 3.69 (s, 3H), 3.12 - 3.30 (m, 2H), 2.32 - 
2.43 (m, 1H), 2.20 - 2.31 (m, 1H), 2.09 - 2.18 (m, 1H), 1.79 - 1.87 (m, 1H), 1.66 - 1.78 (m, 1H), 
1.35 (d, J = 6.64 Hz, 3H); 
13C NMR δ 180.8, 172.8, 172.3, 171.1, 156.3, 136.3, 134.1, 133.5, 
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132.5, 128.6, 128.4, 128.3, 128.3, 128.2, 128.1, 127.8, 127.6, 126.2, 125.8, 67.1, 56.1, 52.6, 51.6, 
49.1, 40.7, 38.6, 38.6, 33.1, 28.3, 18.9; MS, m/z 611.6 (M+Na)
+
.  
 
2-[2-(2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionylamino)-propionylamino]-3-(2-
oxo-pyrrolidin-3-yl)-propionic acid methyl ester (81).  
O
N
H
O
N
H
H
NO
O
H
N
O O
OMe
 
Followed General Procedure A:  (S)-N-Cbz-biphenylalanine was used in place of (S)-N-Cbz-1-
napthylalanine and N-Boc-dipeptide 74 was used in place of N-Boc-dipeptide 76, to give 
compound 81 (95% yield) as a white solid. 
1
H NMR δ 8.11 (d, J = 7.03 Hz, 1H), 7.52 (d, J = 
7.81 Hz, 2H), 7.37 - 7.49 (m, 5H), 7.21 - 7.34 (m, 8H), 6.86 (s, 1H), 5.90 (d, J = 7.81 Hz, 1H), 
4.96 - 5.10 (m, 2H), 4.61 - 4.69 (m, 1H), 4.53 - 4.61 (m, 1H), 4.41 - 4.49 (m, 1H), 3.67 (s, 3H), 
3.00 - 3.25 (m, 4H), 2.35 - 2.44 (m, 1H), 2.14 - 2.27 (m, 2H), 1.78 - 1.87 (m, 1H), 1.65 - 1.77 (m, 
1H), 1.37 (d, J = 6.64 Hz, 3H); 
13C NMR δ 180.1, 173.0, 172.4, 171.2, 156.4, 140.9, 139.8, 
136.5, 135.8, 130.1, 129.0, 128.7, 128.3, 128.2, 127.5, 127.4, 127.2, 67.2, 56.2, 52.7, 51.6, 49.1, 
40.8, 38.6, 38.3, 33.2, 28.2, 19.1; MS, m/z 637.1 (M+Na)
+
.  
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-3-tert-butoxy-
propionylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (83).  
O
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Followed General Procedure A:  N-Boc-dipeptide 75 was used in place of N-Boc-dipeptide 76, 
to give compound 83 (69% yield) as a white solid.  
1
H NMR δ  8.20 (d, J = 8.59 Hz, 1H), 7.85 
(d, J = 8.20 Hz, 1H), 7.76 (d, J = 7.81 Hz, 1H), 7.45 - 7.60 (m, 3H), 7.24 - 7.40 (m, 7H), 6.85 (d, 
J = 6.64 Hz, 1H), 6.09 (br. s., 1H), 5.49 (d, J = 7.03 Hz, 1H), 5.06 (s, 2H), 4.55 - 4.68 (m, 2H), 
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4.39 - 4.45 (m, 1H), 3.75 - 3.81 (m, 1H), 3.73 (s, 3H), 3.61 - 3.68 (m, 2H), 3.52 (dd, J = 7.42, 
14.06 Hz, 1H), 3.17 - 3.31 (m, 2H), 2.29 - 2.41 (m, 2H), 2.12-2.22 (m, 1H), 1.74 - 1.86 (m, 2H), 
1.09 (s, 9H); 
13C NMR δ 179.5, 171.9, 170.8, 169.9, 156.1, 135.9, 133.9, 132.4, 131.9, 128.8, 
128.5, 128.1, 128.0, 127.6, 126.5, 125.8, 125.4, 123.6, 73.8, 67.2, 61.2, 55.8, 53.2, 52.5, 50.8, 
40.3, 37.9, 35.5, 33.6, 28.1, 27.2; MS, m/z 683.5 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methyl-
pentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (84). 
O
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 Followed General Procedure A: The N-Boc-dipeptide 76 (1 mmol) was dissolved in 10% 
TFA/CH2Cl2 (5 mL) and stirred at 25
o
C for 4 h. The solvent was removed on a rotary evaporator 
to yield a sticky oil that was re-dissolved in chloroform followed by removal of the solvent once 
again on the rotary evaporator to yield a semi-solid material. After sitting under high vacuum for 
0.5 h, a white solid (amine intermediate) was obtained in quantitative yield. To this amine 
intermediate (1 mmol) was added (S)-N-Cbz-1-naphthylalanine (1 mmol), EDCI (2 mmol) and 
DMAP (2 mmol) followed by dry CH2Cl2 (15 mL) and the resulting solution was stirred at 25
o
C 
for 18 h under argon atmosphere. The reaction mixture was partitioned between water (150 mL) 
and CH2Cl2 (150 mL), the aqueous layer was acidified to pH = 2 using 2 N HCl, and extracted 
three times with CH2Cl2 (150 mL each). The combined organic layers were dried (anhydrous 
MgSO4), filtered, and concentrated to yield a solid which was purified by silica gel 
chromatography (30:1 CH2Cl2:MeOH) to yield compound 84, 0.5 g (72% yield) as a white solid, 
mp 119 – 121oC.  1H NMR δ 8.12 (d, J = 7.4 Hz, 1H), 8.05 (d, J = 5.9 Hz, 1H), 7.80 - 7.85 (m, 
1H), 7.72 (d, J = 5.5 Hz, 1H), 7.42 - 7.51 (m, 2H), 7.19 - 7.33 (m, 8H), 6.95 (d, J = 9.8 Hz, 1H), 
5.62 - 5.68 (m, 1H), 4.98 (s, 2H), 4.61 - 4.72 (m, 2H), 4.41 - 4.49 (m, 1H), 3.70 (s, 3H), 3.65 (dd, 
J = 5.5, 14.8 Hz, 1H), 3.39 (dd, J = 5.5, 14.5 Hz, 1H), 3.16 - 3.28 (m, 2H), 2.15 - 2.44 (m, 3H), 
1.55 - 1.87 (m, 4H), 1.41 - 1.50 (m, 1H), 0.89 (d, J = 5.9 Hz, 6H); 
13C NMR δ 179.9, 172.7, 
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172.4, 171.4, 156.3, 136.3, 134.1, 132.9, 132.3, 129.1, 128.7, 128.4, 128.2, 128.0, 127.8, 126.6, 
126.0, 125.5, 123.8, 67.2, 55.9, 52.6, 51.9, 51.4, 42.2, 40.8, 38.6, 35.5, 33.3, 28.2, 24.8, 23.1, 
22.3; MS, m/z 653.2 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-3-cyclohexyl-
propionylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (85).  
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Followed General Procedure A:  N-Boc-dipeptide 77 was used in place of N-Boc-dipeptide 76, 
to give compound 85 (74% yield) as a white solid. 
1
H NMR δ  8.15 (d, J = 7.81 Hz, 1H), 7.83 (d, 
J = 9.37 Hz, 1H), 7.74 (d, J = 7.42 Hz, 1H), 7.44 - 7.53 (m, 2H), 7.28 - 7.36 (m, 6H), 7.21 - 7.26 
(m, 2H), 6.94 (d, J = 6.64 Hz, 1H), 6.44 (br. s., 1H), 5.52 (d, J = 7.03 Hz, 1H), 5.01 (br. s., 2H), 
4.56 - 4.65 (m, 2H), 4.43 - 4.50 (m, 1H), 3.71 (s, 3H), 3.64 (dd, J = 5.66, 14.25 Hz, 1H), 3.39 - 
3.47 (m, 1H), 3.22 - 3.29 (m, 2H), 2.30 - 2.42 (m, 2H), 2.11 - 2.20 (m, 1H), 1.97 (br. s., 2H), 
1.71 - 1.89 (m, 4H), 1.56 - 1.70 (m, 4H), 1.37 - 1.47 (m, 1H), 1.08 - 1.21 (m, 2H), 0.80 - 0.95 (m, 
2H); 
13C NMR δ 179.9, 172.7, 172.3, 171.3, 156.2, 136.3, 134.0, 132.9, 132.2, 128.9, 128.6, 
128.2, 128.0, 127.9, 127.7, 126.5, 125.8, 125.4, 123.7, 67.0, 55.8, 52.5, 51.3, 51.2, 40.6, 40.5, 
38.4, 35.4, 34.0, 33.6, 33.3, 32.8, 28.0, 26.5, 26.3, 26.2; MS, m/z 693.5 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methyl-
pentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (87).  
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Followed General Procedure A: (R)-N-Cbz-1-naphthylalanine was used in place of (S)-N-Cbz-1-
naphthylalanine, to give compound 87 (83% yield) as a white solid, mp 195 – 197oC. 1H NMR δ 
8.18 (d, J = 7.8 Hz, 1H), 8.04 (d, J = 6.3 Hz, 1H), 7.82 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 7.4 Hz, 
1H), 7.43 - 7.54 (m, 3H), 7.27 - 7.36 (m, 6H), 6.34 (br. s., 1H), 6.17 (br. s., 1H), 6.03 (d, J = 7.8 
Hz, 1H), 5.00 (s, 2H), 4.58 - 4.66 (m, 1H), 4.47 - 4.54 (m, 1H), 4.30 - 4.38 (m, 1H), 3.64 - 3.69 
(s, 3H), 3.53 (d, J = 5.9 Hz, 2H), 3.09 - 3.21 (m, 2H), 2.28 (br. s., 2H), 2.04 - 2.14 (m, 1H), 1.66 
- 1.84 (m, 2H), 1.41 - 1.51 (m, 1H), 1.17 - 1.28 (m, 1H), 1.05 - 1.15 (m, 1H), 0.79 (s, 6H); 
13
C 
NMR δ 179.9, 172.6, 172.2, 171.0, 156.2, 136.5, 134.1, 133.0, 132.3, 129.0, 128.7, 128.4, 128.3, 
128.1, 128.0, 126.7, 126.0, 125.7, 123.9, 67.15, 56.4, 52.5, 51.9, 51.7, 41.5, 40.7, 38.8, 36.2, 
32.9, 28.5, 24.5, 23.0, 22.1; MS, m/z 653.1 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-4-methyl-pentanoylamino]-3-
(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (88).  
O
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Followed General Procedure A: (S)-N-Cbz-phenylalanine was used in place of (S)-N-Cbz-1-
naphthylalanine, and furnished compound 8 (87% yield) as a white solid, mp 71 – 73oC. 1H 
NMR δ 7.96 (d, J = 5.9 Hz, 1H), 7.05 - 7.36 (m, 11H), 6.81 (br. s., 1H), 5.47 (d, J = 7.8 Hz, 1H), 
4.99 - 5.08 (m, 2H), 4.63 - 4.71 (m, 1H), 4.42 - 4.53 (m, 2H), 3.70 (s, 3H), 3.17 - 3.33 (m, 2H), 
2.97 - 3.14 (m, 2H), 2.17 - 2.42 (m, 3H), 1.73 - 1.89 (m, 2H), 1.55 - 1.70 (m, 2H), 1.43 - 1.51 (m, 
1H), 0.90 (d, J = 5.9 Hz, 6H, 2 x CH3); 
13C NMR δ 179.9, 172.7, 172.3, 171.1, 156.2, 136.6, 
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136.4, 129.6, 128.8, 128.4, 128.2, 127.1, 67.3, 56.2, 52.6, 51.8, 51.4, 42.2, 40.7, 38.6, 38.4, 33.2, 
28.2, 24.8, 23.1, 22.3; MS, m/z 603.2 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-tert-butoxy-butyrylamino)-4-methyl-pentanoylamino]-
3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (89). 
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Followed General Procedure A: (S)-N-Cbz-O-t-butyl-threonine was used in place of (S)-N-Cbz-
1-napthylalanine, to give compound 89 (43% yield) as a white solid. 
1
H NMR δ 7.76 (d, J = 5.86 
Hz, 1H), 7.48 (d, J = 7.81 Hz, 1H), 7.29 - 7.37 (m, 5H), 6.42 (br. s., 1H), 5.90 (d, J = 4.69 Hz, 
1H), 5.03 - 5.16 (m, 2H), 4.45 - 4.55 (m, 2H), 4.14 - 4.19 (m, 1H), 3.70 (s, 3H), 3.22 - 3.33 (m, 
3H), 2.30 - 2.42 (m, 3H), 2.14 - 2.24 (m, 1H), 1.97 - 2.02 (m, 1H), 1.75 - 1.89 (m, 2H), 1.64 - 
1.73 (m, 3H), 1.48 - 1.58 (m, 1H), 1.25 (s, 9H), 1.05 (d, J = 5.86 Hz, 3H), 0.89 - 0.97 (m, 6H); 
13C NMR δ 179.8, 172.4, 172.4, 169.7, 156.4, 136.4, 128.8, 128.4, 128.3, 75.6, 67.2, 67.0, 59.1, 
52.6, 52.1, 51.3, 42.0, 40.7, 38.4, 33.2, 28.4, 25.0, 23.1, 22.4, 17.4; MS, m/z 613.2 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-2-yl-propionylamino)-4-methyl-
pentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (90). 
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Followed General Procedure A: (S)-N-Cbz-2-naphthylalanine was used in place of (S)-N-Cbz-1-
naphthylalanine, to give compound 90 (54% yield) as a white solid, mp 98 – 101oC. 1H NMR δ 
8.10 (br. s., 1H), 7.73 - 7.78 (m, 1H), 7.66 - 7.72 (m, 2H), 7.59 (s, 2H), 7.39 - 7.44 (m, 3H), 7.17 
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- 7.30 (m, 5H), 6.85 (br. s., 1H), 5.61 (br. s., 1H), 4.95 - 5.07 (m, 2H), 4.68 - 4.75 (m, 1H), 4.61 - 
4.67 (m, 1H), 4.41 - 4.48 (m, 1H), 3.69 (s, 3H), 3.25 - 3.31 (m, 1H), 3.18 (t, J = 8.0 Hz, 2H), 
3.01 - 3.10 (m, 1H), 2.30 - 2.41 (m, 1H), 2.16 - 2.26 (m, 2H), 1.78 - 1.86 (m, 1H), 1.55 - 1.75 (m, 
3H), 1.44 - 1.53 (m, 1H), 0.89 (d, J = 6.3 Hz, 3H, CH3), 0.87 (d, J = 6.3 Hz, 3H, CH3); 
13
C NMR 
δ 179.9, 172.9, 172.3, 171.2, 156.3, 136.4, 134.2, 133.6, 132.6, 128.7, 128.4, 128.3, 128.1, 127.9, 
127.7, 126.3, 125.9, 67.2, 56.1, 52.6, 51.9, 51.5, 42.2, 40.7, 38.6, 33.1, 28.2, 24.8, 23.0, 22.3; 
MS, m/z 653.3 (M+Na)
+
. 
 
2-[2-(2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionylamino)-4-methyl-
pentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (91). 
O
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Followed General Procedure A: (S)-N-Cbz-biphenylalanine  was used in place of (S)-N-Cbz-1-
napthylalanine, to give compound 91 (73% yield) as a white solid, mp 95 – 98oC. 1H NMR δ 
8.03 (d, J = 5.5 Hz, 1H), 7.53 (d, J = 7.4 Hz, 2H), 7.39 - 7.48 (m, 4H), 7.25 - 7.35 (m, 6H), 7.19 - 
7.24 (d, J = 8.1 Hz, 2H), 6.96 (br. s., 1H), 6.56 (br. s., 1H), 5.46 (d, J = 7.4 Hz, 1H), 5.01 - 5.11 
(m, 2H), 4.60 - 4.68 (m, 1H), 4.48 - 4.56 (m, 1H), 4.39 - 4.47 (m, 1H), 3.69 (s, 3H), 3.05 - 3.29 
(m, 4H), 2.33 - 2.40 (m, 1H), 2.14 - 2.31 (m, 2H), 1.98 (br. s., 1H), 1.79 - 1.89 (m, 1H), 1.71 - 
1.78 (m, 1H), 1.55 - 1.70 (m, 2H), 1.45 - 1.54 (m, 1H), 0.91 (d, J = 6.2 Hz, 3H, CH3), 0.90 (d, J 
= 6.2 Hz, 3H, CH3); 
13C NMR δ 179.9, 172.7, 172.3, 171.0, 156.3, 140.8, 140.0, 136.3, 135.6, 
130.0, 129.0, 128.8, 128.4, 128.2, 127.5, 127.4, 127.1, 67.3, 56.2, 52.6, 51.9, 51.7, 42.2, 40.7, 
38.7, 37.9, 33.1, 28.4, 24.8, 23.1, 22.3; MS, m/z 679.4 (M+Na)
+
.  
2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionic acid (91a). 
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 N-Boc-biphenylalanine (1.17 mmol) was dissolved in 20% TFA/CH2Cl2 (10 mL) and stirred at 
25
o
C for 2 h. The solvent was removed and remaining residue was placed under high vacuum to 
yield the amine intermediate as a sticky solid. The amine was immediately dissolved in (1:1) 
water/dioxane (20 mL) and treated with NaHCO3 (3.51 mmol) and benzylchloroformate (1.4 
mmol) followed by stirring at 25
o
C for 3 h. The reaction was combined with water (200 mL) and 
basified to pH 10 using aq. NaOH followed by extraction with ether (100 mL). The aqueous 
layer was acidified to pH 2 using aq. HCl and then extracted three times with CH2Cl2 (100 mL 
each). The combined CH2Cl2 layers were dried (anhydrous Na2SO4), filtered, and concentrated 
using a rotary evaporator to yield a solid which was recrystallized from ether/hexane (two crops) 
to give compound 91a,
9
 395 mg (90% yield) as a white solid. 
1
H NMR δ 7.52 - 7.55 (m, 2H), 
7.49 (d, J = 7.8 Hz, 2H), 7.40 - 7.45 (m, 2H), 7.36 (br. s., 1H), 7.31 - 7.35 (m, 5H), 7.19 (d, J = 
8.2 Hz, 2H), 5.15 (d, J = 8.2 Hz, 1H), 5.10 (d, J = 2.3 Hz, 2H), 4.65 - 4.71 (m, 1H), 3.06 - 3.18 
(m, 2H); 
13C NMR δ 176.3, 156.2, 140.8, 140.2, 136.2, 134.8, 131.2, 129.9, 128.9, 128.7, 128.4, 
128.3, 127.5, 127.2, 67.4, 54.9, 37.5;  MS, m/z 398.0 (M+Na)
+
.  
 
 [2-Hydroxy-1-(2-oxo-pyrrolidin-3-ylmethyl)-2-thiazol-2-yl-ethyl]-carbamic acid tert-butyl 
ester (92).  
O
O N
H OH
H
NO
N
S
 
n-BuLi (4.68 mmol) was added drop wise to a solution of thiazole (4.68 mmol) in dry THF (15 
mL) at -78
o
C and stirred for 2 h. A solution of aldehyde 53a (1.17 mmol) in dry THF (15 mL) 
was then added drop wise over 30 min and the resulting mixture was stirred at -78
o
C for 3 h. The 
reaction was quenched with aq. NH4Cl (15 mL) and slowly warmed to 0
o
C. Brine water (30 mL) 
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and CH2Cl2 (20 mL) were added and the organic layer was removed. The aqueous layer was 
extracted with CH2Cl2 (20 mL x 5) and the combined organic layers were dried (MgSO4), 
filtered and concentrated to give a yellow solid which was purified by silica gel column 
chromatography (9:1 CH2Cl2:MeOH) to separate two diastereomers of compound 92 (combined 
total = 142 mg, 36%) as yellow solids. (less polar isomer) 
1
H NMR δ 7.75 (d, J = 3.51 Hz, 1H), 
7.31 (d, J = 3.51 Hz, 1H), 6.12 (br. s., 1H), 5.97 (d, J = 7.42 Hz, 1H), 5.32 - 5.37 (m, 1H), 5.06 - 
5.10 (m, 1H), 4.10 - 4.18 (m, 1H), 3.29 - 3.35 (m, 2H), 2.37 - 2.53 (m, 2H), 2.10 - 2.19 (m, 1H), 
1.92 - 1.96 (m, 1H), 1.73 - 1.84 (m, 1H), 1.44 (s, 9H); MS, m/z 363.7 (M+Na)
+
; (more polar 
isomer) 
1
H NMR δ 7.75 (d, J = 3.12 Hz, 1H), 7.30 (d, J = 3.12 Hz, 1H), 6.16 (br. s., 1H), 5.60 (d, 
J = 8.98 Hz, 1H), 5.40 (br. s., 1H), 5.08 (br. s., 1H), 4.12 - 4.21 (m, 1H), 3.30 - 3.41 (m, 2H), 
2.50 - 2.62 (m, 1H), 2.37 - 2.49 (m, 1H), 1.99 - 2.11 (m, 1H), 1.81 - 1.97 (m, 1H), 1.67 - 1.77 (m, 
1H), 1.37 (s, 9H); MS, m/z 363.9 (M+Na)
+
. 
 
[2-Oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-2-thiazol-2-yl-ethyl]-carbamic acid tert-butyl ester 
(93).  
O
O N
H O
H
NO
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To a solution of 92 (0.19 mmol) in CH2Cl2 (2 mL) was added DMP (0.38 mmol). The reaction 
was stirred at 25
o
C for 2 h after which the reaction was diluted with CH2Cl2 (15 mL) and water 
(15 mL). The organic layer was removed and the aqueous layer was extracted with CH2Cl2 (15 
mL x 4), combined organic layers were dried (MgSO4), filtered and concentrated to give a solid 
that was purified by silica gel column chromatography (30:1 EtOAc:MeOH) to give compound 
93 (52 mg, 80%) as a white solid. 
1
H NMR δ 8.03 (d, J = 3.12 Hz, 1H), 7.71 (d, J = 3.12 Hz, 
1H), 6.07 (br. s., 1H), 5.79 (d, J = 8.59 Hz, 1H), 5.41 - 5.49 (m, 1H), 3.34 - 3.40 (m, 2H), 2.55 - 
2.67 (m, 2H), 1.99 - 2.14 (m, 3H), 1.44 (s, 9H); 
13C NMR δ 191.8, 179.9, 164.7, 156.0, 145.3, 
127.0, 80.1, 55.5, 40.6, 38.6, 34.9, 28.5, 28.2; MS, m/z 362.2 (M+Na)
+
. 
 
{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-2-thiazol-2-yl-ethylcarbamoyl]-butyl}-
carbamic acid tert-butyl ester (94).  
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Followed General Procedure A:  Compound 93 was used in place of N-Boc-dipeptide 76, to give 
compound 94 (31 mg, 55% yield) as a white solid. 
1
H NMR δ 8.03 (d, J = 3.12 Hz, 1H), 7.87 - 
7.91 (m, 1H), 7.71 (d, J = 3.12 Hz, 1H), 6.03 - 6.08 (m, 1H), 5.59 - 5.67 (m, 1H), 4.98 - 5.04 (m, 
1H), 4.20 - 4.28 (m, 1H), 3.29 - 3.41 (m, 2H), 2.50 - 2.64 (m, 2H), 1.97 - 2.21 (m, 3H), 1.63 - 
1.70 (m, 3H), 1.44 (s, 9H), 0.93 - 0.99 (m, 6H); 
13C NMR δ 190.8, 179.9, 173.2, 164.8, 155.7, 
145.1, 127.0, 80.0, 54.7, 53.2, 42.4, 40.7, 38.9, 34.0, 28.6, 28.5, 24.9, 23.2, 22.3; MS, m/z 475.2 
(M+Na)
+
. 
 
[2-Hydroxy-3-methyl-1-(2-oxo-pyrrolidin-3-ylmethyl)-but-3-enyl]-carbamic acid tert-butyl 
ester (95).  
O
O N
H
OH
H
NO
 
CrCl3 was suspended in dry THF (4 mL) under argon and cooled to 0
o
C. LiEt3BH was added 
drop wise and after stirring at 0
o
C for 45 min the stirring was stopped and the solid contents was 
allowed to settle to the bottom. The supernatant was carefully syringed out and the remaining 
solid was suspended in dry DMF (2 mL). To the suspension was added drop wise a solution of 
aldehyde 53a (0.16 mmol), 2-bromopropene (0.31 mmol) and NiCl2 (0.008 mmol) followed by 
stirring at 25
o
C for 1 h. The reaction was partitioned between brine (15 mL) and CH2Cl2 (15 
mL), organic layer removed and aqueous layer was extracted with CH2Cl2 (15 mL x 6). The 
combined organic layers were dried (Na2SO4), filtered and concentrated to yield a green residue 
that was purified by silica gel column chromatography (5:1 EtOAc:MeOH) to yield compound 
95 (18 mg, 39%) as a clear oil.  
1
H NMR δ 5.04 - 6.08 (m, 2H), 5.27 - 5.34 (m, 1H), 5.00 - 5.12 
(m, 3H), 4.90 - 4.97 (m, 2H), 4.12 - 4.16 (m, 1H), 3.92 - 3.99 (m, 1H), 3.75 - 3.84 (m, 2H), 3.28 - 
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3.37 (m, 4H), 3.21 (d, J = 3.12 Hz, 1H), 2.83 (br. s., 1H), 2.41 - 2.52 (m, 2H), 1.90 - 2.10 (m, 
4H), 1.78 - 1.85 (m, 4H), 1.76 (s, 6H), 1.42 (s, 18H); MS, m/z 321.0 (M+Na)
+
.   
 
[2-(2-Methyl-oxiranyl)-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethyl]-carbamic acid tert-
butyl ester (96).  
O
O N
H
O
H
NO
O
             
O
O N
H
O
H
NO
O
 
NaHCO3 (3.6 mmol) and m-CPBA (1.2 mmol) were added to a solution of alkene 95 (0.6 mmol) 
in CH2Cl2 (10 mL) at 0
o
C and stirred at 0
o
C for 2 h. The reaction was partitioned between 
CH2Cl2 (20 mL) and 10% aq. Sodium thiosulfate (20 mL). The organic layer was removed and 
the aqueous layer was extracted with CH2Cl2 (20 mL x 6), the combined organic layers were 
dried (Na2SO4), filtered and concentrated to give a mixture of epoxy-alcohol intermediates. To a 
solution of epoxy-alcohols (0.61 mmol) in CH2Cl2 (5 mL) was added DMP (1.2 mmol). The 
reaction was stirred at 25
o
C for 2 h after which the reaction was diluted with CH2Cl2 (15 mL) 
and filtered through a plug of celite. The filtrate was concentrated to give a solid that was 
purified by silica gel column chromatography (1:1 CH2Cl2:Acetone) to give compound two 
diastereomers (1:1) of 96 (104 mg, 55%) as white solids. (more polar isomer: 96-mp) 
1
H NMR δ 
6.22 (br. s., 1H), 5.55 (d, J = 8.20 Hz, 1H), 4.21 - 4.29 (m, 1H), 3.29 - 3.41 (m, 2H), 3.24 (d, J = 
5.08 Hz, 1H), 2.90 (d, J = 4.69 Hz, 1H), 2.40 - 2.54 (m, 2H), 1.88 - 1.99 (m, 1H), 1.73 - 1.81 (m, 
2H), 1.52 (s, 3H), 1.40 (s, 9H); 
13C NMR δ 208.1, 179.9, 156.1, 80.0, 59.3, 52.7, 52.0, 40.5, 38.5, 
33.2, 28.5, 28.0, 17.0; MS, m/z 335.0 (M+Na)
+
. (less polar isomer: 96-lp) 
1
H NMR δ 6.07 (br. s., 
1H), 5.52 (s, 1H), 4.56 - 4.65 (m, 1H), 3.28 - 3.39 (m, 2H), 3.09 (d, J = 5.08 Hz, 1H), 2.85 (d, J = 
5.08 Hz, 1H), 2.37 - 2.52 (m, 2H), 1.94 - 2.02 (m, 1H), 1.79 - 1.87 (m, 1H), 1.62 - 1.69 (m, 1H), 
1.55 (s, 3H), 1.43 (s, 9H); 
13C NMR δ 207.0, 179.7, 155.6, 80.2, 59.5, 53.4, 52.9, 40.5, 38.0, 
33.3, 28.6, 28.5, 18.0; MS, m/z 335.1 (M+Na)
+
.  
 
 
{3-Methyl-1-[2-(2-methyl-oxiranyl)-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-
ethylcarbamoyl]-butyl}-carbamic acid tert-butyl ester (97-lp).  
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Followed General Procedure A:  Compound 96-lp was used in place of N-Boc-dipeptide 76, to 
give compound 97-lp (51% yield) as a white solid. 
1
H NMR δ 7.91 (br. s., 1H), 6.24 (br. s., 1H), 
4.95 (d, J = 7.81 Hz, 1H), 4.38 - 4.46 (m, 1H), 4.16 - 4.26 (m, 1H), 3.28 - 3.41 (m, 3H), 2.91 (d, 
J = 5.08 Hz, 1H), 2.36 - 2.51 (m, 1H), 1.76 - 1.97 (m, 3H), 1.71 (br. s., 2H), 1.57 - 1.66 (m, 2H), 
1.51 (s, 3H), 1.43 (s, 9H), 0.91 - 0.98 (m, 6H); 
13C NMR δ 207.0, 179.9, 173.5, 155.7, 80.0, 59.6, 
52.9, 52.8, 51.4, 42.6, 40.7, 39.0, 32.1, 28.5, 24.8, 23.1, 22.3, 17.0; MS, m/z 448.1 (M+Na)
+
. 
 
{3-Methyl-1-[2-(2-methyl-oxiranyl)-2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-
ethylcarbamoyl]-butyl}-carbamic acid tert-butyl ester (97-mp).  
O
N
H
N
H
O
H
NO
O
O
O
 
Followed General Procedure A:  Compound 96-mp was used in place of N-Boc-dipeptide 76, to 
give compound 97-mp (47% yield) as a white solid. 
1
H NMR δ  7.78 (d, J = 5.86 Hz, 1H), 6.19 
(br. s., 1H), 5.00 (d, J = 7.81 Hz, 1H), 4.75 - 4.82 (m, 1H), 4.13 - 4.21 (m, 1H), 3.26 - 3.38 (m, 
2H), 3.02 (d, J = 4.69 Hz, 1H), 2.82 - 2.86 (m, 1H), 2.37 - 2.48 (m, 2H), 1.96 - 2.07 (m, 2H), 
1.76 - 1.88 (m, 2H), 1.59 - 1.73 (m, 2H), 1.57 (s, 3H), 1.43 (s, 9H), 0.95 (d, J = 6.25 Hz, 6H); 
13
C 
NMR δ 206.2, 180.0, 173.0, 155.7, 80.1, 59.9, 53.1, 53.0, 52.7, 42.0, 40.7, 38.4, 32.5, 28.9, 28.5, 
24.9, 23.2, 22.2, 18.0; MS, m/z 448.0 (M+Na)
+
. 
 
2-[2-(2-Amino-3-naphthalen-1-yl-propionylamino)-4-methyl-pentanoylamino]-3-(2-oxo-
pyrrolidin-3-yl)-propionic acid methyl ester (98). 
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Palladium (on carbon) (10 mg) was added to a solution of 84 (0.16 mmol) in MeOH (2 mL) and 
the flask was flushed with hydrogen gas (1 atm). The reaction was stirred for 3 h at 25
o
C. The 
reaction was filtered through a layer of celite and the filtrate was concentrated to yield compound 
98 (80 mg, 100%) as a white solid. 
 1
H NMR δ 8.22 (d, J = 7.81 Hz, 1H), 8.17 (d, J = 5.86 Hz, 
1H), 7.87 (d, J = 7.42 Hz, 1H), 7.78 (d, J = 8.20 Hz, 1H), 7.47 - 7.57 (m, 2H), 7.31 - 7.44 (m, 
3H), 6.34 - 6.61 (m, 1H), 4.68 - 4.75 (m, 1H), 4.34 - 4.44 (m, 1H), 3.92 - 4.00 (dd, J = 2.73, 
11.15 Hz, 1H), 3.82 (dd, J = 2.73, 10.15 Hz, 1H), 3.72 (s, 3H), 3.24 - 3.39 (m, 2H), 2.85 (dd, J = 
10.35, 13.86 Hz, 1H), 2.30 - 2.44 (m, 2H), 2.14 - 2.26 (m, 1H), 1.68 - 1.92 (m, 4H), 1.54 - 1.63 
(m, 1H), 0.91 - 1.03 (m, 6H); 
13C NMR δ 179.8, 174.8, 173.2, 134.2, 134.2, 132.0, 129.0, 127.9, 
127.6, 126.4, 126.0, 125.5, 124.0, 55.9, 52.5, 51.8, 51.1, 42.2, 40.7, 38.7, 38.6, 32.9, 28.3, 24.9, 
23.1, 22.3. 
 
2-[4-Methyl-2-(2-{2-[methyl-(4-methyl-2-oxo-2H-chromen-7-yl)-amino]-acetylamino}-3-
naphthalen-1-yl-propionylamino)-pentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic 
acid methyl ester (99).  
O
N
H
N
H
H
NO
H
N
O
O
OMe
OO N
Me O
 
Followed General Procedure E: The amine 98 was used in place of 53 and the acid 104 was 
used in place of N-Boc-leucine, to give compound 99 (36 mg, 62% yield) as a yellow solid. 
1
H 
NMR δ 8.06 (d, J = 7.01 Hz, 1H), 7.94 (d, J = 7.03 Hz, 1H), 7.76 (dd, J = 2.93, 6.44 Hz, 1H), 
7.60 - 7.64 (m, 1H), 7.41 - 7.48 (m, 2H), 7.17 - 7.25 (m, 3H), 7.06 (d, J = 8.20 Hz, 1H), 6.78 (d, 
J = 7.03 Hz, 1H), 6.37 (d, J = 2.34 Hz, 1H), 6.30 (dd, J = 2.34, 8.98 Hz, 1H), 6.27 (s, 1H), 6.04 
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(s, 1H), 4.76 - 4.84 (m, 1H), 4.47 - 4.60 (m, 2H), 3.86 - 3.92 (m, 2H), 3.72 (s, 3H), 3.63 (dd, J = 
5.86, 14.45 Hz, 1H), 3.38 (dd, J = 8.98, 14.45 Hz, 1H), 3.27 - 3.33 (m, 2H), 2.76 (s, 3H), 2.36 - 
2.47 (m, 1H), 2.34 (s, 3H), 2.09 - 2.19 (m, 1H), 1.85 - 1.93 (m, 1H), 1.76 - 1.85 (m, 1H), 1.66 - 
1.75 (m, 1H), 1.53 - 1.63 (m, 1H), 1.39 - 1.48 (m, 1H), 0.90 (d, J = 6.25 Hz, 6H); 
13C NMR δ 
180.0, 172.4, 172.3, 170.8, 170.2, 161.8, 155.5, 152.8, 151.6, 134.0, 132.5, 132.2, 129.1, 128.1, 
127.7, 126.7, 126.0, 125.8, 125.4, 123.5, 111.4, 110.8, 109.1, 99.5, 57.5, 54.4, 52.6, 52.2, 51.7, 
41.8, 40.7, 39.6, 38.7, 34.2, 33.3, 28.7, 25.0, 23.2, 22.2, 18.7; MS, m/z 748.2 (M+Na)
+
.  
 
2-(4-Methyl-2-{2-[(2-methyl-thiazole-5-carbonyl)-amino]-3-naphthalen-1-yl-
propionylamino}-pentanoylamino)-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester 
(100).  
O
N
H
N
H
H
NO
H
N
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O
OMe
O
N
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Followed General Procedure E: The amine 98 was used in place of 53 and 2-methyl-thiazole-5-
carboxylic acid was used in place of N-Boc-leucine, to give compound 100 (37 mg, 74% yield) 
as a white solid. 
1
H NMR δ 8.17 (d, J = 8.20 Hz, 1H), 7.92 (d, J = 7.42 Hz, 1H), 7.83 (s, 1H), 
7.79 (d, J = 7.81 Hz, 1H), 7.70 (d, J = 7.81 Hz, 1H), 7.27 - 7.51 (m, 6H), 6.59 (br. s., 1H), 4.98 - 
5.05 (m, 1H), 4.48 - 4.58 (m, 2H), 3.72 (s, 3H), 3.59 - 3.63 (m, 2H), 3.21 - 3.32 (m, 2H), 2.60 (s, 
3H), 2.33 - 2.44 (m, 1H), 2.10 - 2.20 (m, 1H), 1.96 (br. s., 1H), 1.84 - 1.92 (m, 1H), 1.76 - 1.83 
(m, 1H), 1.62 - 1.71 (m, 1H), 1.53 - 1.61 (m, 1H), 1.42 - 1.50 (m, 1H), 0.85 (d, J = 6.25 Hz, 6H); 
13C NMR δ 180.0, 172.5, 172.3, 171.3, 170.7, 160.9, 143.5, 134.1, 133.8, 132.8, 132.2, 129.1, 
128.1, 127.8, 126.7, 126.0, 125.6, 123.7, 54.7, 52.6, 52.5, 51.5, 41.7, 40.8, 38.7, 35.0, 33.6, 29.9, 
28.4, 24.9, 23.0, 22.2, 19.6; MS, m/z 644.2 (M+Na)
+
. 
 
(4-Methyl-2-oxo-2H-chromen-7-ylamino)-acetic acid methyl ester (102).  
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A solution containing 7-amino-4-methylcoumarin 101 (0.57 mmol), NaI (0.57 mmol), 
methylbromoacetate (0.63 mmol) and DIPEA (0.63 mmol) in dry acetonitrile (6 mL) was heated 
at 82
o
C for 18 h. The reaction was filtered and the filtrate was concentrated to give an oil that 
was purified by silica gel column chromatography (15:1 CH2Cl2:MeOH) to afford compound 
102 (120 mg, 85%) as a yellow solid. 
1
H NMR δ 7.39 (d, J = 8.98 Hz, 1H), 6.56 (dd, J = 2.34, 
8.98 Hz, 1H), 6.42 (d, J = 2.34 Hz, 1H), 6.02 (s, 1H), 4.78 - 4.84 (m, 1H), 3.97 (d, J = 5.08 Hz, 
2H), 3.82 (s, 3H), 2.35 (s, 3H); 
13C NMR δ 170.8, 161.9, 156.0, 153.0, 150.3, 125.9, 111.6, 
110.8, 110.4, 98.7, 52.8, 45.1, 18.8; MS, m/z 270.1 (M+Na)
+
. 
 
[Methyl-(4-methyl-2-oxo-2H-chromen-7-yl)-amino]-acetic acid methyl ester (103).  
OO N
Me O
OMe
 
Methyl iodide (0.73 mmol) and K2CO3 (0.98 mmol) were added to a solution of 102 (0.49 mmol) 
in dry acetonitrile (5 mL) and refluxed at 82
o
C for 18 h. The reaction was filtered and partitioned 
between CH2Cl2 (20 mL) and water (20 mL). The organic layer was removed and the aqueous 
layer was extracted with CH2Cl2 (20 mL x 3), the combined organic layers were dried (MgSO4), 
filtered and concentrated to give a yellow oil that was purified by silica gel chromatography 
(15:1 CH2Cl2:MeOH) to yield compound 103 (31 mg, 24%) as a yellow solid. 
1
H NMR δ 7.43 
(d, J = 8.83 Hz, 1H), 6.61 (dd, J = 2.54, 8.83 Hz, 1H), 6.53 (d, J = 2.54 Hz, 1H), 6.02 (s, 1H), 
4.15 (s, 2H), 3.76 (s, 3H), 3.15 (s, 3H); 
13C NMR δ 170.6, 162.0, 155.8, 152.9, 151.9, 125.7, 
110.9, 110.3, 109.0, 99.1, 54.2, 52.5, 39.9, 18.7; MS, m/z 284.0 (M+Na)
+
. 
 
[Methyl-(4-methyl-2-oxo-2H-chromen-7-yl)-amino]-acetic acid (104).  
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The ester 103 (0.08 mmol) was dissolved in 1:1 dioxane:water (1 mL) and treated with 2N 
NaOH (0.12 mL). After stirring at 25
o
C for 1 h the reaction was partitioned between water (20 
mL) and CH2Cl2 (20 mL) then acidified to pH 2 using aq. HCl. The aqueous layer was extracted 
with CH2Cl2 (15 mL x 3), the combined CH2Cl2 layers were dried (Na2SO4), filtered and 
concentrated to yield compound 104 (20 mg, 100%) as a yellow solid. 
1
H NMR δ 8.58 (br. s., 
1H), 7.42 (d, J = 8.98 Hz, 1H), 6.62 (d, J = 8.98 Hz, 1H), 6.51 (s, 1H), 6.01 (s, 1H), 4.16 (s, 2H), 
3.13 (s, 3H), 2.34 (s, 3H); 
13C NMR δ 174.4, 162.7, 155.6, 153.5, 151.9, 125.8, 110.9, 110.0, 
109.2, 99.0, 61.4, 39.9, 18.7; MS, m/z 270.0 (M+Na)
+
.  
 
14-tert-Butoxycarbonylamino-2-isobutyl-3,8,15-trioxo-1,4,9triaza-cyclopentadec-11-ene-5-
carboxylic acid methyl ester (106).  
O
N
H
O
N
H
H
N O
O
H
N
O
O
OMe
 
Grubbs second generation catalyst (0.098 mmol) was added to a degassed solution of diene 105 
(0.98 mmol) in CH2Cl2. The resulting pink solution was heated at 40
o
C for 48 h. The reaction 
was filtered through a layer of celite and the filtrate was concentrated to give a solid that was 
purified by silica gel column chromatography (15:1 CH2Cl2:MeOH) to yield compound 106 (269 
mg, 57%) as a white solid. 
1
H NMR δ 7.16 (d, J = 8.20 Hz, 1H), 7.06 (d, J = 7.81 Hz, 1H), 6.55 
(br. s., 1H), 5.43 - 5.59 (m, 3H), 4.58 - 4.66 (m, 1H), 4.51 - 4.57 (m, 1H), 4.37 - 4.44 (m, 1H), 
3.84 - 3.92 (m, 1H), 3.73 (s, 3H), 3.49 - 3.57 (m, 1H), 2.44 - 2.52 (m, 2H), 2.33 - 2.42 (m, 2H), 
1.80 - 2.05 (m, 2H), 1.53 - 1.75 (m, 2H), 1.43 (s, 9H), 1.23 - 1.28 (m, 1H), 0.87 - 0.97 (m, 6H); 
13C NMR δ 172.8, 172.6, 171.6, 171.2, 155.3, 131.1, 126.4, 80.1, 54.4, 52.6, 52.0, 51.8, 42.2, 
41.0, 35.9, 32.3, 28.6, 26.1, 24.7, 23.0, 22.4; MS, m/z 505.3 (M+Na)
+
. 
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14-tert-Butoxycarbonylamino-2-isobutyl-3,8,15-trioxo-1,4,9triaza-cyclopentadecane-5-
carboxylic acid methyl ester (107). 
O
N
H
O
N
H
H
N O
O
H
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Palladium (carbon) (5 mg) was added to a solution of 106 (0.10 mmol) in MeOH (2 mL) and the 
flask was flushed with hydrogen gas (1 atm). After stirring at 25
o
C for 20 h the reaction was 
filtered through a layer of celite and the filtrate was concentrated to yield 107 (50 mg, 100%) as 
a light brown solid. 
1
H NMR δ 7.03 (br. s., 1H), 6.60 (br. s., 1H), 6.21 (br. s., 1H), 5.28 (br. s., 
1H), 4.61 - 4.67 (m, 1H), 4.38 - 4.45 (m, 1H), 4.15 - 4.22 (m, 1H), 3.75 (br. s., 3H), 3.49 - 3.58 
(m, 1H), 3.01 - 3.09 (m, 1H), 2.40 - 2.43 (m, 1H), 2.24 - 2.33 (m, 3H), 2.09 - 2.17 (m, 1H), 1.55 - 
1.96 (m, 9H), 1.44 (m, 9H), 1.19 - 1.29 (m, 2H), 0.89 - 0.99 (m, 6H); 
13C NMR δ 184.1, 172.5, 
172.2, 155.5, 80.2, 54.0, 52.9, 52.7, 52.2, 41.2, 37.4, 31.8, 30.5, 28.5, 28.1, 26.6, 24.8, 23.0, 22.2, 
20.8; MS, m/z 507.5 (M+Na)
+
. 
Synthesis of Graphene Oxide (108). (AP8-19) 
OH
OH
O
HO
O
OH
OH
O  
Portions of graphite flakes (3 x 330 mg) were separately heated in a microwave reactor (30 W, 4 
min) under argon atmosphere. The expanded graphite flakes were added to a solution of P2O5 (30 
g) and K2S2O8 (30 g) in concentrated HCl at 90
o
C with vigorous stirring. The mixture was stirred 
at 85
o
C for 4 h. The mixture was allowed to cool to 10
o
C after which it was added slowly to 
chilled deionized water (1.5 L). The mixture was passed through a glass frit funnel (medium 
gauge) and the black residue was washed with copious amount of deionized water (5 L). The 
black residue was dried in an incubator at 60
o
C for 18 h to provide a fluffy black solid (1.12 g). 
The solid was added to H2SO4 (120 mL) at 0
o
C followed by the addition of KMnO4 (36 g) and 
the mixture was heated at 40
o
C for 2 h with vigorous stirring. The mixture was allowed to cool to 
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25
o
C and diluted with cold deionized water (1 L) followed by stirring for 2 h. A solution of 30% 
H2O2 (40 mL) was added drop wise at 0
o
C using a dropping funnel. The yellow mixture that 
formed was allowed to stand of 25
o
C for 2 days. The supernatant layer was carefully decanted 
and the bottom layer containing the graphene oxide was transferred to many 15 mL centrifuge 
tubes. The tubes were centrifuged for 30 min at 2500 rpm. The supernatant layer from each tube 
was carefully decanted and the graphene oxide residue was suspended in 10% HCl (10 mL each). 
The tubes were centrifuged once again after which the supernatant layer was carefully decanted. 
The graphene oxide was washed three more times with deionized water (10 mL each) using the 
above mentioned centrifugation method. The graphene oxide was transferred into a dialysis bag 
(12000 Mw cut off) and dialyzed at 25
o
C with water changes twice daily for 1 week until the pH 
of the wash water remained constant between water changes (~ pH 5.3). The graphene oxide was 
suspended in deionized water, frozen and lyophilized to provide graphene oxide 108, 600 mg (~ 
60%) as light brown solid. FTIR (neat) ʋ 3339, 1736, 1631, 1373, 1279, 1224, 1076, 978 cm-1; 
Raman ʋ 2436, 1593, 1361 cm-1.       
 
t-Butyl ester functionalized graphene oxide (109). (AP8-136) 
OH
O
O
O
O
OH
O
O
O
O
O
O
O
O
 
Sodium hydride (2.3 mmol) in a 25 mL round bottom flask was flame dried and purged with 
argon. Distilled ether (10 mL) was added and the mixture was shaken for 30 sec after which it 
was allowed to stand and the NaH was settled to the bottom. The ether was carefully syringed 
out and the remaining grey solid was dried under vacuum. Graphene oxide 108 (40 mg) was 
added followed by dry DMF (10 mL) and the mixture was shaken for 1 hr. t-Butylbromoacetate 
(2.23 mmol) was added and the mixture was allowed to stand for 2 days with intermittent 
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shaking. The reaction was transferred to two 15 mL centrifuge tubes. The tubes were centrifuged 
for 30 min at 2500 rpm. The supernatant layer from each tube was carefully decanted and the t-
butyl ester functionalized-graphene oxide residue was re-suspended in deionized water (10 mL 
each). The tubes were centrifuged once again after which the supernatant layer was carefully 
decanted. The t-butyl ester functionalized-graphene oxide was washed three more times with 
deionized water (5 mL each) and once with diethyl ether (5 mL) using the above mentioned 
centrifugation method. The brown residue was suspended in deionized water (5 mL), frozen and 
lyophilized to give t-butyl ester functionalized-graphene oxide 109, 29 mg (~ 72%) as a brown 
fluffy solid.  IR (neat) ʋ 3359, 2977, 2930, 1721, 1632, 1455, 1366, 1313, 1250, 1142, 983, 844, 
725 cm
-1
; Raman ʋ 2435, 1589, 1345 cm-1.    
 
13
C-2-bromoacetic acid (111). 
O
OH
Br
*  
TFA anhydride (32.8 mmol) was added to 
13
C-acetic acid (16.4 mmol) at 0
o
C followed by 
stirring for 2 hr at 25
o
C. The solution was cooled to 0
o
C and Br2 (16.4 mmol) was added 
followed by stirring overnight at 25
o
C. Water (32.8 mmol) was added at 0
o
C and the solution 
was stirred for 5 min. The volatiles were removed by distillation at atmospheric pressure (bath 
temp = 120
o
C) until approximately 2 mL of liquid remained. The distillation apparatus was 
removed and the remaining liquid evaporated by purging with a stream of argon gas overnight to 
provide compound 111, 2.3 g (100%) as a yellow solid. 
1
H NMR δ 8.41 (br. s., 1H), 3.91 (d, J = 
4.7 Hz, 2H). 
 
13
C-t-Butylbromoacetate (112). 
O
O
Br
*  
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13
C-2-bromoacetic acid 111 (16.4 mmol) was dissolved in CH2Cl2 (15 mL) and chilled to – 78
o
C. 
Chilled isobutylene liquid was obtained by flowing isobutylene gas into a chilled round bottom 
flask. The chilled isobutylene liquid (26.2 mmol) was added to the 
13
C-2-bromoacetic acid 
solution and the temperature was allowed to stabilize at – 78oC. H2SO4 (100 µL) was added and 
the reaction vessel was sealed tightly. The solution was allowed to warm to 25
o
C and sit for 3 
days.  The cap was released and excess isobutylene gas was allowed to boil off. The reaction was 
poured into aqueous NaHCO3 (50 mL) and the organic layer was removed followed by 
extraction of aqueous layer with ether (50 mL). The combined organic portions were dried 
(MgSO4), filtered and concentrated to yield a colorless oil which was purified by column 
chromatography (3:1 hexane:ether) to yield pure compound 112, 2 g (63%) as a clear oil. 
1
H 
NMR δ 3.75 (d, J = 4.7 Hz, 2H), 1.49 (s, 9H); 13C NMR δ 166.3, 82.9, 82.9, 28.1, 27.9, 27.9, 
27.5.  
  
13
C-t-Butyl ester functionalized graphene oxide (113). (AP9-125) 
OH
O
O
O
O
OH
O
* O
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O
O
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Sodium hydride (3.3 mmol) in a 25 mL round bottom flask was flame dried and purged with 
argon. Distilled ether (15 mL) was added and the mixture was shaken for 30 sec after which it 
was allowed to stand and the NaH was settled to the bottom. The ether was carefully syringed 
out and the remaining grey solid was dried under vacuum. Graphene oxide 108 (170 mg) was 
added followed by dry DMF (34 mL) and the mixture was shaken for 4 h. 
13
C-t-
butylbromoacetate (3.8 mmol) was added and the mixture was allowed to stand for 2 days with 
intermittent shaking. The reaction was transferred to four 15 mL centrifuge tubes. The tubes 
were centrifuged for 30 min at 2500 rpm. The supernatant layer from each tube was carefully 
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decanted and the 
13
C-t-butyl ester functionalized-graphene oxide residue was re-suspended in 
deionized water (10 mL each). The tubes were centrifuged once again after which the 
supernatant layer was carefully decanted. The t-butyl ester functionalized-graphene oxide was 
washed three more times with deionized water (10 mL each) and once with diethyl ether (10 mL) 
using the above mentioned centrifugation method. The brown residue was suspended in 
deionized water (8 mL), frozen and lyophilized to give 
13
C-t-butyl ester functionalized-graphene 
oxide 113, 120 mg (~ 71%) as a brown fluffy solid.  IR (neat) ʋ 3386, 2929, 1655, 1385, 1361, 
1248, 1139, 1100, 1045, 963 cm
-1
. 
 
Carboxylic acid functionalized graphene oxide (114). (AP8-35) 
OH
O
O
O
O
OH
O
O
O
HO
OH
OH
O
O
 
t-Butyl ester functionalized-graphene oxide 109 (40 mg) was suspended in 20% TFA/deionized 
water (12 mL) and allowed to stand at 25
o
C for 3 days with intermittent shaking. The reaction 
was transferred to two 15 mL centrifuge tubes. The tubes were centrifuged for 30 min at 2500 
rpm. The supernatant layer from each tube was carefully decanted and the carboxylic acid 
functionalized-graphene oxide was re-suspended in deionized water (10 mL each). The tubes 
were centrifuged once again after which the supernatant layer was carefully decanted. The 
carboxylic acid functionalized-graphene oxide was washed three more times with deionized 
water (5 mL each) using the above mentioned centrifugation method. The brown residue was 
suspended in deionized water (5 mL), frozen and lyophilized to give carboxylic acid 
functionalized-graphene oxide 114, 31 mg (~ 78%) as a brown fluffy solid. FTIR (neat) ʋ 3195, 
1725, 1631, 1369, 1186, 1135, 1057, 790 cm
-1
; Raman ʋ 2436, 1591, 1351 cm-1.        
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13
C-Carboxylic acid functionalized graphene oxide (115). (AP8-138) 
OH
O
O
O
O
OH
O
* O
O
*
*
HO
OH
OH
O
O
 
13
C-t-butyl ester functionalized-graphene oxide 113 (40 mg) was suspended in 20% 
TFA/deionized water (10 mL) and allowed to stand at 25
o
C for 3 days with intermittent shaking. 
The reaction was transferred to two 15 mL centrifuge tubes. The tubes were centrifuged for 30 
min at 2500 rpm. The supernatant layer from each tube was carefully decanted and the 
carboxylic acid functionalized-graphene oxide was re-suspended in deionized water (10 mL 
each). The tubes were centrifuged once again after which the supernatant layer was carefully 
decanted. The 
13
C-carboxylic acid functionalized-graphene oxide was washed three more times 
with deionized water (5 mL each) using the above mentioned centrifugation method. The brown 
residue was suspended in deionized water (5 mL), frozen and lyophilized to give 
13
C-carboxylic 
acid functionalized-graphene oxide 115, 26 mg (~ 65%) as a brown fluffy solid. IR (neat) ʋ 
3195, 1725, 1631, 1369, 1186, 1135, 1057, 790 cm
-1
. 
 
Solid State Synthesis-attachment of carboxylic acid functionalized graphene oxide to resin 
(116). (AP10-39) and (AP18-48) 
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O
O
O
O
OO
O
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O
OH
OH
O
O
O
chlorotrityl-resin
(black)  
A 25 mL round bottom flask was silylated with 20% TMSCl in CHCl3 (10 mL) for 1 hour. 
Solution was decanted and flask was washed with CHCl3 (3 x 1 mL) and dried under vacuum. 2-
Chlorotrityl resin (1 g) was added to the flask and purged with argon. Dry CH2Cl2 was added via 
syringe and resin was allowed to swell for 1 hr. Carboxylic acid functionalized-graphene oxide 
114 (5 mg) was added followed by N,N-diisopropylethylamine (1.35 mL). The mixture was put 
in a shaker for 2 days. The reaction mixture was filtered and the black colored resin was washed 
with dry CH2Cl2 (20 mL). This whole process was repeated a second time and the black GO 
coated resin beads were combined. The GO-resin 116 was used immediately for of 
oligonucleotide attachment.  
 
Solid State Synthesis-Attachment of oligonucleotide to graphene oxide coated resin (117). 
(AP10-41) 
O
O
O
O
OO
O
O
O
H
N
HN
O
O
O
ssDNA
ssDNA
11
11
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Dry DMF (5 mL) was added to the carboxylic acid functionalized graphene oxide coated-resin 
116. HATU (0.6 mg) was added and the mixture was shaken at 25
o
C for 10 min. The 
oligonucleotide-GII, (sequence: 5’/5AmMC12/TGG GAG GGC GAT CGC AAT C), (0.074 
μmol) was added and the mixture was reacted in microwave reactor (75 oC, 25 W, 5 min). The 
mixture was filtered and the black beads were washed with DMF (50 mL) to yield 
oligonucleotide-functionalized graphene oxide coated resin 117 as black beads.  
 
Solid State Synthesis-Cleavage of oligonucleotide functionalized graphene oxide from resin 
(118). (AP10-43) 
HO
O
O
O
OHO
O
O
O
H
N
HN
HO
O
O
ssDNA
ssDNA
11
11
 
The solid black beads (oligonucleotide functionalized-GO coated resin) 117 was suspended in 
10% TFA in trifluoroethanol (5 mL) and sonicated (1 h x 4) allowing the mixture to stand for 6 
hours at room temperature in between each sonication period. The solution became red/brown in 
color and was centrifuged at 1500 rpm for 10 min. The oligonucleotide functionalized-GO sinks 
to the bottom while the resin resides on the top of the solvent. The top layer (resin and 
trifluoroethanol) was carefully decanted and the remaining solid (bottom) was washed with 
deionized water (x3) using the centrifugation method. The remaining solid was suspended in 
deionized water and lyophilized to give oligonucleotide functionalized graphene oxide 118, 5 mg 
(~ 50%) as a brown solid. IR (neat) ʋ 2968, 2909, 1717.3, 1568.7, 1451.5, 1177.9 cm-1; Raman ʋ 
2436, 1592, 1350 cm
-1
.        
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Experimental Details for the Synthesis of H2N-(CH2)4CO-Ala-Ala-Asn-Leu-NHCH2-Fc 
(119) for legumain detection. 
 
Ala-Ala-Asn-Leu (122).  AP8-93 
Starting with Leucine 2-chlorotrityl resin, N-Fmoc protected amino acids were coupled using 
conventional solid state peptide synthesis by coupling (General Procedure F) and deprotection 
(General Procedure G) strategy in the order Asn, Ala and Ala. Standard procedure H was used 
to cleave and recover the peptide from the resin to give compound 122, 95 mg (45%) as a white 
solid. MS calcd for C16H30N5O6 (M+H)
+
 388.2, found 388.4. 
 
Boc-Ala-Ala-Asn-Leu-NHCH2-Fc (123). AP8-98   
To compound 122 (50 mg, 0.13 mmol) was added triethylamine (36 μL, 0.26 mmol) and 
dioxane:water (1:1) (10 mL), and the resulting solution was stirred for 10 min. Di-t-butyl 
dicarbonate (Boc2O) (56 mg, 0.26 mmol) was added and the solution stirred at 25
o
C for 12 h.  
The reaction solution was concentrated to dryness yielding a N-Boc intermediate 122a, 60 mg 
(96%) as a white solid which was directly used without further purification. MS calcd for 
C21H37N5NaO8 (M+Na)
+
 510.3, found 510.4. To a solution of Boc-122 (60 mg, 0.12 mmol) in 
DMF (2 mL) under argon atmosphere was added HATU (47 mg, 0.12 mmol) and the solution 
was stirred at 25
o
C for 10 min.  Aminomethylferrocene (26 mg, 0.12 mmol) was added and the 
solution was stirred at 25
o
C for 2 h followed by filtration (0.2 micron filter) and purification by 
HPLC using a preparative column (Phenomenex-Jupiter C18) and eluting with 40% 
acetonitrile/water to 80 % acetonitrile/water over 40 min with a 10 ml/min flow rate.  The 
fractions containing the desired product were combined and lyophilized to yield compound 123, 
40 mg (48% yield) as a yellow solid. MS calcd for C32H48FeN6NaO7 (M+Na)
+
 707.3, found 
707.5. 
 
Boc-HN-(CH2)4CO-Ala-Ala-Asn-Leu-NHCH2-Fc (124). AP9-85  
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Compound 123 (18 mg, 26 mol) was dissolved in 10% TFA in dichloromethane (2 mL) and 
stirred at 25
o
C for 30 min, concentrated gently on a rotovap to give a residue.  The residue was 
dissolved in deionized water (2 mL), frozen, and lyophilized to give a de-Boc intermediate 123a, 
15 mg (100%) as a green solid.  MS calcd for C27H40FeN6NaO5 (M+Na)
+
 607.2, found 607.1. To 
a solution of N-Boc-5-aminovaleric acid (5.6 mg, 26 mol) in DMF (2 mL) was added HATU (9 
mg, 24 mol), and the resulting solution was stirred at 25oC for 10 min. This solution was 
transferred via cannula to intermediate 123a (10 mg, 17 mol) and the resulting solution was 
stirred for 2 h at 25
o
C, filtered, and separated on a HPLC using a preparative column 
(Phenomenex-Jupiter C18) and eluting with 40% acetonitrile/water to 80 % acetonitrile/water 
over 40 min with a 10 ml/min flow rate and λ=254 nm.  The fractions containing the desired 
product were combined and lyophilized to yield compound 124, 6 mg (45% yield) as a yellow 
solid. MS calcd for C37H57FeN7NaO8 (M+Na)
+
 806.4, found 806.5. 
 
H2N-(CH2)4CO-Ala-Ala-Asn-Leu-NHCH2-Fc (119). AP9-87   
Compound 124 (6 mg, 8 mol) was dissolved in 10% TFA in dichloromethane (1 mL) and 
stirred at 25
o
C for 30 min.  The reaction solution was concentrated gently on a rotary evaporator 
to give a residue which was dissolved in deionized water (2 mL), frozen and lyophilized to give 
compound 119, 4 mg (75% yield) as a green solid. MS calcd for C32H50FeN7O6 (M+H)
+
 684.3, 
found 684.4. 
 
Experimental Details for the Synthesis of H2N-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc 
(120) for cathepsin B detection. 
 
H2N-(CH2)4CO-Leu-Arg-Phe-Gly (126). AP14-88  
Starting with glycine 2-chlorotrityl resin, N-Fmoc protected amino acids were coupled using 
conventional solid state peptide synthesis by coupling (General Procedure F) and deprotection 
(General Procedure G) strategy in the order Phe, Arg, Leu and N-Boc-5-aminovaleric acid. 
Standard procedure H (cleavage) was used to cleave and recover the peptide from the resin to 
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give compound 126, 0.32 g (94% yield) as a white solid. MS calcd for C28H47N8O6 (M+H)
+
 
591.4, found 591.4. 
 
Boc-HN-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc (127). AP14-97   
A solution of sodium bicarbonate (86 mg, 1.2 mmol) and compound 126 (0.300 g, 0.5 mmol) in 
30 mL of dioxane:water (1:1) was stirred at 25
o
C for 10 min. Di-t-butyl dicarbonate (Boc2O) 
(0.22 g, 1.2 mmol) was added and the solution stirred at 25
o
C for 12 h, concentrated to dryness 
yielding a N-Boc intermediate 126a 0.35 g, (99% yield) as a white solid.  MS calcd for 
C33H54N8O8Na (M+Na)
+
 713.4, found 713.5. A solution of N-Boc intermediate 126a (60 mg, 
0.09 mmol) and HATU (47 mg, 0.12 mmol) in DMF (2 mL) was stirred at 25
o
C for 10 min.  
Aminomethylferrocene (26 mg, 0.12 mmol) was added and the solution was stirred at 25
o
C for 2 
h followed by filtration (0.2 micron filter) and purification by HPLC using a preparative column 
(Phenomenex-Jupiter C18) and eluting with 40% acetonitrile/water to 80 % acetonitrile/water 
over 40 min with a 10 ml/min flow rate.  The fractions containing the desired product were 
combined and lyophilized to yield compound 127, 40 mg (50% yield) as a yellow solid. MS 
calcd for C44H66FeN9O7 (M+H)
+
 888.4, found 888.5. 
 
H2N-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc (120).  AP14-103/AP17-64 
A solution of compound 127 (50 mg; 56 mol) in 10% TFA in dichloromethane (2 mL) was 
stirred at 25
o
C for 30 min, concentrated gently on a rotary evaporator, dissolved in deionized 
water (2 mL), frozen, and lyophilized to give compound 120, 43 mg (98% yield) as a green solid.
 
1
H NMR (400 MHz, DMSO-d6)  8.13 - 8.34 (m, 1H), 7.86 - 8.10 (m, 2H), 7.73 (br. s., 2H), 7.57 
(br. s., 1H), 6.82 - 7.42 (m, 8H), 4.48 (br. s., 1H), 4.03 - 4.33 (m, 11H), 3.96 (br. s., 2H), 3.52 - 
3.77 (m, 2H), 2.64 - 2.87 (m, 3H), 2.02 - 2.22 (m, 2H), 1.14 - 1.66 (m, 16H), 0.70 - 0.93 (m, 6H);  
13
C NMR (100 MHz, DMSO-d6)  173.1, 172.6, 172.0, 171.7, 168.7, 157.4, 138.2, 129.8, 128.7, 
126.9, 86.5, 69.1, 68.5, 68.0, 54.6, 52.8, 51.6, 42.7, 39.3, 38.3, 38.0, 35.1, 29.7, 27.3, 25.6, 24.9, 
23.8, 22.8, 22.1. MS calcd for C39H58FeN9O5 (M+H)
+
 788.4, found 788.3. 
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Reactivity Test of the Guanidine NH Function of Arginine Residue of Boc-HN-(CH2)4CO-
Leu-Arg-Phe-Gly-NHCH2-Fc (127).  In order to test that the guanidine NH of arginine residue 
side chain in compound 127 does not couple with the carboxylic acid functionality on carbon 
nanofibers during peptide attachment, a model reaction was performed using the same coupling 
conditions used to coupling peptide to carbon nanofiber surface.  
To a solution of compound 127 (3 mg, 3.4 μmol), benzoic acid (0.4 mg, 3.4 μmol) and N-
hydroxysuccinimide (0.4 mg, 3.4 μmol) in deionized water (1 mL) was added 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.66 mg, 3.4 μmol) and the resulting solution 
was stirred at 25
o
C for 2 h. Mass spectrometry analysis showed that no reaction took place 
between the NH group of arginine residue and the carboxylic acid moiety of benzoic acid. Since 
the N-terminal amine of compound 127 (Boc-HN-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc) is 
protected with a Boc group, no reaction took place.  This result suggests that the NH moiety of 
the guanidine side chain of arginine residue does not react with the carboxylic acid function of 
carbon nanofibers. The peptide attachment to the carbon nanofiber under normal reaction 
conditions must be made possible via the available primary N-terminal amine of the linker.  
 
Synthesis of H2N-(CH2)4CO-Leu-Asn-Phe-Gly-NHCH2-Fc (131) non-substrate “negative 
control” tetrapeptide for cathepsin B enzymatic study. 
 
H2N-(CH2)4CO-Leu-Asn-Phe-Gly (129). AP17-46 
Starting with glycine 2-chlorotrityl resin, N-Fmoc protected amino acids were coupled using 
conventional solid state peptide synthesis by coupling (General Procedure F) and deprotection 
(General Procedure G) strategy in the order Phe, Asn, Leu and N-Boc-5-aminovaleric acid. 
Standard procedure H (cleavage) was used to cleave and recover the peptide from the resin to 
give compound 129, 260 mg (83%) as a white solid. 
1
H NMR (400 MHz, DEUTERIUM 
OXIDE)  7.28 - 7.37 (m, 3H), 7.22 - 7.26 (m, 2H), 4.61 - 4.66 (m, 1H), 4.22 - 4.27 (m, 1H), 
3.92 (d, J = 5.47 Hz, 1H), 3.15 - 3.21 (m, 1H), 2.93 - 3.01 (m, 4H), 2.61 - 2.76 (m, 2H), 2.28 - 
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2.34 (m, 2H), 1.60 - 1.66 (m, 4H), 1.49 - 1.58 (m, 2H), 1.37 - 1.45 (m, 2H), 0.90 (d, J = 6.25 Hz, 
3H), 0.85 (d, J = 6.64 Hz, 3H); MS calcd for C26H41N6O7 (M+H)
+
 549.3, found 549.1. 
 
Boc-HN-(CH2)4CO-Leu-Asn-Phe-Gly-NHCH2-Fc (130). AP17-65   
A solution containing sodium bicarbonate (46 mg, 0.55 mmol) and compound 129 (0.15 g, 0.27 
mmol) in 20 mL of dioxane:water (1:1) was stirred at 25
o
C for 10 min. Di-t-butyl dicarbonate 
(Boc2O) (0.12 g, 0.55 mmol) was added, and the solution stirred for 24 h, concentrated to 
dryness to yield a N-Boc intermediate 129a, (0.18 g; 100% yield) as a white solid.  MS calcd for 
C31H48N6O9Na (M+Na)
+
 671.3, found 671.3. A solution of N-Boc intermediate 129a (177 mg, 
0.27 mmol) and HATU (115 mg, 0.30 mmol) in distilled DMF (4 mL) was stirred at 25
o
C for 5 
min.  Aminomethylferrocene (65 mg, 0.30 mmol) was added, and the solution was stirred for 18 
h, filtered (0.2 micron paper) and purified by HPLC using a preparative column (Phenomenex-
Jupiter C18) and eluting with 40% acetonitrile/water to 80 % acetonitrile/water over 40 min with 
a 10 ml/min flow rate.  The fractions containing the desired product were combined and 
lyophilized to yield compound 130, 150 mg (65% yield) as a yellow solid. MS calcd for 
C42H59FeN7O8Na (M+Na)
+
 868.4, found 868.4. 
 
H2N-(CH2)4CO-Leu-Asn-Phe-Gly-NHCH2-Fc (131). AP17-72   
A solution of compound 130 (60 mg; 71 mmol) in 10% TFA in dichloromethane (3 mL) was 
stirred at 25
o
C for 30 min, concentrated gently on a rotary evaporator, dissolved in deionized 
water (2 mL), frozen, and lyophilized to give compound 131, 52 mg (100% yield) as a green 
solid. 
1
H NMR (400 MHz, DMSO-d6)  8.31 (t, J = 5.66 Hz, 1H), 8.17 (d, J = 7.81 Hz, 1H), 8.13 
(d, J = 7.81 Hz, 1H), 7.99 (d, J = 7.81 Hz, 1H), 7.73 (br. s., 5H), 7.49 (br. s., 1H), 7.14 - 7.27 (m, 
6H), 7.02 (br. s., 1H), 4.48 (q, J = 6.64 Hz, 1H), 4.36 - 4.42 (m, 1H), 4.15 - 4.31 (m, 9H), 4.11 
(br. s., 2H), 3.97 (br. s., 2H), 3.59 - 3.75 (m, 2H), 3.11 (dd, J = 4.10, 13.86 Hz, 1H), 2.87 (d, J = 
9.76 Hz, 1H), 2.84 (d, J = 9.76 Hz, 1H), 2.76 (d, J = 5.86 Hz, 2H), 2.56 (d, J = 6.64 Hz, 1H), 
2.52 (d, J = 6.64 Hz, 1H), 2.44 (d, J = 6.25 Hz, 1H), 2.40 (d, J = 6.64 Hz, 1H), 2.10 - 2.18 (m, 
2H), 1.45 - 1.59 (m, 4H), 1.28 - 1.44 (m, 2H), 0.86 (d, J = 6.64 Hz, 3H), 0.82 (d, J = 6.25 Hz, 
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3H); 
13
C NMR (100 MHz, DMSO-d6)  172.9, 172.7, 172.6, 171.8, 171.7, 168.7, 138.6, 129.7, 
128.7, 126.9, 86.6, 69.1, 68.4, 68.0, 55.1, 51.5, 50.3, 42.9, 41.4, 39.3, 38.2, 37.4, 35.0, 27.3, 24.9, 
23.8, 22.7, 22.1;  MS calcd for C37H52FeN7O6 (M+H)
+
 746.3, found 746.2. 
 
Synthesis of Leu-NHCH2-Fc (133) fragment for HPLC analysis.   
 
Fmoc-Leu-NHCH2-Fc (132). AP9-115 
To a solution of Fmoc-Leu-OH (126 mg, 0.36 mmol) and HATU (123 mg, 0.33 mmol) in DMF 
(1 mL) was added H2NCH2-Fc (70 mg, 0.33 mmol) and the resulting solution was stirred at 25
o
C 
for 30 min. The reaction was diluted with ethyl acetate (100 mL) and the organic layer was 
washed with water (50 mL x 3) and brine (50 mL), dried (MgSO4), filtered and concentrated to 
yield a brown oil which was purified by silica gel chromatography using (EtOAc/hexane 1:1) to 
give compound 132, 98 mg (54% yield) as a yellow solid.  MS calc'd for C32H34FeN2NaO3 573.2 
(M+Na)
+
, found to be 573.3.   
 
Leu-NHCH2-Fc (133). AP9-117 
Compound 132 (81 mg, 0.15 mmol) was dissolved in 20% piperidine/DMF (5 mL) and stirred at 
25 
o
C for 30 min. The DMF was removed under reduced pressure and the resulting crude oil was 
purified by silica gel column chromatography (MeOH/EtOAc 5:95) to give compound 133, 33 
mg (67% yield) as a yellow solid. MS calc'd for C17H24FeN2NaO 351.1 (M+Na)
+
, found to be 
351.1. 
 
Synthesis of Phe-Gly-NHCH2-Fc (136) fragment for HPLC analysis.   
 
Boc-Gly-NHCH2-Fc (134). KC-1-67 
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To a solution of Boc-Gly-OH (32 mg, 0.19 mmol) in dry DMF under argon was added HATU 
(77 mg, 0.20 mmol), and the resulting solution was stirred for 5 minutes.  To the above solution, 
H2NCH2-Fc (40 mg, 0.185 mmol) was added and the solution stirred at 25
o
C for 12 h.  The 
reaction solution was partitioned between deionized water (20 mL) and dichloromethane (20 
mL).  The organic layer was removed and the aqueous layer was extracted once with 
dichloromethane (20 mL).  The organic layers were combined and dried (MgSO4), filtered, 
concentrated and purified by silica gel column chromatography (CH2Cl2:MeOH 30:1) to give 
compound 134, 25 mg (36% yield) as an orange oil. MS calc'd for C18H24FeN2NaO3 395.1 
(M+Na)
+
, found to be 395.1.  
 
Boc-Phe-Gly-NHCH2-Fc (135). KC-1-70  
 
To a solution of compound 134 (25 mg, 0.092 mmol) in dichloromethane (4 mL) under argon 
was added TFA (0.4 mL) and the solution was stirred at 25
o
C for 1 h.  The resulting solution was 
gently concentrated on a rotary evaporator and placed under high vacuum for 1 h to yield a de-
Boc intermediate 134a, 25mg (100%) as a green solid.  MS calc'd for C13H17FeN2O 273.1 (M+H)
 
+
, found to be 273.2. A solution of de-Boc intermediate 134a (25 mg, 0.092 mmol), Boc-Phe-OH 
(24 mg, 0.092 mmol), 4-(dimethylamino)pyridine (23 mg, 0.184 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) (35 mg, 0.184 mmol) in dry DMF (1 mL) under 
argon atmosphere was stirred for 1 min at 25
o
C followed by dilution with dry CH2Cl2 (2 mL) and 
additional stirring at 25
o
C for 12 h.  The reaction mixture was partitioned between CH2Cl2 (20 
mL) and water (20 mL) and acidified to pH 2 using drop wise addition of 2N HCl. The combined 
organic layers were washed with brine, dried (anhydrous Na2SO4), filtered and concentrated to 
yield a crude oil that was purified by silica gel column chromatography (CH2Cl2:MeOH 40:1) to 
afford compound 135, (23 mg, 48% yield) as a sticky yellow oil.  MS calc'd for 
C27H33FeN3NaO4 542.1 (M+Na)
+
 and found to be 541.9. 
 
Phe-Gly-NHCH2-Fc (136). KC-1-71   
 
A solution of compound 135 (23 mg, 0.044 mmol) in 10% TFA/CH2Cl2 (5 mL) was stirred at 
25
o
C for 1 h. The reaction solution was gently concentrated on a rotary evaporator to yield a 
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sticky oil.  CH2Cl2 (20 mL) was added and concentrated again and the residue was placed under 
high vacuum to furnish compound 136, 18 mg (98% yield) as a green solid. 
1
H NMR (CDCl3)  
7.3 (s, 5 H), 7.12 (s, 2 H), 5.4 (s, 1 H), 4.4 - 4.0 (m, 9 H), 3.85 (m, 2 H), 3.5 (s, 2 H), 3.2 (s, 2 H), 
2.85 (s, 2 H); MS calc'd for C22H25FeN3NaO2 445.1 (M+Na)
+
, found to be 445.1. 
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